

CURRICULUM VITAE

Revised 2023-02-08

Jose de Leon, M.D.

Marital status: **Married with three children and one grandchild**
Date and place of birth: **3-16-59 Bilbao (Spain)**
Languages: **English and Spanish**

CURRENT ADDRESSES

Room 3A15A
Mental Health Research Center
Eastern State Hospital
1350 Bull Lea Road
Lexington, KY 40511
USA
Phone (859) 246-8440 Fax (859) 246-8446
e-mail: jdeleon@uky.edu

University of Kentucky, Department of Psychiatry
245 Fountain Court, Lexington, KY 40509-1810,
USA
Phone (859) 323-6021, Fax (859) 323-1194

Home: 4765 Pleasant Grove Road
Lexington, KY 40515-1236

EDUCATION

Sep. 1976- July 1982

Licentiate Diploma in Medicine and Surgery
Basque Country University, Bilbao, Spain: 1976-78
University of Navarra, Pamplona, Spain: 1978-82

Oct. 1993

Doctoral Thesis Cum Laude
(Needed for academic career in Spain)
"Study of factors associated with somatizations in medical and surgical patients"
University of Navarra, Spain

POSTGRADUATE TRAINING

- Feb. 1983-Feb.1987 **Residency in Psychiatry**
Hospital Ramon y Cajal
Madrid, Spain
- May 1983-Dec.1984 **Psychotherapy Seminar**
Madrid, Spain
- Jul. 1987-Jun.1988 **Fellowship in Clinical Research, Psychiatry**
University of Pennsylvania
Philadelphia Veterans Administration
Medical Center
Philadelphia, PA
- Jul.1988-Jun. 1991 **Fellowship in Clinical Psychopharmacology**
Department of Psychiatry, EPPI
Medical College of Pennsylvania
Philadelphia, PA

CERTIFICATION AND LICENSURE

- 1983 **Examination for Medical Degree: A**
University of Navarra
(Equivalent to U.S. National Boards)
- 1983 **ECFMG (VQE examination):**
Passed both Basic and Clinical Sciences
- 1987 **Certification in Psychiatry (Spain)**
(Equivalent to U.S. Specialty Boards in
Psychiatry)
- 1987 **Passed FLEX Exam, Component I: 87**
Component II: 85
- 1992-1996 **Pennsylvania MD License #046687-L**
- 1996-present **Kentucky MD License #31857**

MILITARY SERVICE

- 1982 **Medical Corps, Spanish Army:** Department of
Internal Medicine (Oncology) Military Hospital
Gomez Ulla, Madrid

EMPLOYMENT HISTORY

MADRID, SPAIN

March-June 1987 **Private Practice in Psychiatry**
Madrid, Spain

PHILADELPHIA, PA

July 1991-June 1995 **Research Assistant Professor, Psychiatry**
Medical College of Pennsylvania

July-Dec. 1995 **Research Associate Professor, Psychiatry**
Medical College of Pennsylvania &
Hahnemann University

George M. Simpson, M.D., was Dr. de Leon's mentor for 7.5 years (3 years of fellowship and 4.5 years in a faculty position).

LEXINGTON, KY

May 1996-June 1998 **Associate Professor, Psychiatry**

July 1998-June 2006 **Associate Professor with Tenure, Psychiatry**
College of Medicine, University of Kentucky (UK)

July 1997-July 2006 **Associate Professor,**
Pharmacy Practice & Science
College of Pharmacy, University of Kentucky (UK)

July 2006-present **Professor,**
Psychiatry
College of Medicine, University of Kentucky (UK)

Pharmacy Practice & Science
College of Pharmacy, University of Kentucky (UK)

Nov. 2010-present **Evelyn Anderson Edwards Professor, Endowed Chair**
Supporting schizophrenia and chronic mental illness research
Department of Psychiatry

College of Medicine, University of Kentucky (UK)

Jan. 2012-present **Associate,**
Center on Drug and Alcohol Research (CDAR)
University of Kentucky (UK)

ACADEMIC TITLES IN SPANISH UNIVERSITY SYSTEM

Apr. 1999 **Equivalent to Associate Professor of Psychiatry**

Feb. 2007 **Equivalent to Professor of Psychiatry (based on examination)**

CLINICAL ACTIVITIES

MAJOR CLINICAL ACTIVITIES:

1988-1991	Research Unit Director (acting) Haverford State Hospital, Haverford, PA
1992-1995	Medical Director (acting until 4/93) MCP/NSH Clinical Research Center Norristown State Hospital, Norristown, PA
1996-present	Medical Director , UK Mental Health Research Center Eastern State Hospital, Lexington, KY
1996-6/2004	Managed the 30-bed treatment-refractory psychosis unit. This unit handled 1% of hospital admissions.
2001-present	Consultant , Kentucky Department of Behavioral Health, Developmental and Intellectual Disabilities. This includes: 1) Assisting clinicians with complex patients at 4 state hospitals, 2 nursing homes, and 4 facilities for adults with intellectual disability. 2) Reviewing deaths at state facilities and community placements. 3) Helping with Strategic Action Plan developed by the Department of Justice for improving facilities for adults with intellectual disabilities. This includes developing pharmacological guidelines and teaching clinicians about chart documentation.
07/2012-04/13	Consultant Psychiatrist , Bingham Gardens, Louisville, KY This is a 24-bed facility for adults with IDs.

**PROFESSIONAL COMMITTEES (UNIVERSITY/PUBLIC SERVICE)
REVIEWER OF MANUSCRIPTS FOR 85 INTERNATIONAL JOURNALS:**

1992, 2020	Journal of the Academy of Consultation-Liaison Psychiatry (Psychosomatics)
1992, 95, 05, 07, 12	New England Journal of Medicine
1992-2012	Biological Psychiatry
1993-2012	Psychiatric Services
1994-present	Schizophrenia Research
1995, 2018	(Archives of General Psychiatry) JAMA Psychiatry
1995-present	Psychiatry Research
1995-present	Schizophrenia Bulletin
1996-present	Journal of Clinical Psychopharmacology
1997-2007	Journal of Neuropsychiatry and Clinical Neurosciences
1998-present	Journal of Clinical Psychiatry
1998, 2003	Nicotine and Tobacco Research
1998-2012, 2021	Journal of Psychiatric Research
2001, 2006	Neuropsychopharmacology
2001-2013, 2018-2021	Progress in Neuro-Psychopharmacology & Biol. Psychiatry
2002-present	American Journal of Psychiatry
2003-2013	Addictive Behaviors
2004	Preventive Medicine
2004	Cancer Detection and Prevention
2004, 2006, 2015, 2021	Acta Psychiatrica Scandinavica
2004-2013	Psychosomatic Medicine
2004	Neuroscience and Biobehavioural Reviews
2005	CNS Drugs
2005	Current Pharmaceutical Design
2005	Pharmacy & Therapeutics
2005-present	Bipolar Disorders
2005	NeuroMolecular Medicine
2005	Journal of Dual Diagnosis
2005	Journal of Pharmacy and Pharmacology
2005	European Psychiatry
2006-2017	Pharmacogenomics Journal
2006	Journal of Medical Genetics
2006-2016	Molecular Psychiatry
2006	BMC Health Services
2006, 2009, 2015	Drug and Alcohol Dependence
2006-2008	Personalized Medicine
2006	Alcohol and Alcoholism
2006, 2010, 2015	International Journal of Psychiatry in Medicine
2007, 2018-2020	British Journal of Psychiatry
2007, 2009, 2010	Addiction
2007-2013	General Hospital Psychiatry
2007	Pain Practice

2007, 2017	European Journal of Psychiatry
2007	Current Pharmacogenomics
2007-present	Pharmacopsychiatry
2007	American Journal of Medical Genetics
2007, 2008, 2011	International Journal of Neuropsychopharmacology
2007	Pharmacogenetics and Genomics
2007	Canadian Medical Association Journal
2007, 2011, 2014	Human Psychopharmacology
2007	Journal of Child and Adolescent Psychiatry
2007, 2014-5, 2019	Clinical Pharmacokinetics
2008, 2014-5, 2018	CNS Spectrums
2008, 2011, 2012	Pharmacogenomics
2008	Fundamentals and Clinical Pharmacology
2008, 2021	Pharmacological Research
2009	Comprehensive Psychiatry
2009	Current Opinion in Molecular Therapeutics
2009, 2014, 2019	International Clinical Psychopharmacology
2009	Expert Review of Neurotherapeutics
2009, 2014, 2017	Expert Opinion in Drug Metabolism & Toxicology
2009	Annals of Internal Medicine
2009	Drug Discovery Today
2009, 2014	Current Drug Safety
2009, 2014	International Journal of Clinical Practice
2009	Journal of Affective Disorders
2009, 2015, 2022	Psychopharmacology
2009-2010, 2108	Journal of Psychopharmacology
2010	Current Drug Metabolism
2010-present	Clinical Pharmacology & Therapeutics
2010, 2013, 2015	International Journal of Psychiatry in Medicine
2011	Expert Opinion in Investigational Drugs
2011, 2016	Expert Opinion in Drug Safety
2011, 2018	Expert Opinion On Pharmacotherapy
2011, 2021	Revista Brasileira de Psiquiatria
2011	Nature Reviews Endocrinology
2011, 2015, 2017	JAMA
2011	Psychiatry Investigation
2011-present	Psychiatria Danubina
2011, 2018	Expert Opinion in Pharmacotherapy
2012	Australian and New Zealand Journal of Psychiatry
2013-2018	Acta Neuropsychiatrica
2013	Psychiatry and Clinical Neurosciences
2013	Clinical Pharmacology and Drug Development
2014, 2020, 2021	British Journal of Clinical Pharmacology
2014, 2019	Lancet Psychiatry
2015-present	Psychotherapy & Psychosomatics

2015	Annals of General Psychiatry
2015, 2020,2021	Expert Review of Clinical Pharmacology
2015	Nordic Journal of Psychiatry
2015	Journal of Clinical Epidemiology
2015	NPJ Psychiatry
2015	Journal of Nervous and Mental Diseases
2015-2021	Revista Colombiana de Psiquiatría
2016	British Medical Journal Open
2016, 2021	Psychological Medicine
2016	Lancet Respiratory Medicine
2016	Journal of Medical Ethics
2016-present	Revista de Psiquiatría y Salud Mental
2017	Psychoneuroendocrinology
2017	Archives of Psychiatric Nursing
2018	Journal of Personalized Medicine
2019-present	Expert Opinion on Drug Metabolism and Toxicology
2019	European Archives of Psychiatry and Clinical Neurosciences
2019	Journal of Comparative Effectiveness Research
2019	British Medical Journal
2019-2021	Therapeutic Advances in Psychopharmacology
2020	Frontiers in Genetics
2021	General Psychiatry
2021	Schizophrenia Bulletin Open
2021	Annals of Clinical Psychiatry

EDITORIAL BOARD

2005-2020	BMC Psychiatry (Editorial Advisor)
2005-2013	Current Clinical Pharmacology
2007-present	Revista Colombiana de Psiquiatría
2010-2020	Pharmacopsychiatry
2012	Psychiatry Investigation
2012-present	Psychiatria Danubina (International Advisory Board)
2014-2018	Acta Neuropsychiatrica
2015-present	Psychotherapy and Psychosomatics
2016-present	Journal of Clinical Psychopharmacology
2019-2020	Journal of Personalized Medicine
2020-present	Revista de Psiquiatría y Salud Mental

REVIEWER OF BOOKS FOR INTERNATIONAL JOURNALS:

1996, 1998	New England Journal of Medicine
2005	Community Mental Health Journal
2008	American Journal of Psychiatry

REVIEWER OF GRANTS:

2000, 2005 **Department of Veterans Affairs: Independent Reviewer**
 2002 **The Wellcome Trust (United Kingdom)**
 2003 **Medical Research Council (United Kingdom)**
 2005 **Kentucky SBIR/STTR Phase Zero Program**
 2007 **German government: Long-Term Health Studies**
 2011 **Lightfighter Trust**

PHARMACOGENETIC REVIEWER (INTERNATIONAL EXPERT):

2007 **European Commission,**
Institute for Prospective Technological Studies
 Improving pharmacovigilance in Europe: Cost-effectiveness of CYP2D6
 and TMTP genotyping in clinical practice (see article #195).

2019 June 24 **Expert Panel on Pharmacogenomics for Medicare coverage**
 One of 5 experts on panel (I presented a 13-page report)

MEMBER OF INSTITUTIONAL REVIEW BOARD:

1998-2013 **Bluegrass Regional MH-MR Board, Inc.**
 (It reviewed research projects for Eastern State Hospital, Lexington, KY)

AWARDS

- 1991 **ACNP/Mead Johnson Honorable Mention Award**
American College of Neuropsychopharmacology
- 1991 **Fidia Research Foundation Travel Award**
International School of Neurosciences
- 1994 **CINP Rafaelsen Fellowship Award. Collegium**
Internationale NeuroPsychopharmacologicum
- 1997 **Chairman's Award, Psychiatry, College of Medicine,**
University of Kentucky
- 1998 **Residents' Special Recognition Award, Psychiatry,**
College of Medicine, University of Kentucky
- 1998 **Annual Exemplary Psychiatrists Award**
National Alliance for the Mentally Ill (NAMI)
- 1999 **Research Award, Kentucky Psychiatric Association**
- 2001 **Residents' Special Recognition Award as a Research Mentor**
Psychiatry, College of Medicine, University of Kentucky
- 2002 **Distinguished Fellow, American Psychiatric Association**
- 2006 **Residents' Award for Community Faculty**
Psychiatry, College of Medicine, University of Kentucky
- 2011 **Residents' Outstanding Teaching Award**
Psychiatry, College of Medicine, University of Kentucky
- 2013 **Residents' Outstanding Teaching in Didactics Award**
Psychiatry, College of Medicine, University of Kentucky
- 2015 **Honorary Member,**
Spanish Society of Biological Psychiatry
- 2016 **Residents' Outstanding Adult Didactics Teaching Award**
Psychiatry, College of Medicine, University of Kentucky
- 2017 **Robert F. Kraus Legacy in Teaching Award**
Psychiatry, College of Medicine, University of Kentucky

- 2018 **W.R. Martin Research Mentor Award and
Tagalie Heister Scholarship Mentor Award and
Psychiatry, College of Medicine, University of Kentucky**
- Excellence in Resident Mentorship
Unofficial Award given by two Psychiatry Residents**
- 2019 **W.R. Martin Research Mentor Award and
Tagalie Heister Scholarship Mentor Award and
Psychiatry, College of Medicine, University of Kentucky**
- 2021 **Residents' Outstanding Adult Didactics Teaching Award
Psychiatry, College of Medicine, University of Kentucky**

MEMBERSHIPS

- 1988-present **American Psychiatric Association**
- 1989-2012 **National Alliance for the Mentally Ill (NAMI)**
- 1992-2012 **Society of Biological Psychiatry**
- 1994-present **Collegium Internationale Neuro-Psychopharmacologicum (CINP)**
- 1996-2010 **American Foundation for Suicide Prevention**
- 1997-present **Kentucky Psychiatric Medical Association**
- 1998-2012 **NAMI-Lexington**
- 1999-2010 **Society for Research on Nicotine and Tobacco**
- 2015-present **Spanish Society of Biological Psychiatry, honorary member**

EDUCATIONAL ACTIVITIES

VISITING PROFESSOR AT UNIVERSITY OF GRANADA:

- 09/98-06/08 Neurosciences and Clinical Psychiatry
 A course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 and organized by the Federico Oloriz Neuroscience Institute and
 Department of Psychiatry, Medical School
 University of Granada,
 Granada, Spain
- 2011 Helped with development of a rotation for UK medical students
 Department of Psychiatry, Medical School
 University of Granada,
 Granada, Spain

VOLUNTARY PROFESSOR:

- 09/03-09/08 Department of Statistics
 Science School
 Universidad Nacional
 Medellin, Colombia

EDUCATIONAL VISIT:

- 08/23-24/01 Department of Psychiatry and Internal Medicine
 Marshall University
 Huntington, WV
 (supported by Pfizer)
- 01/9-11/06 Sant Joan de Déu Hospital,
 Sant Boi de Llobregat, Barcelona, Spain
- 03/13/15 Pharmacology Department,
 University of Barcelona
 Barcelona, Spain
- 10/25/16 Hospital El Sauce (a public psychiatric hospital)
 Mendoza, Argentina

COURSES:

- 7/92-6/95 **"Clozapine"** (2 hours for PGY-1 and 1 hour for PGY-2)
 Medical College of Pennsylvania
 Psychiatry Residents
- 7/92-6/94 **"Journal Club"** (1 hour monthly)
 Norristown State Hospital
 Psychiatry Residents
- 7/92-6/95 **"Biological Psychiatry"** PGY-4
 Norristown State Hospital
 Psychiatry Residents
- 7/92-6/94 Teacher
 (1 hour weekly co-taught with George M. Simpson)
- 7/94-6/95 Developer and coordinator
 (1 hour weekly shared with other faculty)
- 7/96-12/96 **"Schizophrenia and Bipolar Disorder"**
 Eastern State Hospital
 UK Psychiatry Residents
 Developer and teacher
 (1 hour weekly)
- 7/97-6/98 **"Neuropsychiatric Aspects of Schizophrenia"**
 Eastern State Hospital
 University of Kentucky Psychiatry Residents
 Teacher
 (1 hour weekly for 2 weeks, every 2 months)
- 7/98-6/99 **"Cytochrome P450" and "Schizophrenia"**
 University of Kentucky
 Psychiatry Residents
 Teacher
 (3 hours one time)
- 2/15-18/99 **"Neurosciences and Clinical Psychiatry"**
 Course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute, Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)

- 6/27-28/02 **"Neurosciences and Clinical Psychiatry"**
 course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute, Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)
- 6/14-18/04 **"Neurosciences and Clinical Psychiatry"**
 course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute, Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)
- 6/27-7/01/05 **"Neurosciences and Clinical Psychiatry"**
 course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute,
 Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)
- 7/1/04-6/30/14 **Director, Residency Education at Eastern State Hospital**
 4-hour course (1 hour/week for 1-month resident rotation)
 Course usually focused on 4 topics: schizophrenia, mood disorders,
 suicide, and violence. Alternative topics offered to interested residents.
- 7/06-present **"Movement Disorders"**
 University of Kentucky
 Psychiatry Residents
 Teacher
 (1-2 hours every 1-2 years)
- 6/25-7/02/07 **"Neurosciences and Clinical Psychiatry"**
 course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute,
 Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)
- 6/23-27/08 **"Neurosciences and Clinical Psychiatry"**
 course for M.D.s and Ph.D.s co-taught with Manuel Gurpegui, M.D.,
 organized by the Federico Oloriz Neuroscience Institute,
 Medical School,
 University of Granada
 Granada, Spain (20 hours by Dr. de Leon)

- 11/14/08 **“A Forensic Case”**
Lecture in the Forensic Psychiatry Master.
Medical School,
International University of Catalunya
Barcelona, Spain (1.5 hours by Dr. de Leon)
- 11/14/08 **“The Future of Personalized Medicine in Psychiatry”**
Lecture to the first promotion of first-year medical students.
Medical School,
International University of Catalunya
Barcelona, Spain (1 hour by Dr. de Leon)
- 09/10-03/11 Weekly lecture
- 10/12-03/13 **“Case Studies in Advanced Psychopharmacology”**
- 01/15-05/15 University of Kentucky
- 04/16-06/16 Psychiatry Residents (PGY-3 and PGY-4)
Teacher
- 03/17-06/17 Psychiatry Residents (PGY-3 and PGY-4)
Teacher
- 03/18-05/18 Psychiatry Residents (PGY-3 and PGY-4)
Teacher
- 03/19-05/19 Psychiatry Residents (PGY-3 and PGY-4)
Teacher
- 01/20-05/20 Psychiatry Residents (PGY-3 and PGY-4)
Teacher
- 01/21-03/21 Psychiatry Residents (PGY-3 and PGY-4)
Teacher

TUTORING:**1) TUTORING AT HAVERFORD STATE HOSPITAL, HAVERFORD PA:****1.1) Supervisor of Research Rotations for PGY-4 Psychiatry Residents: 1989-1991**

Medical College of Pennsylvania

Andrew Bott, M.D.

Years of involvement: 01/89-06/89

Next position: Community Psychiatrist

Cambridge Community Mental Health Center

Cambridge, MA

Outcome of collaboration: 1 article

Gloria Ellis, M.D.

Years of involvement: 07/89-06/90

Next position: Forensic Psychiatrist

Reichars State Prison, New York

Outcome of collaboration: 1 article

Kimberly Walker, M.D.

Years of involvement: 07/90-06/91

Next position: Fellowship

Medical College of Pennsylvania/EPPI

Aruby Odom-White, M.D.

Years of involvement: 10/90-12/95 (Colleague until 1995)

Next position: NIMH Minority Fellowship

MCP/NSH Clinical Research Center

Norristown State Hospital, Norristown, PA

and Clinical Instructor

Medical College of Pennsylvania/EPPI

Outcome of collaboration: 6 articles, 2 letters to the editor and 7 posters

Joseph K. Stanilla, M.D.

Years of involvement: 07/91-12/91 (Colleague until 1995)

Next position: Research Unit Director

MCP/NSH Clinical Research Center

Norristown State Hospital, Norristown, PA

and Clinical Instructor

Medical College of Pennsylvania/EPPI

Outcome of collaboration: 9 articles, 2 letters to the editor and 8 posters

1.2) Supervisor of Research Rotations for Medical Students: 1989-1991

(1 month in summer)

funded by a Stanley Foundation Award to George M. Simpson, M.D.

Orren Pearlman, M.D.

Years of involvement: 1989

Next position: Psychiatry Resident

Cambridge Community Mental Health Center

Outcome of collaboration: 1 article

Carla Canuso, M.D.

Years of involvement: 1990, 1991

Next position: Psychiatry Resident

University of Chicago

Outcome of collaboration: 3 articles and 2 posters

Christian Büchel, M.D.

Years of involvement: 1992

Next position: Neurology Resident

Germany

Outcome of collaboration: 3 articles and 1 poster

Others:

1990 Tami Collins and Joanne Warren

1991 Robert Blake and Ken Gelman

1.3) Supervisor of Research Rotations for Psychiatry Fellows: 1990-1991

Medical College of Pennsylvania

Mahmood Dadvand, M.D.

Years of involvement: 1990-1991

Next position: Attending Psychiatrist

Norristown State Hospital

Norristown, PA

Outcome of collaboration: 2 articles and 1 poster

**2) TUTORING AT MCP/NSH CLINICAL RESEARCH CENTER
NORRISTOWN STATE HOSPITAL, NORRISTOWN, PA:**

2.1) Supervisor of Research Rotations for PGY-4 Psychiatry Residents: 1992-1995

Norristown State Hospital (part-time for 3 months)

Violet Henighan, D.O.

Years of involvement: 1992

Next position: Forensic Psychiatrist

Farview State Hospital

Waymart, PA

Outcome of collaboration: 1 letter to editor

Muhammed Ajanah, M.D.

Years of involvement: 1993

Next position: Attending Psychiatrist

Norristown State Hospital

Norristown, PA

2.2) Supervisor of Research Rotations for Medical Students: 1992-1993

(1 month in summer) funded by a Stanley Foundation Award to
George M. Simpson, M.D.

Christian Büchel, MD.

Years of involvement: 1993

Next position: Neurology Resident

Germany

Outcome of collaboration: 2 articles and 1 poster

Others:

1992: Karyn Lewis, Ivette Jordan, Cecelia Johnson and Ghayyir Qureshi

2.3) Mentor of Research Rotations for International Visitors: 1993-1995

Jorge Muñoz, M.D.

Director, Department of Psychiatry,

Colegio Virgen de Lourdes

(School for the Mentally Retarded)

Majadahonda, Madrid, Spain.

Duration: 1 month (3/93)

Javier Alarcon, M.A.

Psychology School Complutense University

Madrid, Spain

Duration: 5 months (06/93 to 11/93)

Outcome of collaboration: 1 article

Manuel Gurpegui, M.D.
Associate Professor (Profesor Titular)
Department of Psychiatry, School of Medicine
University of Granada
Granada, Spain
Duration: 1 week (6/93)
Collaboration continues to present

Antonio Ciudad-Herrera, M.D.
PGY-4 Psychiatry Resident
Department of Psychiatry
Hospital Ramon y Cajal
Madrid, Spain
Duration: 3 months (03/94 to 05/94)
Outcome of collaboration: 1 article

Enrique Baca-Garcia, M.D.
Before starting residence
Psychiatry Resident
Department of Psychiatry
Hospital Ramon y Cajal
Madrid, Spain
Duration: 4 months (08/94 to 11/94)
Collaboration continues to present

**3) TUTORING AT UK MENTAL HEALTH RESEARCH CENTER
EASTERN STATE HOSPITAL, LEXINGTON, KY:**

3.1) Supervisor of Clinical Rotations for Psychiatry Residents: 1996-2004

Gragg 2, Eastern State Hospital (1-6 months)

3.2) Supervisor for Psychiatry Residents (weekly meetings): 1998-present

Stephen Durrenberger, M.D., 1998-1999

Jayne Bork, D.O., 1998-1999

Sheneggang Li, M.D., Ph.D., 1999-2002

Duke Ruktanonchai, M.D., 2003-2004

Cindy Rossetti, M.D., 2009-2011

Fareesh Kanga, M.D., 2009-2010

Pixie Yung, M.D., 2010-2012

Jaaneali Mehdi, M.D., 2010-2012

Megan White, M.D., 2011-2014

Brooke Beehler, O.D., 2012-2014

Kara Stebbins, M.D., 2013 (6 months)

Mathew Meek, M.D., 2013-2014

Casey Berson, M.D., 2013-2014

Rocio Puentes, M.D., 2014-2015

Erin K Knopf, M.D., 2014-2015

Amit K. Bhakhri, M.D., 2015-2017

Priti R. Patel, M.D., 2015-2016

Nasratullah Wahidi, M.D., 2015-2018

**3.3) Supervisor of Elective Psychopharmacology Rotations for PGY-IV Psychiatry
Residents (half day/week): 2011-present**

Caithiry Jayaraman, M.D. 2011-2012

Pixie Yung, M.D., 2012 (6 months)

Jaaneali Mehdi, M.D., 2012 (6 months)

3.4) Supervisor of Research Rotations for Medical Students: 1996-1999**One month elective:**

Pat Triplett (07/96)
Melanie Coffman (12/97)
Christopher Pund (07/98-08/98)
Latonia Sweet (07/98-08/99)
Jenawik Marcum (07/98-08/99)

Elective:

James Jackson (10/11-1/15 in his free time and one-month rotation 02/15)
Outcome of collaboration: 2 articles and 1 letter to editor
Next job: Resident in psychiatry and family medicine,
University of Iowa

Dustin B. Stephens (rotation for two months 09/15 and 12/15 and in his
free time 7/15-5/16).
Outcome of collaboration: 1 letter to editor and 1 article
Next job: Resident in psychiatry,
UCLA

John Bilbily (rotation for two months 09/16 and 2/17).
Outcome of collaboration: 1 letter to editor and 1 article
Next job: Resident in psychiatry,
Washington University in St. Louis

3.5) Supervisor of Research Rotations for International Visitors: 1996-present

Ana Gonzalez-Pinto, M.D.
Research Psychiatrist, Department of Psychiatry
Hospital Santiago Apostol, Vitoria, Spain
Duration: 1 month (07/96)
Collaboration continues to present

Tamara Kouznetsova, M.D.
Attending Psychiatrist
Penza Regional Association of Psychiatry
Penza, Russia
Duration: 1 month (09/96)

Enrique Baca-Garcia, M.D.
Psychiatry Resident/Fellow, Department of Psychiatry
Hospital Ramon y Cajal
Madrid, Spain
Duration: 1 week (07/97) and 2 months (07/98-08/98)
Collaboration continues to present

Noemi Villanueva, Pharm.D.
Pharmacy Resident
Hospital Gregorio Marañon
Madrid, Spain
Duration: 4 months (02/04-06/04)
Outcome of collaboration: 2 articles

Manuel Gurpegui, M.D.
Associate Professor (Profesor Titular)
Department of Psychiatry, School of Medicine
University of Granada
Granada, Spain
Duration: 1 month (8/05)
Collaboration continues to present

3.6) Supervisor of Clinical Rotations for Physician Assistant Students: 1999-2000

3.7) Supervisor of Research Rotations for Psychiatry Residents: 1997-present

Stephen Durrenberger, M.D.

PGY-3: 1 afternoon/week in 1997-1998

PGY-4: 1 day and a half/week in 1998-1999

Outcome of collaboration: 1 internal grant, 1 article, 1 letter to editor and 1 poster

Next position: Attending at a state hospital
affiliated with the Department of Psychiatry
Marshall University, Huntington, WV

Jayne Bork, D.O.

PGY-3: 1 month (12/97)

PGY-4: 1 day and a half/week in 1998-1999

Outcome of collaboration: 1 article, 2 letters to editor, 1 poster and 1 oral presentation

Next position: Attending at a psychiatric hospital
St. Mary's/Duluth Clinic Health System
Duluth, MN

Karen Kinney, D.O.

PGY-3: 1 afternoon/week in 1998

PGY-4: 1 half day/week in 1998-1999

Outcome of collaboration: 1 small internal grant and 1 poster

Karen Jorgensen, M.D.

PGY-2: clinical rotation

Outcome of collaboration: 1 small internal grant and 1 poster

Circe Cooke, M.D.

PGY-2: 1-month clinical rotation (9/98)

Outcome of collaboration: 1 letter to editor.

Next position: Clinical Assistant Professor (part-time)
Departments of Psychiatry
College of Medicine
University of Kentucky

Paul E. A. Glaser, M.D., Ph.D.

PGY-5: 1 half day/week in 2000-2001

Outcome of collaboration: see next page.

Next position: Assistant Professor (70% research)
Departments of Psychiatry, Anatomy and Neurobiology
College of Medicine, University of Kentucky

Sheneggang Li, M.D., Ph.D.
PGY-3/4: 1 half day/week in 2001-2002
Outcome of collaboration: 1 article
Next position: Bluegrass Community Mental Health Centers
Kentucky

Duke Ruktanonchai, M.D.
PGY-2/3: weekly supervision in 2003-2004
Outcome of collaboration: 1 article

Courtney Markham-Abedi, M.D.
PGY-4: 1 half day/week in 2005-2006
Outcome of collaboration: 2 letters to editor and 2 articles
Next position: Eastern State Hospital
Lexington, Kentucky

Beth Housman, M.D.
PGY-4: 1 half day/week in 2007-2008
Next position: Private Practice
Lexington, Kentucky

Vidyashree Chikkaramanjegowda, M.D.
PGY-4: for 6 months during her time off in 2013
Outcome of collaboration: 1 article
Next position: North Dakota State Hospital
Jamestown, North Dakota

Megan White, M.D.
PGY-5: for 3 months during her time off in 2015
Outcome of collaboration: 1 article
Next Position: Assistant Professor of Psychiatry,
University of Texas at Austin Dell Medical School

Nitin Chopra, M.D.
PGY-3/4: for 15 months during his time off in 2015-2016
Outcome of collaboration: 2 articles
Next position: Addiction Fellowship
Centre for Addiction and Mental Health
University of Toronto

Rocio Puentes, M.D.
PGY-3 during her time off & PGY-4: 1 half day/week in 2015-2017
Outcome of collaboration: 1 article
Next position: Mental Health Care Inc (Community Mental Health Center)
Tampa, Florida

Nasrat Wahidi, M.D.

PGY-2/4: during his time off in 2015-2018

Outcome of collaboration: 1 article and 1 letter to editor

Next position: Neuropsychiatry Fellowship

Department of Psychiatry

Case Western Reserve University

Samantha Zwiebel, M.D.

PGY-2/4: 1 half day/week in 2016-2018

Outcome of collaboration: 2 articles and 2 posters

3.8) Supervisor of Research Rotation for Pharmacy Resident: 2002-2003

Gara Coffey, Pharm.D.

1-year rotation

Outcome of collaboration: 1 article and 1 letter to editor

3.9) Supervisor of Research Rotations for Pharmacy Student: 2007-2008

Danielle James

1-year elective rotation

Outcome of collaboration: 1 article and 1 poster

3.10) Mentor of Faculty: 1996-2014

John Barnhill, M.D. (1996-2005)

Attending Psychiatrist, Admissions Unit, ESH

Outcome of collaboration: 1 small internal grant, 2 articles, 1 letter to editor, 1 poster and 1 oral presentation

Thea Rogers, Pharm.D. (1996/1999)

Clinical Assistant Professor,

Pharmacy Practice & Science, College of Pharmacy

Associate Director, UK MHRC at ESH

Outcome of collaboration: 1 NARSAD Young Investigator Award grant, 8 articles, 2 letters to editor and 9 posters

Sheila Botts, Pharm.D. (2000-2008)

Clinical Assistant Professor,

Pharmacy Practice & Science, College of Pharmacy

Outcome of collaboration: 5 articles, 1 letter to editor and 1 poster

Paul E. A. Glaser, M.D., Ph.D. (2001-2005)

Assistant Professor (70% research)

Departments of Psychiatry, and Anatomy and Neurobiology

College of Medicine

University of Kentucky

Outcome of collaboration: 2 articles, 1 poster and 1 NARSAD Young Investigator Award grant

Amy O'Neill, M.D. (2005-2014)

Clinical Assistant Professor, Psychiatry

College of Medicine

Outcome of collaboration: 1 article and 1 letter to editor

Betsy McCollum, Pharm.D. (2015-present)

Pharmacist

Eastern State Hospital

Outcome of collaboration: 2 articles and 2 letters to editor

RESEARCH ACTIVITIES

SUPPORT (>\$2,500,000 of direct costs brought to University of Kentucky):

- 06/94-09/97 Principal Investigator
Young Investigator National Alliance for Research on Schizophrenia and Depression (NARSAD)
"Cotinine Levels in Chronic Schizophrenic Inpatients"
 (\$60,000 of direct costs for 2 years)
- 12/94-11/00 Principal Investigator
National Institute of Mental Health First Award
"Longitudinal Study of Polydipsia and Water Intoxication"
 (\$350,000 of direct costs for 5 years)
- 10/96-11/96 Mentor
Kentucky Department of Mental Health and Mental Retardation/Department of Psychiatry University of Kentucky through the University Collaboration Project
"A Pilot Study for Screening the Cytochrome P-450 2D6 at Eastern State Hospital"
 Principal Investigator: John Barnhill, M.D.
 (\$7,500 for 1 month)
- 07/97-03/00 Mentor
Young Investigator National Alliance for Research on Schizophrenia and Depression (NARSAD)
"Nicotine Metabolism and Schizophrenia"
 Principal Investigator: Thea Rogers, Pharm.D.
 (\$60,000 for 2 years)
- 07/97-07/98 Principal Investigator
UK Medical Center Research Fund
"Using Pharmacological Probes to Test for Risperidone Metabolism"
 (\$15,000 for 1 year)
- 07/97-06/00 Principal Investigator
Kentucky Department of Mental Health and Mental Retardation/Department of Psychiatry University of Kentucky through the University Collaboration Project
"General Support to UK Mental Health Research Center at Eastern State Hospital" (approximately \$70,000 per year or \$210,000)

- 07/00-07/04 Principal Investigator
Kentucky Department of Mental Health and Mental Retardation
"Research at Eastern State Hospital"
(\$322,000 of direct costs for 4 years to promote research activities and provide consultation and education in state facilities)
- 07/00-07/01 Principal Investigator
UK Medical Center Research Fund
"An Improved Method to Measure Tobacco Smoke Exposure"
(\$15,000 for 1 year)
- 07/00-11/03 Principal Investigator
Eli Lilly Research Fund
"Risperidone Response: Therapeutic Complications from Genetic Variation in Cytochrome P450-2D6 Expression"
(\$211,000 of direct costs for 2 years and extensions)
- 09/00-03/03 Principal Investigator
Independent Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD)
"Cytochrome P4502D6 Genotype and Risperidone Response"
(\$92,000 of direct costs for 2 years and extensions)
- 07/02-06/05 Mentor
Young Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD)
"Risperidone Metabolism in Children and Adolescents"
Principal Investigator: Paul E. A. Glaser, M.D., Ph.D.
(\$60,000 of direct costs for 2 years and extensions)
- 07/03-06/07 Principal Investigator
Roche Molecular Systems
"A Prospective Clinical Study to Determine the Impact of CYP2D6 Genotype on Therapy Discontinuation and Costs Savings in Severe Mental Illness"
(\$1,099,628 of direct costs for 4 years)
- 03/04-02/06 Principal Investigator
Stanley Scholars program
(\$15,000 of direct costs for 1 year with 1 year extension)

- 03/05-06/11 Principal Investigator
2004 Independent Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD)
"Antidepressant Medication Intolerance and Pharmacogenetics of the Serotonin System"
(\$92,000 of direct costs for 2 years)
- 10/05-06/07 Mentor
Eli Lilly Research Fund
"A Retrospective Review of Olanzapine Levels in a State Hospital"
Principal Investigator: Sheila Botts, Pharm.D.
(\$20,000 of direct costs for 1 year)
- 08/07-07/10 Co-investigator
National Institute of Health SBIR Phase II grant (2R44MH073291-02)
"DNA Diagnostics for Minimizing Metabolic Side Effects of Antipsychotics"
Principal Investigator: Gualberto Ruaño, MD, Ph.D., Genomas, Inc.
(\$146,929 of direct costs for Dr. de Leon's subcontract)

COLLABORATIONS WITH UK RESEARCHERS:

- 1996-2005 Peter Wedlund, Ph.D.
Associate Professor, Pharmaceutical Sciences
College of Pharmacy
Field of expertise: drug metabolism and genotyping of cytochrome P450
Collaborative projects focused on
- 1) the cost effectiveness of using the Gene Chip in psychiatry to predict drug response; and
 - 2) genetic and environmental influences in metabolism of atypical antipsychotics and their relationship to therapeutic outcome
- Outcome of collaboration: 11 articles, 1 letter to editor and 4 posters
- 1996-2011 Peter Crooks, Ph.D.
George A. Digenis Professor in Drug Design and Discovery
College of Pharmacy
Field of expertise: nicotine metabolism
Collaborative projects focused on:
- 1) differences in nicotine (and caffeine) metabolism in different races and in psychiatric patients versus the normal population; and
 - 2) CNS versus peripheral nicotine metabolism in humans
- Outcome of collaboration: 6 articles, 1 letter to editor and 1 poster.
- 2015-present Betsy McCollum, Pharm.D.
Pharmacy
Eastern State Hospital
Field of expertise: clinical pharmacology
Current collaborative projects focus on: unusual patients
Outcome of collaboration: 4 articles, and 2 letters to editor.

COLLABORATIONS WITH US COMPANIES:

- 2005-2011 Gualberto Ruaño M.D., Ph.D.
CEO, Genomas
Hartford, CT
Field of expertise: pharmacogenetic testing and metabolic syndrome
Collaborative projects focused on pharmacogenetic testing of the metabolic syndrome.
Outcome of collaboration: 1 NIH grant, 5 articles, and 1 poster.

COLLABORATIONS AS SENIOR INVESTIGATOR WITH SPANISH RESEARCHERS:

- 1991-1996 Victor Peralta, M.D. and Manuel Cuesta, M.D.
 h-index of 45 in September 2019 at ResearchGate
 Psychiatrists, Hospital Virgen del Camino
 Pamplona, Spain
 Outcome of collaboration: 14 articles and 3 posters
 Since 1996, Drs. Peralta and Cuesta have continued publishing independently.
 Focus of collaborative projects was on symptomatology in schizophrenia
- 1992-present Manuel Gurpegui, M.D.
 Retired from being Professor and Chairman
 Department of Psychiatry, School of Medicine
 University of Granada
 Granada, Spain
 Outcome of collaboration: 10 articles & 1 letter in PubMed, 2 other articles,
 1 abstract and 1 video
 Current focus of collaborative projects is on mental illness and nicotine addiction.
- 2004-2022 "Psychiatry and Neurosciences Research Group" (CTS-549)
 was established by the University of Granada, making the collaboration official.
- 1993-1995 Jorge Muñoz, M.D.
 Director, Department of Psychiatry
 Colegio Virgen de Lourdes (School for the Mentally Retarded)
 Majadahonda
 Madrid, Spain
 Outcome of collaboration: 1 letter to editor
- 1994-present Enrique Baca-Garcia, M.D.
 h-index of 41 in September 2019 at ResearchGate
 Department of Psychiatry, Fundacion Jimenez Diaz
 Madrid, Spain
 Outcome of collaboration: 2 NARSAD Young Investigator Awards, 3 small
 Spanish grants, 40 articles in PubMed, 1 editorial,
 1 other article, 4 letters to editor and 14 posters.
 His first NARSAD was the first NARSAD awarded to a researcher in Spain.
 Current focus of collaborative projects is on:
- 1) influence of sexual hormones on female suicide
 - 2) pharmacogenetics of suicide
 - 3) impulsivity and suicide
 - 4) pharmacogenetics of antipsychotic response

- 1996-present Ana Gonzalez-Pinto, M.D.
h-index of 47 in September 2019 at ResearchGate
Research Psychiatrist
Department of Psychiatry, Hospital Santiago Apostol, Vitoria, Spain
Outcome of collaboration: 9 articles, 1 letter to editor, 1 oral presentation and 5 posters.
Current focus of collaborative projects is on clinical studies in bipolar disorder including nicotine addiction.
- 2013-present This collaboration was formalized by including me in the research group funded by the Spanish government: Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain
- 2001-2003 Elisardo Becoña, Ph.D.
Department of Clinical Psychology and Psychobiology, School of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Outcome of collaboration: 2 articles.
Focus of collaborative projects was on nicotine dependence.
- 2001-2006 Cristina Pinet, M.D.
Addiction Unit, Department of Psychiatry, Hospital de la Santa Creu i Santa Pau, Barcelona, Spain
Outcome of collaboration: 1 article.
Focus of collaborative projects was on nicotine dependence.
- 2007-2010 Monica Pérez-Ríos, Ph.D.
Directorate-General for Public Health, Galician Regional Health Authority. Santiago de Compostela. Spain.
Outcome of collaboration: 1 article.
Focus of collaborative projects was on nicotine dependence.
- 2008-present Manuel Arrojo, M.D.
Department of Psychiatry, Complejo Hospitalario Universitario, Santiago de Compostela, Spain.
Outcome of collaboration: 5 articles and 2 letter to editor.
Current focus of collaborative projects is on pharmacological treatment of refractory psychosis.
- 2009-present Benedicto Crespo-Facorro, M.D.
Department of Psychiatry
University Hospital Marqués de Valdecilla
University of Cantabria, Santander, Spain
Outcome of collaboration: 5 articles
Current focus of collaborative projects is on pharmacological treatment of first psychotic episode.

- 2009-present Hilario Blasco Fontecilla
h-index of 21 September 2019 at ResearchGate
- 2009-2011 Department of Psychiatry, Fundacion Jimenez Diaz
Madrid, Spain
- 2011-present Villalba Mental Health Center, Collado Villalba, Madrid, Spain
Department of Psychiatry, Puerta de Hierro Hospital, Madrid, Spain
Outcome of collaboration: 16 articles, 2 editorials, 3 letters to the editor and 1 poster.
Current focus of collaborative projects is on:
1) suicide
2) psychopharmacology
- 2015-present Fernando Lana, M.D.
Institut de Neuropsiquiatria i Addicions,
Centre Emili Mira,
Parc de Salut Mar,
Universidad Autónoma de Barcelona,
Barcelona, Spain
Outcome of collaboration: 3 articles and 1 letter to editor.
Current focus of collaborative projects is on the drug-drug interaction between valproate and ibuprofen.
- 2016-present Carlos De las Cuevas, M.D.
Department of Internal Medicine, Dermatology and Psychiatry,
University of La Laguna,
Canary Islands,
Spain
Outcome of collaboration: 20 articles, 5 editorials and 4 letters to the editor
Current focus of collaborative projects are on: 1) drug adherence in psychiatric patients and 2) pharmacoepidemiology of clozapine.

COLLABORATION AS SENIOR INVESTIGATOR WITH COLOMBIAN RESEARCHERS:

- Francisco J. Diaz, Ph.D.
h-index of 32 in September 2019 at ResearchGate
- 1999-2002 UK Mental Health Research Center
Lexington, KY
- 2003-2009 Department of Statistics
Science School, Universidad Nacional
Medellin, Colombia
- 2009-present Department of Biostatistics
The University of Kansas Medical Center
Kansas City, KS
Outcome of collaboration: 57 articles, 1 editorial, 4 letters to editor and 3 posters
Dr. Diaz is the main statistician collaborating with Dr. de Leon.
- 2005-2007 Adalberto Campo-Arias, M.D.
Neuropsychiatry Research Group,
Universidad Autónoma de Bucaramanga (UNAB),
Bucaramanga, Colombia
Outcome of collaboration: 1 poster and 1 article on mental illness and nicotine addiction.

INTERNATIONAL COLLABORATIONS IN OTHER COUNTRIES:

- 2004-2005 Henri Chabrol, M.D.,
Centres d'Etude et de Recherche en Psychopathologie,
Université de Toulouse-Le Mirail,
Toulouse, France.
Outcome of collaboration: 1 article on nicotine dependence.
- 2005-2012 Maria J. Arranz, Ph.D.,
Clinical Neuropharmacology,
Division of Psychological Medicine,
Institute of Psychiatry-King's College
London, United Kingdom.
Current focus of collaborative projects is on antipsychotic pharmacogenetics.
Outcome of collaboration: 7 articles.
- 2006-present Edoardo Spina, M.D., Ph.D.
Section of Pharmacology,
Department of Clinical and Experimental Medicine and Pharmacology,
University of Messina
and IRCCS Centro Neurolesi "Bonino-Pulejo",
Messina, Italy.
Current focus of collaborative projects is on antipsychotic pharmacokinetics and
drug-drug interactions.
Outcome of collaboration: 30 articles, 3 editorials and 1 letter to editor.
- 2010-2012 Victor Voicu, M.D.
Department of Clinical Pharmacology, Toxicology and Psychopharmacology
University of Medicine and Pharmacy Carol Davila
Bucharest, Romania.
Focus of collaborative projects is on pharmacokinetics.
Outcome of collaboration: 1 article.
- 2011-present Chin Eap, Ph.D.
Unit of Pharmacogenetics and Clinical Psychopharmacology,
Centre for Psychiatric Neurosciences, Department of Psychiatry,
Lausanne University, Hospital of Cery, Prilly-Lausanne
School of Pharmaceutical Sciences,
University of Geneva, University of Lausanne, Geneva.
Switzerland.
Current focus of collaborative projects is on pharmacogenetics.
Outcome of collaboration: 4 articles.

- 2014-present Can-Jun Ruan, Ph.D.
Laboratory of Clinical Psychopharmacology,
Beijing Key Laboratory of Mental Disorders,
Beijing Anding Hospital, Capital Medical University,
Beijing, China
Current focus of collaborative projects is on psychopharmacology,
particularly on clozapine.
Outcome of collaboration: 15 articles, 4 editorials and 1 letter to editor
2019 NARSAD Young Investigator Award (Confirming in 1000 Chinese
Inpatients that Around 4% are Clozapine Poor Metabolizers and Studying Them
with CYP1A2 Gene DNA Sequencing). The funding had to be returned to
NARSAD.
- Yi-Lang Tang, M.D., Ph.D.
Department of Psychiatry and Behavioral Sciences,
Emory University School of Medicine,
Atlanta, GA
Outcome of collaboration: 12 articles
- 2015-present Trino Baptista, M.D., Ph.D.
Department of Medical Physiology,
Los Andes University Medical School,
Mérida, Venezuela.
Current focus of collaborative projects is on clozapine.
Outcome of collaboration: 7 articles, 2 editorial and 3 letters to editor.
- 2016-present Christoph Hiemke, Ph.D.
Department of Psychiatry and Psychotherapy,
University Medical Center of Mainz,
Germany.
Current focus of collaborative projects is on therapeutic drug monitoring.
Outcome of collaboration: 6 articles.
- 2017-present Georgios Schoretsanitis, M.D.
Before University Hospital of Psychiatry, Bern, Switzerland,
Currently Zucker Hillside Hospital, Psychiatry Research,
Northwell Health, Glen Oaks, NY;
Hofstra Northwell School of Medicine, Hempstead, NY;
Feinstein Institute for Medical Research, Manhasset, NY, USA.
Current focus of collaborative projects is on therapeutic drug monitoring.
Outcome of collaboration: 16 articles, 3 editorials and 4 letters to editor.

2018-present Mariano Motuca, M.D.,
Instituto Vilapriño,
Center for Studies, Assistance and Research in Neurosciences,
Mendoza, Argentina
Current focus of collaborative projects is on clozapine.
Outcome of collaboration: 6 articles and 1 editorial.

MAIN CONTRIBUTIONS

Dr. de Leon's most important scientific contributions to the literature include demonstrating: 1) that the association between smoking and schizophrenia is present worldwide, and may be partly explained by shared vulnerability; 2) the association of polydipsia with smoking and schizophrenia in patients with severe mental illness; 3) that CYP3A4 inducers and the CYP2D6 poor metabolizer phenotype may influence risperidone pharmacokinetics and response; 4) valproate's inductive properties for valproate, olanzapine and clozapine metabolism, 5) that a small number of psychiatric patients behave as ultrarapid metabolizers due to genetic or drug-drug interactions and need high doses of atomoxetine, risperidone, clozapine, valproate or lamotrigine, or have unusual responses due to activation of hydrocodone, oxycodone or diphenhydramine, and 6) clozapine metabolism is influenced by ethnicity (Asians have lower ability to metabolize clozapine than Caucasians) and is impaired during pneumonia, which is particularly lethal in clozapine patients. In 2022, he published an international clozapine titration guideline with a total of 104 authors from 50 countries/regions.

PUBLICATIONS ORCID 0000-0002-7756-2314

A) 417 ARTICLES AND LETTERS TO EDITOR INCLUDED IN PUBMED:

(313 articles, 36 editorials and 68 letters to editor).

Research Gate (<https://www.researchgate.net>) offers information similar to the better established Institute of Scientific Information (ISI), which calculates the impact factor of articles. Research Gate includes more articles than ISI and can be freely accessed after registration. Hirsch (PNAS 102:16569-72, 2005) proposed the "h" index to summarize a researcher's articles. According to ResearchGate in February of 2023 (<https://www.researchgate.net/profile/Jose-De-Leon-8>), Dr. de Leon's scientific publications have been cited more than 19,000 times, and have had more than 104,000 reads. He has an h-index of 71 (he has at least 71 articles with ≥ 71 citations). Many of his articles are freely available at ResearchGate.

1. Chinchilla-Moreno A, **de Leon Molina J**, Morales-Socorro MP, Gonzalez Pinto-Arrillaga A, Dios-Perrino C de, Martin-Carrasco M. Interconsultation in an outpatient department: study of demand (in Spanish). Actas Luso-Españolas de Neurologia, Psiquiatria y Ciencias Afines 13(5):266-275, 1985. PMID: 4096281.
2. **de Leon Molina J**, Gobernado-Serrano JM. Disturbances of emotional function in neurology (in Spanish). Medicina Clinica 88(10):423-430, 1987. PMID: 3553763.
3. **de Leon J**, Saiz-Ruiz J, Ayuso-Gutierrez JL. Depression on an organic basis (in Spanish). Medicina Clinica 88(6):252-255, 1987. PMID: 3561062.
4. **de Leon J**, Saiz-Ruiz J, Chinchilla A, Morales P. Why do some psychiatric patients somatize? Acta Psychiatrica Scandinavica 76(2):203-209, 1987. PMID: 3673644.
5. **Leon J de**, Mauri JA, Medrano M, Gobernado J, Saiz-Ruiz J, O'Neill A. Pathological crying and affective incontinence: therapeutical importance of their distinction (in Spanish). Revista de Medicina de la Universidad de Navarra 32(3):149-152, 1988. PMID: 3238248.

6. **de Leon J**, Bott A, Simpson G M. Dymorphophobia: Body dysmorphic disorder or delusional disorder, somatic subtype? Comprehensive Psychiatry 30(6):457-472, 1989. PMID: 2684497.
7. Simpson GM, **de Leon J**. Tyramine and new monoamine oxidase inhibitor drugs. British Journal of Psychiatry 155, Supplement 6:32-37, 1989. PMID: 2695125.
8. **de Leon J**, Wilson WH, Simpson GM. Measurement of negative symptoms in schizophrenia. Psychiatric Developments 7(3):211-234, 1989. PMID: 2700801.
9. **de Leon J**. Atypical psychoses (letter to the editor). Comprehensive Psychiatry (4):355, 1989. PMID: 2818734.
10. **de Leon J**, Saiz-Ruiz J, Alonso-Abolafia A, Pica-Soler E, Muñoz-Ruata J, Serna I de. Neuroleptic-induced catatonia: Neuroleptic malignant syndrome? Progress in Neuro-Psychopharmacology & Biological Psychiatry 14(1):129-136, 1990. PMID: 1967846.
11. Vitiello B, **de Leon J**. Dymorphophobia misdiagnosed as obsessive-compulsive disorder. Psychosomatics 31(2):220-222, 1990. PMID: 2330405.
12. **de Leon J**, Moral L, Camuñas C. Clozapine and jaw dyskinesia: A case report. Journal of Clinical Psychiatry 52(2):494-495, 1991. PMID: 14709959.
13. Peralta V, Cuesta MJ, **de Leon J**. Premorbid personality and positive and negative symptoms in schizophrenia. Acta Psychiatrica Scandinavica 84(4):336-339, 1991. PMID: 1746284.
14. **de Leon J**, Wilson W, Simpson GM. Negative symptoms, defect state and Huber's basis symptoms: A comparison of the concepts. Psychiatric Quarterly 62(4):277-298, 1991. PMID: 1809980.
15. Peralta V, Cuesta MJ, **de Leon J**. A study of the interrater reliability of the schizophrenic negative symptoms (in Spanish). Actas Luso-Españolas de Neurologia, Psiquiatria y Ciencias Afines 19(4):221-225, 1991. PMID: 1957714.
16. **de Leon J**, Simpson GM, Peralta V. Positive and negative symptoms in schizophrenia: Where are the data? (editorial). Biological Psychiatry 31(5):431-434, 1992. PMID: 1349829.

17. Peralta V, **de Leon J**, Cuesta MJ. Are there more than two syndromes in schizophrenia: A critique of the positive-negative dichotomy. British Journal of Psychiatry 161:335-343, 1992. PMID: 1356572. *In May of 2022, according to ResearchGate there were more than 300 citations of this article.* pdf available at https://www.researchgate.net/publication/21798282_Are_there_more_than_two_syndromes_in_schizophrenia_A_critique_of_positiva-negative_dichotomy
18. Verghese C, **de Leon J**, Simpson GM. Clozapine treatment of polydipsia: a prolactin connection? (letter to the editor). Journal of Clinical Psychopharmacology 12(3):218-219, 1992. PMID: 1445577.
19. Peralta V, Cuesta MJ, **de Leon J**. Formal thought disorder in schizophrenia: A factor analytic study. Comprehensive Psychiatry 33(2):105-110, 1992. PMID: 1544294.
20. **de Leon J**, Antelo RE, Simpson GM. Delusion of parasitosis or chronic tactile hallucinosis: Hypothesis about their brain physiopathology. Comprehensive Psychiatry 33(1):25-33, 1992. PMID: 1555406.
21. Peralta V, Cuesta MJ, **de Leon J**. Positive versus negative schizophrenia and basic symptoms. Comprehensive Psychiatry 33(3):202-206, 1992. PMID: 1591913.
22. **de Leon J**, Pino Morales M, Alonso A, de la Serna I. Neuropsychological findings in a case of malingering (in Spanish). Actas Luso-Españolas de Neurología, Psiquiatría y Ciencias Afines 21(4):127-130, 1993. PMID: 8105641.
23. Verghese C, **de Leon J**, Simpson GM. Neuroendocrine factors influencing polydipsia in psychiatric patients: an hypothesis. Neuropsychopharmacology 9(2):157-166, 1993. PMID: 8105791. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/8105791>
24. **de Leon J**, Cuesta MJ, Peralta V. Delusions and hallucinations in schizophrenic patients. Psychopathology 26(5-6):286-291, 1993. PMID: 8190849.
25. **de Leon J**, Ellis G, Rosen P, Simpson GM. The test-retest reliability of the Mini Mental State Examination in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 88(3):188-192, 1993. PMID: 8249651.
26. **de Leon J**, Peralta V, Cuesta MJ. Negative symptoms and emotional blunting in schizophrenic patients. Journal of Clinical Psychiatry 54(3):103-108, 1993. PMID: 8468308.
27. Peralta V, Cuesta MJ, **de Leon J**. An empirical analysis of latent structures underlying schizophrenic symptoms: A four-syndrome model. Biological Psychiatry 36(11):726-736, 1994. PMID: 7858068.

28. Cuesta MJ, Peralta V, **de Leon J**. Schizophrenic syndromes associated with treatment response. Progress in Neuro-Psychopharmacology & Biological Psychiatry 18(1):87-99, 1994. PMID: 7906897.
29. Verghese C, **de Leon J**, Simpson GM. Polydipsia, tardive dyskinesia and dopamine supersensitivity (letter to the editor). American Journal of Psychiatry 151(11):1716-1717, 1994. PMID: 7943468.
30. **de Leon J**, Verghese C, Tracy J, Josiassen R, Simpson GM. Polydipsia and water intoxication in psychiatric patients: A review of the epidemiological literature. Biological Psychiatry 35(6):408-419, 1994. PMID: 8018788. *In May of 2022, according to ResearchGate there were more than 250 citations of this article.*
31. **de Leon J**, Stanilla JK, White AO, Simpson GM. Anticholinergics to treat clozapine withdrawal (letter to the editor). Journal of Clinical Psychiatry 55(3):119-120, 1994. PMID: 8071251.
32. **de Leon J**, Canuso C, White AO, Simpson GM. A pilot effort to determine benzotropine equivalents of anticholinergic medications. Hospital and Community Psychiatry 45(6):606-607, 1994. PMID: 8088744.
33. Abraham G, Friedman RH, Verghese C, **de Leon J**. Osteoporosis and schizophrenia: Can we limit known risk factors? (letter to the editor). Biological Psychiatry 38(2):131-132, 1995. PMID: 7578648.
34. White AO, **de Leon J**, Stanilla JK, Cloud BS, Simpson GM. Misidentification syndromes in schizophrenia: Case reviews with implications for classification and prevalence. Australian and New Zealand Journal of Psychiatry 29(1):63-68, 1995. PMID: 7625978.
35. Cuesta M, Peralta V, Caro F, **de Leon J**. Is poor insight in psychotic disorders associated with poor performance on the Wisconsin Card Sorting Test? American Journal of Psychiatry 152(9):1380-1382, 1995. PMID: 7653699.
36. Büchel C, **de Leon J**, Gattaz WF, Simpson GM. Oral tardive dyskinesia: Validation of a measuring device using digital image processing. Psychopharmacology 117(2):162-165, 1995. PMID: 7753962.
37. **de Leon J**, Verghese C, Stanilla JK, Lawrence T, Simpson GM. Treatment of polydipsia and hyponatremia in psychiatric patients: Can clozapine be a new option? Neuropsychopharmacology 12(2):133-138, 1995. PMID: 7779241. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/7779241>

38. Peralta V, Cuesta MJ, **de Leon J**. Positive and negative symptoms/syndromes in schizophrenia: Reliability and validity of different diagnostic systems. Psychological Medicine 25(1):43-50, 1995. PMID: 7792361.
39. **de Leon J**, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: An epidemiological survey in a state hospital. American Journal of Psychiatry 152(3):453-455, 1995. PMID: 7864277. *In May of 2022, according to ResearchGate there were more than 400 citations of this article.*
40. Cuesta M, Peralta V, Caro F, **de Leon J**. Schizophrenic syndrome and Wisconsin Card Sorting Test dimensions. Psychiatry Research 58(1):45-51, 1995. PMID: 8539311.
41. White AO, **de Leon J**. Clozapine levels and caffeine (letter to the editor). Journal of Clinical Psychiatry 57(4):175-176, 1996. PMID: 8601555.
42. **de Leon J**, Henighan V, Stanilla JK, Simpson GM. Clozapine levels after clozapine discontinuation (letter to the editor). Journal of Clinical Psychopharmacology 16(2):193-194, 1996. PMID: 8690839.
43. Verghese C, **DeLeon J**, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biological Psychiatry 39(2):135-138, 1996. PMID: 8717612.
44. Mueser KT, Doonan R, Penn DL, Blanchard JJ, Bellack AS, Nishith P, **DeLeon J**. Emotion recognition and social competence in chronic schizophrenia. Journal of Abnormal Psychology 105(2):271-275, 1996. PMID: 8723008. *In May of 2022, according to ResearchGate there were more than 350 citations of this article.*
45. Stanilla JK, Büchel C, Alarcon J, **de Leon J**, Simpson GM. Diurnal and weekly variation of tardive dyskinesia measured by digital image processing. Psychopharmacology 124(4):373-376, 1996. PMID: 8739553.
46. **de Leon J**, Dadvand M, Canuso C, Odom-White A, Stanilla JK, Simpson GM. Polydipsia and water intoxication in a long-term psychiatric hospital. Biological Psychiatry 40(1):28-34, 1996. PMID: 8780852.
47. Cuesta M, Peralta V, Caro F, **de Leon J**. Neurological frontal signs and neuropsychological deficits in schizophrenic patients. Schizophrenia Research 20(1-2):15-20, 1996. PMID: 8794489.
48. Tracy J, **de Leon J**, Querishi G, McCann E, McGrory A, Josiassen R. Repetitive behaviors in schizophrenia: a single disturbance or discrete symptoms?. Schizophrenia Research 20(1-2):221-229, 1996. PMID: 8794513.

49. **de Leon J.** Smoking and vulnerability for schizophrenia (editorial). Schizophrenia Bulletin 22(3):405-409, 1996. PMID: 8873291. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/8873291>
50. Verghese C, **de Leon J**, Josiassen R. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophrenia Bulletin 22(3):455-464, 1996. PMID: 8873296. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/8873296>
51. **de Leon J**, Pearlman O, Doonan R, Simpson GM. A study of bedside screening procedures for cognitive deficits in chronic psychiatric inpatients. Comprehensive Psychiatry 37(5):328-336, 1996. PMID: 8879907.
52. Tracy JI, **de Leon, J**, Doonan R, Musciante J, Ballas T, Josiassen RC. Clock drawing in schizophrenia. Psychological Reports 79(3 Pt 1):923-928, 1996. PMID: 8969101.
53. Stanilla JK, **de Leon J**, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: A report of three cases. Journal of Clinical Psychiatry 58(6):252-255, 1997. PMID: 9228890.
54. **de Leon J**, Bork JA. Risperidone and the cytochrome P450 3A (letter to the editor). Journal of Clinical Psychiatry 58(10):450, 1997. PMID: 9375597.
55. Tracy J, Nematbakhsh A, **de Leon J**, McCann E, McGrory, Querishi G, Josiassen R. A comparison of polydipsia prevalence among chronic psychiatric patients using three measurement approaches. Biological Psychiatry 42(12):1097-1104, 1997. PMID: 9426879.
56. Pinninti NR, **de Leon J**. Interaction of sertraline with clozapine (letter to the editor). Journal of Clinical Psychopharmacology 17(2):119-120, 1997. PMID: 10950477.
57. Baca-Garcia E, Gonzalez Diaz-Corralero P, Sanchez Gonzalez A, Gonzalez Garcia I, **de Leon J**. Menstrual cycle and profiles of suicidal behavior. Acta Psychiatrica Scandinavica 97(1):32-35, 1998. PMID: 9504700.
58. Gonzalez-Pinto A, Gutierrez M, **Leon J**, Mosquera F, Figuerido JL, Elizagarate E, Revuelta B. Smoking in a psychiatric population (in Spanish). Actas Luso-Españolas de Neurologia, Psiquiatria y Ciencias Afines 26(1):48-50, 1998. PMID: 9549135.
59. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, Aizpuru F, Mosquera F, Lopez P, **de Leon J**. Tobacco smoking and bipolar disorder. Journal of Clinical Psychiatry 59(5):225-228, 1998. PMID: 9632031.
60. Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J, Figuerido JL, **de Leon J**. First episode in bipolar disorder: Misdiagnosis and psychotic symptoms. Journal of Affective Disorders 50(1):41-44, 1998. PMID: 9716278.

61. Verghese C, Abraham G, Nair C, Stanilla JK, **de Leon J**, Phillips MI, Simpson GM. Absence of changes in antidiuretic hormone, angiotensin II and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: Two case reports. Journal of Clinical Psychiatry 59(8):415-419, 1998. PMID: 9721821.
62. **de Leon J**, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund P. A pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. American Journal of Psychiatry 155(9):1278-1280, 1998. PMID: 9734555.
63. **de Leon J**, Baca-Garcia E, Simpson GM. A factor analysis of the Mini-Mental State Examination in schizophrenic disorders. Acta Psychiatrica Scandinavica 98(5):366-368, 1998. PMID: 9845174.
64. Baca-Garcia E, Stanilla JK, Büchel C, Gattaz WF, **de Leon J**. Diurnal variability of oro-facial dyskinetic movements. Pharmacopsychiatry 32(2):73-75, 1999. PMID: 10333166.
65. Rogers T, **de Leon J**, Atcher D. Possible interaction between warfarin and quetiapine (letter to the editor). Journal of Clinical Psychopharmacology 19(4):382-383, 1999. PMID: 10440472.
66. Bork J, Rogers T, Wedlund P, **de Leon J**. A pilot study on risperidone metabolism: The role of cytochrome P450 2D6 and 3A. Journal of Clinical Psychiatry 60(7):469-476, 1999. PMID: 10453802.
67. Cooke C, **de Leon J**. Adding other antipsychotics to clozapine (letter to the editor). Journal of Clinical Psychiatry 60(10):710, 1999. PMID: 10549694.
68. Simpson GM, Josiassen RC, Stanilla JK, **de Leon J**, Nair C, Abraham G, Odom-White A, Turner RM. Double-blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry 156(11):1744-1750, 1999. PMID: 10553738.
69. Durrenberger S, **de Leon J**. Acute dystonic reaction to lithium and risperidone (letter to the editor). Journal of Neuropsychiatry and Clinical Neurosciences 11(4):518-519, 1999. PMID: 10570771.
70. Durrenberger S, Rogers T, Walker R, **de Leon J**. Economic grand rounds: the high costs of care for four patients with mania who were not compliant with treatment. Psychiatric Services 50(12):1539-1542, 1999. PMID: 10577867.
71. Baca-Garcia E, Diaz-Sastre C, **de Leon J**, Saiz-Ruiz J. The relationship between the menstrual cycle phases and suicide attempts. Psychosomatic Medicine 62(1):50-60, 2000. PMID: 10705911.

72. Chou, WH, Yan FX, **de Leon J**, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder T, Liu WW, Teiling C, Wedlund PJ. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcomes and costs associated with severe mental illness. Journal of Clinical Psychopharmacology 20(2):246-251, 2000. PMID: 10770465. *In May of 2022, according to ResearchGate there were more than 200 citations of this article.*
73. Ghosheh AO, Browne D, Rogers T, **de Leon J**, Dwoskin LP, Crooks PA. A simple high performance liquid chromatographic method for the quantification of total cotinine, total 3'-hydroxycotinine and caffeine in the plasma of smokers. Journal of Pharmaceutical and Biomedical Analysis 23(2-3):543-549, 2000. PMID: 10933548
74. Baca-Garcia E, Diaz-Sastre C, Saiz-Ruiz J, **de Leon J**. Influence of psychiatric diagnoses on the relationship between suicide attempts and the menstrual cycle (letter to the editor). Psychosomatic Medicine 63(3):509-510, 2001. PMID: 11382281.
75. Baca-Garcia E, Diaz-Sastre C, Basurte E, Prieto R, Ceverino A, Saiz-Ruiz J, **de Leon J**. A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. Journal of Clinical Psychiatry 62(7):560-564, 2001. PMID: 11488369.
76. Lopez P, Mosquera F, **de Leon J**, Gutierrez M, Ezcurra J, Ramirez F, Gonzalez-Pinto A. Suicide attempts in bipolar patients. Journal of Clinical Psychiatry 62(12):963-966, 2001. PMID: 11780877.
77. Wedlund PJ, **de Leon J**. Pharmacogenetic testing: The cost factor. The Pharmacogenomics Journal 1(3):171-174, 2001. PMID: 11908752.
78. Baca-Garcia E, Vaquero C, Diaz-Sastre C, Ceverino A, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J**. A gender-specific association between the serotonin transporter gene and suicide attempts. Neuropsychopharmacology 26(5):692-695, 2002. PMID: 11927194 pdf available <http://www.ncbi.nlm.nih.gov/pubmed/11927194>
79. **de Leon J**, Diaz FJ. Smoking in bipolar and schizophrenic patients (letter to the editor). Journal of Clinical Psychiatry 63(4):368, 2002. PMID: 12000214.
80. **de Leon J**, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophrenia Research 56(1-2):47-54, 2002. PMID: 12084419.
81. **de Leon J**, Tracy J, McCann E, McGrory A, Diaz FJ. Schizophrenia and tobacco smoking: A replication study in another US psychiatric hospital. Schizophrenia Research 56(1-2):55-65, 2002. PMID: 12084420.

82. **de Leon J**, Tracy J, McCann E, McGrory A. Polydipsia and schizophrenia in a psychiatric hospital: A replication study. Schizophrenia Research 57(2-3):293-301, 2002. PMID: 12223261.
83. **de Leon J**, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, Dwoskin LP, Crooks P A. Total cotinine in plasma: A stable biomarker for exposure to tobacco smoke. Journal of Clinical Psychopharmacology 22(5):496-501, 2002. PMID: 12352273.
84. **de Leon J**, Becoña E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. Journal of Clinical Psychiatry 63(9):812-816, 2002. PMID: 12363123.
85. Diaz FJ, **de Leon J**. Excessive antipsychotic dosing in two U.S. state hospitals. Journal of Clinical Psychiatry 63(11):998-1003, 2002. PMID: 12444813.
86. Baca-Garcia E, Diaz-Sastre C, Saiz-Ruiz J, **de Leon J**. How safe are psychiatric medications after a voluntary overdose? European Psychiatry 17(8):466-470, 2002. PMID: 12504263.
87. LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz F, **de Leon J**. Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophrenia Research 60(2-3):313-317, 2003 (this is a corrected version of 58(2-3):323-327, 2002). PMID: 12409173.
88. **de Leon J**, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh O, Dwoskin LP, Crooks P. A pilot study of plasma caffeine concentrations in a US sample of smoker and non-smoker volunteers. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27(1):165-171, 2003. PMID: 12551740.
89. **de Leon J**, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh O, Dwoskin LP, Crooks P. Plasma cotinine, 3'-hydroxycotinine and their glucuronides in white and black smokers (letter to the editor). Journal of Clinical Psychopharmacology 23(2):209-211, 2003. PMID: 12640226.
90. Chou, WH, Yan FX, , Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, **de Leon J**, Koch WH, Wedlund PJ. Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships. Clinical Chemistry 49(4):542-551, 2003. PMID: 12651805.
pdf available <http://www.ncbi.nlm.nih.gov/pubmed/12651805>
91. Baca-Garcia E, Diaz-Sastre C, Ceverino A, Saiz-Ruiz J, Diaz FJ, **de Leon J**. An association between the menses and suicide attempts: a replication study. Psychosomatic Medicine 65(2):237-244, 2003. PMID: 12651991.

92. **de Leon J.** Polydipsia: A study in a long-term psychiatric unit. European Archives of Psychiatry and Clinical Neurosciences 253(1):37-39, 2003. PMID: 12664312.
93. **de Leon J.** Glucuronidation enzymes, genes and psychiatry. International Journal of Neuropsychopharmacology 6(1):57-72, 2003. PMID: 12899737.
94. Diaz FJ, Baca-Garcia E, Diaz-Sastre C, Garcia Resa E, Blasco H, Braquehais Conesa D, Saiz-Ruiz J, **de Leon J.** Dimensions of suicidal behavior according to patient reports. European Archives of Psychiatry and Clinical Neurosciences 253(4):197-202, 2003. PMID: 12910351.
95. **de Leon J,** Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Antimuscarinic activity during clozapine treatment. Journal of Clinical Psychopharmacology 23(4):336-341, 2003. PMID: 12920408.
96. **de Leon J,** Dinsmore L, Wedlund PJ. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers (letter to the editor). Journal of Clinical Psychopharmacology 23(4):420-421, 2003. PMID: 12920424.
97. **de Leon J,** Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27(6):1059-1063, 2003. PMID: 14499324.
98. **de Leon J,** Diaz FJ, Becoña E, Gurpegui M, Jurado D, Gonzalez-Pinto A. Exploring brief measures of nicotine dependence for epidemiological surveys. Addictive Behaviors 28(8):1481-1486, 2003. PMID: 14512071.
99. **de Leon J,** Simpson GM. Postmortem clozapine levels (letter to the editor). Journal of Clinical Psychopharmacology 24(1):100-101, 2004. PMID: 1470995.
100. Baca-Garcia E, Vaquero C, Diaz-Sastre C, Ceverino A, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J.** A pilot study on a gene-hormone interaction in female suicide attempts. European Archives of Psychiatry and Clinical Neurosciences 253(6):281-285, 2003. PMID: 14714116.
101. Baca-Garcia E, Vaquero C, Diaz-Sastre C, Garcia-Resa E, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J.** Lack of association between polymorphic variations in the $\alpha 3$ subunit GABA receptor gene (GABRA3) and suicide attempts. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28(2):409-412, 2004. PMID: 14751442.
102. **de Leon J.** Psychopharmacology. Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants. Psychiatric Services 55(2):125-128, 2004. PMID: 14762234.

103. Wedlund PJ, **de Leon J**. Cytochrome P450 2D6 and antidepressant toxicity and response: What is the evidence? Clinical Pharmacology and Therapeutics 75(5):373-375, 2004. PMID: 15116048.
104. Baca-Garcia E, Diaz-Sastre C, Garcia-Resa E, Ceverino A, Ramirez A, Saiz-Ruiz J, **de Leon J**. Lack of association between plasma apolipoprotein E and suicide attempts (letter to the editor). Journal of Clinical Psychiatry 65(4):580, 2004. PMID: 15119924.
105. Baca-Garcia E, Vaquero C, Diaz-Sastre C, Garcia-Resa E, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J**. Lack of association between the serotonin transporter gene polymorphism and impulsivity or aggressive behavior among suicide attempters and healthy volunteers. Psychiatry Research 126(2):99-104, 2004. PMID: 15123389.
106. **de Leon J**. Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatric Services 55(5):491-493, 2004. PMID: 15128955.
107. Coffey G, Botts S, **de Leon J**. Dosing differences between valproic acid concentrate and divalproex sodium: A case report (letter to the editor). Journal of Clinical Psychiatry 65(5):724-725, 2004. PMID: 15163266.
108. Baca-Garcia E, Diaz-Sastre C, Garcia Resa E, Blasco H, Braquehais Conesa D, Saiz-Ruiz J, **de Leon J**. Variables associated with hospitalization decisions by emergency psychiatrists after a patient's suicide attempt. Psychiatric Services 55(7):792-797, 2004. PMID: 15232019.
109. Vaquero C, Baca-Garcia E, Diaz-Sastre C, Perez-Rodriguez, MM, Navio-Acosta M, Saiz-Ruiz J, **de Leon J**, Fernandez-Piqueras J. New GABA_A receptor alpha5 subunit gene polymorphism that may confound genotyping. American Journal of Medical Genetics (Neuropsychiatric Genetics) 129B(1):27-28, 2004. PMID: 15274034.
110. Botts S, Littrell R, **de Leon J**. Variables associated with high olanzapine dosing in a state hospital. Journal of Clinical Psychiatry 65(8):1138-1143, 2004. PMID:15323601.
111. **de Leon J**. Respiratory infections rather than antibiotics may increase clozapine levels: A critical review of the literature (letter to the editor). Journal of Clinical Psychiatry 65(8):1144-1145, 2004. PMID: 15323602.
112. **de Leon J**, Diaz FJ, Josiassen RC, Simpson GM. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. European Archives of Psychiatry and Clinical Neurosciences 254(5):318-325, 2004. PMID: 15365707.
113. Baca-Garcia E, Diaz-Sastre C, Ceverino A, Garcia Resa E, Oquendo MA, Saiz-Ruiz J, **de Leon J**. Premenstrual symptoms and luteal suicide attempts. European Archives of Psychiatry and Clinical Neurosciences 254(5):326-329, 2004. PMID: 15365708.

114. **de Leon J**, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. Journal of Clinical Psychopharmacology 24(6):656-660, 2004. PMID: 15538130.
115. Baca-Garcia E, Diaz-Satre C, Garcia Resa E, Blasco H, Braqueis Conesa D, Oquendo MA, Saiz-Ruiz J, **de Leon J**. Suicide attempts and impulsivity. European Archives of Psychiatry and Clinical Neurosciences 255(2):152-156, 2005. PMID: 15549343.
116. Li S, Crooks PA, Wei X, **de Leon J**. Toxicity of dipyridyl compounds and related compounds. Critical Reviews of Toxicology 34(5):447-460, 2004. PMID: 15560568.
117. Diaz FJ, **de Leon J**, Josiassen RC, Cooper TB, Simpson GM. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophrenia Research 72(2-3):131-135, 2005. PMID: 15560958.
118. **de Leon J**, Susce MT, Pan RM, Fairchild M, Koch W, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Journal of Clinical Psychiatry 66(1):15-27, 2005. PMID: 15669884. *In May of 2022, according to ResearchGate there were more than 250 citations of this article.*
119. Diaz FJ, Jané M, Saltó E, Pardell H, Salleras L, Pinet C, **de Leon J**. A brief measure of high nicotine dependence for busy clinicians and large epidemiological surveys. Australian and New Zealand Journal of Psychiatry 39(3):161-168, 2005. PMID: 15701065.
120. Susce MT, Villanueva N, Diaz FJ, **de Leon J**. Obesity and associated complications in patients with severe mental illnesses: A cross sectional survey Journal of Clinical Psychiatry 66(2):167-173, 2005. PMID: 15705001.
121. Aguilar MC, Gurpegui M, Diaz FJ, **de Leon J**. Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions. British Journal of Psychiatry 186:215-221, 2005. PMID: 1573850.
pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/15738502>
122. **de Leon J**. Benztropine equivalents for antimuscarinic medication (letter to the editor). American Journal of Psychiatry 162(3):627, 2005. PMID: 15741492.
123. Diaz-Sastre C, Perez-Rodriguez MM, Cebollada A, Saiz-Ruiz J, Baca-Garcia E, **de Leon J**. Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients (letter to the editor). Journal of Clinical Psychiatry 66(3):399-400, 2005. PMID: 15766315.

124. Baca-Garcia E, Perez-Rodriguez MM, Diaz Sastre C, Saiz-Ruiz J, **de Leon J**. Suicidal behavior in schizophrenia and depression: A comparison. Schizophrenia Research 75(1):77-91, 2005. PMID: 15820326.
125. **de Leon J**, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 46(3):262-273, 2005. PMID: 15883149.
126. Baca-Garcia E, Salgado BR, Segal DH, Lorenzo CV, Acosta MN, Romero MA, Hernández MD, Saiz-Ruiz J, Fernandez Piqueras J, **de Leon J**. A pilot genetic study of the continuum between compulsivity and impulsivity in females: The serotonin transporter promoter polymorphism. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29(5):713-717, 2005. PMID 15908092.
127. Coffey GL, Botts S, **de Leon J**. High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29(5):770-774, 2005. PMID: 15927338.
128. Gurpegui M, Martinez-Ortega JM, Aguilar MC, Diaz FJ, Quintana HM, **de Leon J**. Smoking initiation and schizophrenia: A replication study in a Spanish sample. Schizophrenia Research 76(1):113-118, 2005. PMID: 15927805.
129. **de Leon J**, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research 76(2-3):135-157, 2005. PMID 15949648. *In May of 2021, according to ResearchGate there were more than 1000 citations of this article.*
130. **de Leon J**, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Does clozapine decrease smoking? Progress in Neuro-Psychopharmacology & Biological Psychiatry 29(5):757-762, 2005. PMID: 15951089.
131. Gurpegui M, Aguilar MC, Martinez-Ortega JM, Diaz FJ, **de Leon J**. Caffeine intake in outpatients with schizophrenia. Schizophrenia Bulletin 30(4):935-945, 2004. PMID: 15954199. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/15954199>
132. Chabrol H, Niezborala M, Chastan E, **de Leon, J**. Comparison of the Heaviness of Smoking Index and of the Fagerstrom Test for Nicotine Dependence in a sample of 749 cigarette smokers. Addictive Behaviors 30(7):1474-1477, 2005. PMID: 16022945
133. Sabaawi M, Singh NN, **de Leon J**. Guidelines for the use of clozapine in individuals with developmental disabilities. Research in Developmental Disabilities 27(3): 309-336, 2006. PMID: 16040229.

134. **de Leon J**, Susce MT, Pan RM, Koch W, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6 CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. Journal of Clinical Psychopharmacology 25(5):448-456, 2005. PMID: 16160260.
135. Barnhill J, Susce MT, Diaz FJ, **de Leon J**. Risperidone half-life in a patient taking paroxetine: A case report (letter to the editor). Pharmacopsychiatry 38(5):223-225, 2005. PMID: 16189751.
136. **de Leon J**, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 . Psychosomatics 47(1):75-85, 2006. PMID: 16384813. *In May of 2022, according to ResearchGate there were more than 250 citations of this article.*
137. **de Leon J**, Susce MT, Diaz FJ, Rendon, DM, Velasquez DM. Variables associated with alcohol, drug and daily smoking cessation in patients with severe mental illnesses. Journal of Clinical Psychiatry 66(11):1447-1455, 2006. PMID: 16420083.
138. Campo-Arias A, Díaz-Martínez LA, Rueda-Jaimes GE, Rueda-Sánchez M, Farelo-Palacín D, Diaz FJ, **de Leon J**. Smoking is associated with schizophrenia, but not with mood disorders, within a population with low smoking rates: a matched case-control study in Bucaramanga, Colombia. Schizophrenia Research 83(2-3):269-276, 2006. PMID: 16497482.
139. Cai WM, Nikoloff DM, Pan RM, **de Leon J**, Fanti P, Fairchild M, Koch WH, Wedlund PJ. CYP2D6 genetic variations in healthy adults in psychiatric African-American Subjects: implications for clinical practice and genetic testing. Pharmacogenomics Journal 6(5):343-350, 2006. PMID: 16550211.
140. Diaz FJ, Rendon DM, Velasquez DM, Susce MT, **de Leon J**. Datapoints: smoking and smoking cessation among persons with severe mental illness. Psychiatric Services 57(4):462, 2006. PMID: 16603739.
141. Susce MT, Murray-Carmichel E, **de Leon J**. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30(7):1356-1358, 2006. PMID: 16631290.
142. Baca-Garcia E, Oquendo MA, Saiz-Ruiz J, Mann JJ, **de Leon J**. A pilot study of differences in aggression in New York City and Madrid, Spain and their possible impact on suicidal behavior. Journal of Clinical Psychiatry 67(3):375-380, 2006. PMID: 16649822.
143. **de Leon J**. The AmpliChip CYP450 Test: Personalized medicine has arrived in psychiatry. Expert Review in Molecular Diagnosis 6(3):277-286, 2006. PMID: 16706732.

144. Vaquero Lorenzo C, Baca-Garcia E, Diaz Hernandez M, Botillo-Martin C, Perez-Rodriguez MM, Fernandez-Ramos C, Saiz-Gonzalez MD, Quintero-Gutierrez FJ, Saiz-Ruiz J, Fernandez Piqueras J, Gonzalez de Rivera JL, **de Leon J**. Association between the T102C polymorphism of the serotonin-2A receptor gene and schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30(6):1136-1138, 2006. PMID: 16762472.
145. **de Leon J**, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Molecular Diagnosis & Therapy 10(3):135-151, 2006. PMID: 16771600.
146. Gurpegui M., Aguilar MC, Martinez-Ortega JM, Jurado D, Diaz FJ, Quintana HM, **de Leon J**. Fewer but heavier caffeine consumers in schizophrenia: A case-control study. Schizophrenia Research 86(1-3):276-283, 2006. PMID: 16784837.
147. **de Leon J**, Diaz FJ, Aguilar MC, Jurado D, Gurpegui M. Does smoking reduce akathisia?: Testing a narrow version of the self-medication hypothesis. Schizophrenia Research 86(1-3):256-268, 2006. PMID: 16814524.
148. Diaz FJ, Rivera TE, Josiassen RC, **de Leon J**. Individualizing drug dosage by using a random intercept linear model. Statistics in Medicine 26(9): 2052-2073, 2007. PMID: 16847902.
149. Baca-Garcia E, Perez-Rodriguez MM, Basurte-Villamor I, Saiz-Ruiz J, Leiva-Murillo JM, de Prado-Cumplido M, Santiago-Mozos R, Artés-Rodríguez A, **de Leon J**. Using data mining to explore complex clinical decisions: A study of hospitalization after a suicide attempt. Journal of Clinical Psychiatry 67(7):1124-1132, 2006. PMID: 16889457.
150. Villanueva, N, Markham-Abedi C, McNeely C, Diaz FJ, **de Leon J**. Probable association between ziprasidone and worsening of hypertension. Pharmacotherapy 26(9):1352-1357, 2006. PMID: 16945059.
151. Johnson M, Markham-Abedi C, Susce MT, Murray-Carmichael E, McCollum S, **de Leon J**. A poor metabolizer for both Cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19): A case report on antidepressant treatment. CNS Spectrums 11(10):757-760, 2006. PMID: 17008819.
152. Markham-Abedi C, **de Leon J**. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: A case report (letter to the editor). Journal of Clinical Psychiatry 67(9):1473-1474, 2006. PMID: 17017841.

153. **de Leon J.** The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. European Archives of Psychiatry and Clinical Neurosciences 257(3):169-172, 2007. PMID: 17149539.
154. Lorenzo CV, Baca-Garcia E, Hernandez MD, Martin CB, Perez-Rodriguez MM, Saiz-Gonzalez MD, Fernández P, Gutierrez FJ, Saiz-Ruiz J, Piqueras JF, de Rivera JL, **de Leon J.** No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample. American Journal of Medical Genetics (Neuropsychiatric Genetics) 144B(3):344-346, 2007. PMID: 17171662.
155. Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Molecular Psychiatry 12(5):474-482, 2007 PMID: 17199131.
156. Spina E, **de Leon J.** Metabolic drug interactions with newer antipsychotics: a comparative review. Basic and Clinical Pharmacology & Toxicology 100(1): 4-22, 2007. PMID: 17214606. *In May of 2021, according to ResearchGate there were more than 250 citations of this article.*
157. **de Leon J,** Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multi-dosage clozapine study. Journal of Clinical Psychopharmacology 27(1): 22-27, 2007. PMID: 17224708.
158. Gurpegui M, Martinez-Ortega JM, Jurado D, Aguilar MC, Diaz FJ, **de Leon J.** Subjective effects and the main reason for smoking in outpatients with schizophrenia: a case-control study. Comprehensive Psychiatry 48(2): 186-191, 2007. PMID: 17292710.
159. **de Leon J,** Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, Windemuth A, Diaz FJ. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research 92(1-3):95-102, 2007. PMID: 17346932.
160. Diaz-Sastre C, Baca-Garcia E, Perez-Rodriguez MM, Garcia-Resa E, Ceverino A, Saiz-Ruiz J, Oquendo M, **de Leon J.** Low plasma cholesterol levels in suicidal males: a gender- and body mass index-matched case-control study of suicide attempters and nonattempters. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31(4):901-905, 2007. PMID: 17363125.
161. O'Neill A, **de Leon J.** Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. Bipolar Disorders 9(3):310-313, 2007. PMID: 173430308.

162. Baca-Garcia E, Perez-Rodriguez MM, Basurte-Villamor I, Lopez-Castroman J, Fernandez Del Moral AL, Jimenez-Arriero MA, Gonzalez de Rivera JL, Saiz-Ruiz J, Leiva-Murillo JM, de Prado-Cumplido M, Santiago-Mozos R, Artés-Rodríguez A, Oquendo MA, **de Leon J**. Diagnostic stability and evolution of bipolar disorder in clinical practice: A prospective cohort study. Acta Psychiatrica Scandinavica 115(6):473-480, 2007. PMID: 17498159.
163. **de Leon J**. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19 (editorial). Journal of Clinical Psychopharmacology 27(3):241-245, 2007. PMID: 17502769.
164. **de Leon J**, Rendon DM, Baca-Garcia E, Aizpuru F, Gonzalez-Pinto A, Anitua C, Diaz FJ. Association between smoking and alcohol use in the general population: Stable and unstable odds ratios across two years in two different countries. Alcohol and Alcoholism 42(3):252-257, 2007. PMID: 17526636.
pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/17526636>
165. **de Leon J**, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40(3):93-102, 2007. PMID: 17541883.
166. Arranz MJ, **de Leon J**. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry 12(8):707-747, 2007. PMID: 17549063. *In May of 2022, according to ResearchGate there were 350 citations of this article.*
167. Baca-Garcia E, Perez-Rodriguez MM, Basurte-Villamor I, Saiz-Gonzalez D, Saiz-Ruiz J, Leiva-Murillo JM, de Prado-Cumplido M, Santiago-Mozos R, Artés-Rodríguez A, de Leon J. Variables associated with familial suicide attempts in a sample of suicide attempters. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31(6):1312-1316, 2007. PMID: 17614183.
168. **de Leon J**, Diaz FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: The clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophrenia Research 96(1-3):185-197, 2007. PMID: 17618085.
169. Malkawi AH, Al-Ghananeem AM, Nasim S, **de Leon J**, Crooks PA. An HPLC method for the simultaneous determination of neurotoxic dipyrindyl isomers in human plasma. Journal of Pharmaceutical and Biomedical Analysis 45(1):120-124, 2007. PMID: 17706392.

170. **de Leon J.** Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectrums 11(3 Suppl 3): 8-12, 2006. PMID: 17760224.
171. Gelenberg AJ, **de Leon J**, Evins AE, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. Journal of Clinical Psychiatry 68(9):1404-1410, 2007. PMID: 17915980. It was also published Primary Care Companion Journal of Clinical Psychiatry 10(1):52-58, 2008. PMID: 18311422. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/18311422>
172. Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ, **de Leon J.** An investigation of the α_{1A} -adrenergic receptor gene and antipsychotic-induced side-effects. Human Psychopharmacology: Clinical and Experimental 23(2):107-114, 2008. PMID: 17972277.
173. **de Leon J**, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia Research 98(1-3):40-46, 2008. PMID: 18031993.
174. Markham-Abedi C, McNeely C, **de Leon J.** A case report with ziprasidone-induced catatonia symptoms (letter to the editor). Journal of Neuropsychiatry and Clinical Neurosciences 19(4):476-477, 2007. PMID: 18070860.
175. Lorenzo CV, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernández-Navarro P, Giner L, Carballo JJ, Saiz-Ruiz J, Fernandez-Piqueras J, Baldomero EB, **de Leon J**, Oquendo MA. Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts American Journal of Medical Genetics (Neuropsychiatric Genetics) 147B(5):645-649, 2008. PMID: 18163387.
176. **de Leon J**, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectrums 13(2):133-135, 2008. PMID: 18227744. *In May of 2021, according to ResearchGate this is my most read article with >7000 reads.* A pdf is available at https://www.researchgate.net/publication/5623615_Paradoxical_Excitation_on_Diphenhydramine_May_Be_Associated_with_Being_a_CYP2D6_Ultrarapid_Metabolizer_Three_Case_Reports
177. **de Leon J.** CYP2D6 genotyping and codeine (letter to the editor). Pediatric Anesthesia 18(3):274-275, 2008. PMID: 18230077.
178. **de Leon J.** Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial). Journal of Clinical Psychopharmacology 28(2):125-131, 2008. PMID: 18344721.

179. **de Leon J**, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part I. Psychosomatics 49(3):258-270, 2008. PMID: 18448784.
180. Diaz FJ, Santero V, Spina E, Cogollo M, Rivera TE, Botts S, **de Leon J**. Estimating the size of the effects of co-mediations on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41(3):81-91, 2008. PMID: 18484549.
181. Botts S, Diaz FJ, Santoro V, Spina E, Muscatello MR, Cogollo M, Castro FE, **de Leon J**. Estimating the effects of co-mediations on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32(6):1453-1458, 2008. PMID: 18555573.
182. **de Leon J**, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part II. Psychosomatics 49(4):347-361, 2008. PMID: 18621942.
183. Diaz FJ, Vasques DM, Susce MT, **de Leon J**. The association between schizophrenia and smoking: Unexplained either by the illness or the prodromal period. Schizophrenia Research 104(1-3):214-219, 2008. PMID: 18650069.
184. **de Leon J**. The potential of genotyping (letter to the editor). Science 321(5782):769, 2008. PMID: 18687938.
185. **de Leon J**. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34(1):159-172, 2009. PMID: 18800072. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/18800072>
186. **de Leon J**. The future (or lack of future) of personalized prescription in psychiatry. Pharmacological Research 59(2):81-89, 2009. PMID: 18996200.
187. Blasco-Fontecilla H, Baca-Garcia E, Dervic K, Perez-Rodriguez MM, Saiz-Gonzalez MD, Saiz-Ruiz J, Oquendo MA, **de Leon J**. Severity of personality disorders and suicide attempt. Acta Psychiatrica Scandinavica 119(2):149-155, 2009. PMID: 19016671.
188. Perez-Rodriguez MM, Baca-Garcia E, Diaz-Sastre C, Garcia-Resa E, Ceverino A, Saiz-Ruiz J, Oquendo MA, **de Leon J**. Low serum cholesterol may be associated with suicide attempt history. Journal of Clinical Psychiatry 69(10):1920-1927, 2008. PMID: 19026260.
189. Malkawi AH, Al-Ghananeem AM, **de Leon J**, Crooks PA. Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. Journal of Pharmaceutical and Biomedical Analysis 49(1):129-132, 2009. PMID: 19036546.

190. **de Leon J**, Arranz MJ, Rúaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clinics in Laboratory Medicine 28(4):599-617, 2008. PMID: 19059065.
191. **de Leon J**, Greenlee B, Barber J, Sabaawi M, Singh NN. Practical guidelines for the use of new generation antipsychotics (except clozapine) in adult individuals with developmental disabilities. Research in Developmental Disabilities 30(4):612-669, 2009. PMID: 19084370.
192. **de Leon J**, Susce, MT, Johnson M, Hardin M, Maw L, Shao A, Allen AC, Chiafari FA, Hillman G, Nikoloff DM. DNA microarray technology in the clinical environment: The AmpliChip CYP 450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectrums 14(1):1934, 2009. PMID: 19169185.
https://www.researchgate.net/publication/23939496_DNA_microarray_technology_in_the_clinical_environment_The_AmpliChip_CYP450_test_for_CYP2D6_and_CYP2C19_genotyping
193. Gonzalez-Pinto A, Barbeito S, Diaz FJ, Vega P, Mosquera F, Lopez P, Alberich S, Ruiz de Azua S, Ugarte A, Martin M, **de Leon J**. Clinical implications of the age onset in bipolar I disorder: Two subgroups with different prognosis. Revista de Psiquiatria y Salud Mental 2:29-34, 2009. PMID: 23034195.
194. **de Leon J**. The French attempt to include the bouffée délirante in the DSM-V during 2006: A recollection in the year 2050 (editorial). Encephale 35(1):1-3, 2009. PMID: 19250987.
195. Diaz FJ, James D, Botts S, Maw L, Susce MT, **de Leon J**. Tobacco smoking behaviors in bipolar disorder: a comparison with the general population, schizophrenia and major depression. Bipolar Disorders 11(2):154-165, 2009. PMID: 19267698.
196. Rodríguez-Antona C, Gurwitz D, de Leon J, Llerena A, Kirchheiner J, de Mesa EG, Ibarreta, D. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 10(4):685-699, 2009. PMID: 19374522.
197. **de Leon J**, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing and translation into a message understandable to practicing clinicians (editorial). Journal of Clinical Psychopharmacology 29(3):201-205, 2009. PMID: 19440070.
198. Fernández-Pérez R, Álvarez-Dobaño JM, Suárez-Antelo J, Codesido-Barcala R, Carballal-Calvo F, Arrojo-Romero M, **de Leon J**. Eosinophilic pleural effusion associated with the addition of sodium valproate (letter to the editor). Journal of Clinical Psychopharmacology 29(3):310-311, 2009. PMID: 19440094.

199. Baca-Garcia E, Vaquero-Lorenzo C, Perez-Rodriguez MM, Gratacòs M, Bayés M, Santiago-Mozos R, Leiva-Murillo JM, de Prado-Cumplido M, Artes-Rodriguez A, Ceverino A, Diaz-Sastre C, Fernandez-Navarro P, Costas J, Fernandez-Piqueras J, Diaz-Hernandez M, de Leon J, Baca-Baldomero E, Saiz-Ruiz J, Mann JJ, Parsey RV, Carracedo A, Estivill X, Oquendo MA. Nucleotide variation in central nervous system genes among male suicide attempters. American Journal of Medical Genetics B Neuropsychiatric Genetics 153B(1):208-213, 2010. PMID: 19455598.
200. Clark D, Skrobat OA, Adebisi I, Susce MT, **de Leon J**, Blakemore AF, Arranz MJ. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. European Psychiatry 24(7):456-463, 2009. PMID: 19541455.
201. Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, **de Leon J**. Short-and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Progress in Neuro-Psychopharmacology & Biological Psychiatry 33(8):1496-1501, 2009. PMID: 19706318.
202. **de Leon J**, Kiesel JL, Fleming MW, Strobl B. Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report (letter to the editor). Journal of Clinical Psychopharmacology 29(5):509-11, 2009. doi: 10.1097/JCP.0b013e3181b4b07c. PMID: 19745660.
203. Baca-Garcia E, Diaz-Sastre C, Ceverino A, Perez-Rodriguez MM, Navarro-Jimenez R, Lopez-Castroman J, Saiz-Ruiz J, **de Leon J**, Oquendo MA. Suicide attempts among women during low estradiol/low progesterone states. Journal of Psychiatric Research 44(4):209-214, 2010. PMID: 19782376.
204. **de Leon J**. How to assess research productivity in early career psychiatric researchers? Research funding versus scientific productivity (letter to the editor). Journal of Clinical Psychiatry 70(9):1327-1328, 2009. PMID: 19818260.
205. Al-Janabi I, Arranz MJ, Blakemore AIF, Saiz P, Susce MT, Glaser PEA, Clark D, **de Leon J**. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatric Genetics 19(6):305-311, 2009. PMID: 19829168.
206. Diaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, **de Leon J**. Acetyl-coenzyme A carboxylase α gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophrenia Research 115(2-3):136-140, 2009. PMID: 19846279. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/19846279>
207. Spina E, D'Arrigo C, Santoro V, Muscatello MR, Pandolfo G, Zoccali R, Diaz FJ, **de Leon J**. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Therapeutic Drug Monitoring 31(6):758-763, 2009. PMID: 19865002.

208. Ramos-Ríos R, Arrojo-Romero M, Paz Silva E, Fernández-Pérez R, Carballal-Calvo F, Bouzón-Barreiro JL, Seoane-Prado J, Codesido-Barcala R, Crespí-Armenteros A, Fernández-Pérez R, López-Moríñigo JD, Tortajada-Bonaselt I, Diaz FJ, **de Leon J**. QTc interval in a sample of long-term schizophrenia inpatients. Schizophrenia Research 116(1):35-43, 2009. PMID: 19892525.
209. Pérez-Ríos M, Santiago-Pérez MI, Alonso B, Malvar A, Hervada X, de Leon J. Fagerstrom test for nicotine dependence vs heavy smoking index in a general population survey. BMC Public Health 30(9):493, 2009. PMID: 20042106. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/20042106>
210. Blasco-Fontecilla H, Baca-Garcia E, **de Leon J**. Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT_{2A} receptor blockade. Schizophrenia Research 119(1-3):160-163, 2010. PMID: 20053538.
211. **de Leon J**, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51(1):80-8, 2010. doi: 10.1176/appi.psy.51.1.80.PMID: 20118446.
212. Diaz FJ, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Vázquez-Barquero JL, **de Leon J**, Crespo-Facorro B. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophrenia Research 121(1-3):207-212, 2010. PMID: 20580206.
213. **de Leon J**, Spina E, Diaz FJ. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied (letter to the editor). Journal of Clinical Psychiatry 71(7):957-958, 2010. PMID: 20667295.
214. Blasco-Fontecilla H, Baca-Garcia E, Duberstein P, Perez-Rodriguez MM, Dervreic K, Saiz-Ruiz J, Courtet P, **de Leon J**, Oquendo MA. An exploratory study of the relationship between diverse life events and personality disorders in a sample of suicide attempters. Journal of Personality Disorders 24(6):774-785, 2010. PMID: 21158599. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/21158599>
215. Perez-Rodriguez MM, Lopez-Castroman J, Martinez-Vigo M, Diaz-Sastre C, Ceverino A, Núñez-Beltrán A, Saiz-Ruiz J, de Leon J, Baca-Garcia E. Lack of association between testosterone and suicide attempts. Neuropsychobiology 63(2):125-130, 2011. PMID: 21196783. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/21196783>
216. **de Leon J**. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Current Drug Metabolism 12: 635-646, 2011. PMID: 21495973.

217. **de Leon J**. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers (editorial). Journal of Clinical Psychopharmacology 31(3):263-265, 2011. doi: 10.1097/JCP.0b013e318218f3e4 PMID: 21508855.
218. Blasco-Fontecilla H, Alegria AA, Lopez-Castroman JL, Legido-Gil T, Saiz-Ruiz J, **de Leon J**, Baca-Garcia E. Short self-reported sleep duration and suicidal behavior: a cross-sectional study. Journal of Affective Disorders 133(1-2):239-246, 2011. PMID: 21546092.
219. Munro J, Skrobot O, Sanyoura M, Kay V Susce MT, Glaser PEA, **de Leon J**, Blakemore AI, Arranz MJ. Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. Journal of Psychopharmacology 26(3):374-379, 2012. PMID: 21693553.
220. Diaz FJ, Pérez-Iglesias R, Mata I, Martínez-García O, Vázquez-Barquero JL, **de Leon J**, Crespo-Facorro B. Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naïve first-episode psychosis patients. Schizophrenia Research 131(1-3):82-89, 2011. PMID: 21726981.
221. **de Leon J**, Mallory P, Maw L, Susce MT, Perez-Rodriguez MM, Baca-Garcia E. Lack of replication of the association of low serum cholesterol and suicide attempts in another country opens more questions. Annals of Clinical Psychiatry 23(3):163-170, 2011. PMID: 21808747.
222. Windemuth A, **de Leon J**, Goethe JW, Schwartz HI, Woolley S, Susce M, Kocherla M, Bogaard K, Holford TR, Seip RL, Rúaño G. Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 36(2):213-219, 2012. PMID: 21851846.
223. Gonzalez-Pinto A, Alberich S, Ruiz de Azua S, Martinez Cengotitabengoa M, Fernandez M, Gutierrez M, Saenz M, Besga A, Galdos P, **de Leon J**. Psychosis and smoking cessation: difficulties in quitting associated with sex and substance abuse. Psychiatry Research 30;195(1-2):45-50, 2012. PMID: 21885130.
224. Voicu VA, **de Leon J**, Medvedovici AV, Rădulescu FS, Miron DS. New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drug. European Neuropsychopharmacology 22:319-329, 2012. PMID: 21917428.
225. **de Leon J**, Diaz FJ. Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings. Human Genetics 131(6):877-901, 2012. PMID: 22190153. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/22190153>

226. Blasco-Fontecilla H, Delgado-Gomez D, Legido-Gil T, **de Leon J**, Perez-Rodriguez MM, Baca-Garcia E. Can the Holmes-Rahe Social Readjustment Rating Scale (SRRS) be used as a suicide risk scale? An exploratory study. Archives of Suicide Research 16(1):13-28, 2012. PMID: 22289025.
227. **de Leon J**, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology 8(3):2-24, 2012. PMID: 22332980.
228. **de Leon J**. Evidence-based medicine versus personalized medicine: are they enemies? (editorial). Journal of Clinical Psychopharmacology 32(2):153-164, 2012. PMID: 22367661.
229. Diaz FJ, Santero V, Spina E, Cogollo M, Rivera TE, **de Leon J**. Drug dosage individualization in the presence of clinical or demographic factors that have random effects in a linear model. Journal of Biopharmaceutical Statistics 22(3):463-484, 2012. PMID: 22416835.
230. Blasco-Fontecilla H, **de Leon J**. Lower gastrointestinal bleeding and paroxetine use: two case reports. Psychosomatics 53(2):184-187, 2012. PMID: 22424167.
231. Blasco-Fontecilla H, Perez-Rodriguez MM, Garcia-Nieto R, Fernandez-Navarro P, Galfalvy H, **de Leon J**, Baca-Garcia E. Worldwide impact of economic cycles on suicide trends over 3 decades: differences according to level of development. A mixed effect model study. BMJ Open 2012 May 14;2(3). pii: e000785. doi: 10.1136/bmjopen-2011-000785. Print 2012. PMID: 22586285. pdf available <http://www.ncbi.nlm.nih.gov/pubmed/22586285>
232. Masdeu JC, González-Pinto A, Matute C, Ruiz de Azúa S, Palomino A, **De Leon J**, Berman KF, Dalmau J. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia (letter to the editor). American Journal of Psychiatry 169 (10):1120-1121, 2012. doi: 10.1176/appi.ajp.2012.12050646. PMID: 23032395. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/23032395>
233. **de Leon J**, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Therapeutic Drug Monitoring 35(1):30-47, 2013. doi: 10.1097/FTD.0b013e31827ada88. PMID: 23318278. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/23318278>
234. Pérez J, Girón-Irueste F, Gurpegui M, Baldessarini RJ, de Leon J. The lions of Granada Maristan. American Journal of Psychiatry 170(2):152-153, 2013. doi:10.1176/appi.ajp.2012.12081066. PMID: 23377635.

235. Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, Suárez-Pinilla P, Tabarés-Seisdedos R, de León J, Crespo-Facorro B. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine 44(1):37-50, 2014. doi: 10.1017/S0033291713000330. PMID: 23461899.
236. Diaz FJ, Yeh, HW, **de Leon J**. Role of statistical random-effects linear models in personalized medicine. Current Pharmacogenomics & Personalized Medicine 10(1):22-32, 2012. PMID: 23467392.
pdf available <http://www.ncbi.nlm.nih.gov/pubmed/23467392>
237. Diaz FJ, **de Leon J**. The mathematics of drug dose individualization should be built with random effects linear models (letter to the editor). Therapeutic Drug Monitoring 35(2):276-7, 2013. doi: 10.1097/FTD.0b013e318283e3c6. PMID: 23503456.
238. Giner L, Blasco-Fontecilla H, Perez-Rodriguez MM, Garcia-Nieto R, Giner J, Guija J, Rico A, Barrero E, Luna MA, **de Leon J**, Oquendo MA, Baca-Garcia E. Personality disorders and health problems distinguish suicide attempters from completers in a direct comparison. Journal of Affective Disorders 151(2):474-483, 2013. doi: 10.1016/j.jad.2013.06.029. PMID: 23859005.
239. Arrojo-Romero M, Tajés Alonso M, **de Leon J**. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Reports in Psychiatry 2013;2013:612459. doi: 10.1155/2013/612459. PMID: 23936714.
pdf available <http://www.ncbi.nlm.nih.gov/pubmed/23936714>
240. Chikkaramanjegowda V, **de Leon J**. Venlafaxine-induced orthostatic hypotension in a geriatric patient. Case Reports in Psychiatry 2013;2013:761567. doi:10.1155/2013/761567. PMID: 23984153.
pdf available <http://www.ncbi.nlm.nih.gov/pubmed/23984153>
241. **de Leon J**. A post-*DSM-III* wake-up call to European psychiatry. Acta Psychiatrica Scandinavica 2014;129:76-7. doi: 10.1111/acps.12196. PMID: 24033273.
242. Riesselman A, Strobl B, Cooley AT, **de Leon J**. A case report that suggested that aspirin effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism. Journal of Clinical Psychopharmacology 33(6): 812-4, 2013. doi: 10.1097/JCP.0b013e3182a4ea8f. PMID: 24113673.
243. Crettol S, **de Leon J**, Hiemke C, Eap CB. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clinical Pharmacology & Therapeutics 95(3):254-257, 2014. doi: 10.1038/clpt.2013.221. PMID:24196844.

244. **de Leon J.** Is psychiatry scientific? A letter to a 21st century psychiatry resident. Psychiatry Investigation 10(3):205-217, 2013. PMID: 24302942. pdf available http://www.ncbi.nlm.nih.gov/pubmed/24302942_0
Translated to Spanish <http://zl.elsevier.es/es/revista/psiquiatria-biologica-46/linkresolver/es-cientifica-psiquiatria-carta-al-90304793>
245. **de Leon J.** One hundred years of limited impact of Jasper's General Psychiatry on US psychiatry (editorial). Journal of Nervous and Mental Diseases 202(2):79-87, 2014. doi: 10.1097/NMD.0000000000000092. PMID: 24469517. pdf available: http://journals.lww.com/jonmd/Fulltext/2014/02000/One_Hundred_Years_of_Limited_Impact_of_Jaspers_.1.aspx
246. **de Leon J.** Is it time to wake up Sleeping Beauty? European psychiatry has been sleeping since 1980. Revista de Psiquiatria y Salud Mental 7(4):186-194, 2014. doi: 10.1016/j.rpsm.2013.12.004. English, Spanish. PMID: 24486358. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/24486358>
247. Spina E, **de Leon J.** Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology 10(5):721-746; 2014. doi: 10.1517/17425255.2014.885504. PMID: 24494611.
248. **de Leon J**, Shoemaker S, Brenzel A. A. The old and the new Eastern State Hospital in Lexington, Kentucky. American Journal of Psychiatry 171(2):149-150; 2014. PMID: 24500459.
249. **de Leon J.** False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: Focus on epilepsy (editorial). Journal of Clinical Psychopharmacology 34(2):177-183; 2014 doi: 10.1097/JCP.0000000000000093. PMID: 24525637.
250. Artieda-Urrutia P1, Parra Uribe I, Garcia-Pares, Palao D, **de Leon J**, Blasco-Fontecilla, H. Management of suicidal behavior: is the world upside down? Australian and New Zealand Journal of Psychiatry 48 (5):399-401; 2014. PMID: 24589981. http://uknowledge.uky.edu/psychiatry_facpub/23/
251. **de Leon J.** False negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: Focus on bipolar disorder (editorial). Journal of Clinical Psychopharmacology 34(3):291-296, 2014. doi: 10.1097/JCP.0000000000000115. PMID: 24717257.
252. Diaz FJ, Eap CB, Ansermot N, Crettol S, Spina E, **de Leon J.** Can valproic acid be an inducer of clozapine metabolism Pharmacopsychiatry 47:89-96, 2014. PMID: 24764199. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/24764199>

253. **de Leon J.** Paradoxes of US psychopharmacology practice in 2013: Between undertreatment of the severe mentally ill and overtreatment of minor psychiatric problems (editorial). Journal of Clinical Psychopharmacology 34(5):545-548, 2014. doi: 10.1097/JCP.000000000000126. PMID: 24781438.
254. **de Leon J.** DSM-5 and Research Domain Criteria: One hundred years after Jaspers' General Psychopathology. American Journal of Psychiatry 171(5):492-494, 2014. doi: 10.1176/appi.ajp.2013.13091218. PMID: 24788280.
255. **de Leon J.** Response to Gorelick (letter to the editor). American Journal of Psychiatry 171(6):691-692, 2014. doi: 10.1176/appi.ajp.2014.14020166r. PMID: 24880514.
256. Italiano D, Spina E, **de Leon J.** Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opinion on Drug Metabolism and Toxicology 10(11):1457-1489, 2014. doi:10.1517/17425255.2014.956081. PMID: 25200585.
257. **Spina E, de Leon J.** Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission 122(1):5-28, 2015. doi: 10.1007/s00702-014-1300-5. PMID: 25196459.
258. Li X-B, Tang Y-L, Wang C-Y, **de Leon J.** Clozapine for treatment-resistant bipolar disorders: a systematic review. Bipolar Disorders 17(3):235-247, 2015. doi: 10.1111/bdi.12272.2014. PMID: 25346322.
259. **de Leon J.** Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personal medicine in psychiatry. Acta Neuropsychiatrica 26(6):327-333, 2014. PMID: 25455256.
260. Sher L, Rihmer Z, Didia-Attas J, **de Leon J**, Lin SK, Roncero C, Szerman N, Rice T. Future research and clinical directions in the field of Men's Mental Health: The Madrid Declaration. Frontiers in Public Health 2014 Nov 19;2:242. eCollection 2014. PMID: 25478555. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/25478555>
261. Li X-B, Tang Y-L, Zheng W, Wang C-Y, **de Leon J.** QT interval prolongation associated with intramuscular ziprasidone in Chinese patients: a case report and a comprehensive literature review with meta-analysis. Case Reports in Psychiatry 2014:489493, 2014. doi: 10.1155/2014/489493. PMID: 25530900. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/25530900>
262. Blasco-Fontecilla H, Artieda-Urrutia P, Berenguer-Elias N, Garcia-Vega J, Fernandez Rodriguez M, Rodriguez-Lomas C, Gonzalez-Villalobos I, Iruela-Cuadrado L, **de Leon J.** Are major repeater patients addicted to suicidal behavior? Addicciones 26(4):321-333, 2014. PMID: 25580865. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/25580865>

263. Blasco-Fontecilla H, Jausset I, Olié E, Béziat S, Guillaume S, Artieda-Urrutia P, Baca-Garcia E, **de Leon J**, Courtet P. A cross-sectional study of major repeaters: a distinct phenotype of suicidal behavior. The Primary Care Companion to CNS Disorders 16 (4), 2014 doi:10.4088/PCC.14m01633 eCollection 2014. PMID: 25664212. pdf available: <http://www.ncbi.nlm.nih.gov/pubmed/25664212>
264. Arrojo-Romero M, Armas Barbazán C, López-Moriñigo JD, Ramos-Ríos R, Gurpegui M, Martínez-Ortega JM, Jurado D, Diaz FJ, **de Leon J**. Caffeine consumption in a long-term psychiatric hospital: tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. Schizophrenia Research 164(1-3): 234-241, 2015. doi: 10.1016/j.schres.2015.01.042. PMID: 25702972.
265. Blasco-Fontecilla H, Baca-Garcia E, Courtet F, Garcia-Nieto R, **de Leon J**. Horror vacui: Emptiness might distinguish between major repeaters and non-major repeaters. A pilot study. Psychosomatics & Psychotherapy 84(2):117-119, 2015. PMID: 25720355.
266. **de Leon J**. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. Revista de Psiquiatria y Salud Mental 8(2):97-115, 2015. doi: 10.1016/j.rpsm.2014.10.006. pii: S1888-9891(14)00148-7. English, Spanish. PMID: 25745819. pdf available at <https://www.ncbi.nlm.nih.gov/pubmed/25745819>
267. **de Leon J**. Is Psychiatry only neurology? Or only abnormal psychology? Déjà vu after 100 years. Acta Neuropsychiatrica 27(2):69-81, 2015. doi: 10.1017/neu.2014.34 PMID: 25849592.
268. **de Leon J**, Tang Y-L, Baptista T, Cohen D, Schultef PF. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatrica Scandinavica 132(4):242-243, 2015. doi: 10.1111/acps.12421. PMID: 25865620.
269. **de Leon J**. Phenoconversion and therapeutic drug monitoring (letter to the editor). British Journal of Clinical Pharmacology 80(4):777-778, 2015. doi: 10.1111/bcp.12659. PMID: 25881716.
270. Jackson J, McCollum M, Ognibene J, Diaz FJ, **de Leon J**. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Reports in Psychiatry 2015: 542862, 2015. doi: 10.1155/2015/542862. PMID: 26000191. pdf available at <http://www.ncbi.nlm.nih.gov/pubmed/26000191>
271. **de Leon J**. Translating pharmacogenetics to clinical practice: Do cytochrome P4502D6 ultrarapid metabolizers need higher atomoxetine doses? Journal of the American Academy of Child and Adolescent Psychiatry 54(7):532-534, 2015. doi: 10.1016/j.jaac.2015.04.003. PMID: 26088654.

272. **de Leon J.** The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. Revista de Psiquiatria y Salud Mental 8(3):167-188, 2015. doi: 10.1016/j.rpsm.2014.10.005. English, Spanish. PMID: 26111722. pdf available at <https://www.ncbi.nlm.nih.gov/pubmed/26111722>
273. Jackson JG, Diaz FJ, Lopez L, **de Leon J.** A combined analyses of worldwide studies demonstrate an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disorders 7(6):575-597, 2015. doi:10.1111/bdi.12319. PMID: 26238269.
274. Zheng W, Li XB, Tang YL, Xiang YQ, Wang C-Y, **de Leon J.** Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychopharmacology 35(5):499-509, 2015. doi: 10.1097/JCP.0000000000000392. PMID: 26280837.
275. **de Leon J,** Baca-Garcia E, Blasco-Fontecilla H. From the serotonin model of suicide to a mental pain model of suicide (editorial). Psychosomatics & Psychotherapy 84(6):323-329, 2015. PMID: 26398763. pdf available <https://www.ncbi.nlm.nih.gov/pubmed/26398763>
276. Jackson J, McCollum M, O'Neill A, **de Leon J.** A case report that suggested that the patient was very sensitive to induction and needed 1600 mg/day of lamotrigine to get therapeutic concentrations (letter to the editor). Journal of Clinical Psychopharmacology 35(6):745-747, 2015. PMID: 26448400.
277. White M, Maxwell E, Milteer WE, **de Leon J.** Catatonia in older adult individuals with intellectual disabilities. Case Reports in Psychiatry 2015:120617, 2015. doi: 10.1155/2015/120617. PMID: 26495148.
278. **de Leon J,** Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? (editorial). Expert Review in Clinical Pharmacology 9(3):351-4, 2016. doi:10.1586/17512433.2016.1112737. PMID: 26580456.
279. Vélez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A, Tobón C, Rivera D, Villegas A, Cai Y, Peng K, Arkell R, Castellanos FX, Andrews SJ, Silva Lara MF, Creagh PK, Eastel S, **de Leon J,** Wong ML, Licinio J, Mastronardi CA, Arcos-Burgos M. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Molecular Psychiatry 21:916-924, 2015 Dec 1. doi: 10.1038/mp.2015.177. PMID: 26619808.

280. Ruan CJ, Li AN, Dong F, Zhai YM, Li WB, Wang CY, **de Leon J**. Single and multiple-dose milnacipran pharmacokinetics in healthy Han Chinese volunteers. Clinical Pharmacokinetics 55(7):889-896, 2016. doi: 10.1007/s40262-015-0355-2. PMID: 26663198.
281. Chopra N, **de Leon J**. Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy. International Journal of Psychiatry in Medicine 51(1):104-115, 2016. doi: 10.1177/0091217415621269. PMID: 26681239.
282. **de Leon J**, Stephens DB. The limitations of pathophysiology and clinical trials in some areas of medicine: focus on psychiatry (Letter commenting: J Clin Epidemiol. 2014;67(4):361-3.) (letter to the editor). Journal of Clinical Epidemiology 2016 Jan 22. pii:S0895-4356(16)00056-1. doi: 10.1016/j.jclinepi.2016.01.019. PMID: 26808819.
283. **de Leon J**, Baca-Garcia E, Blasco-Fontecilla H. Reply to the multifaceted aspects of suicide behavior by Tondo (letter to the editor). Psychotherapy and Psychosomatics 85(2):112-113, 2016. PMID: 26809133.
284. Bo Q-J, Wang ZM, Li XB, Ma X, Wang CY, **de Leon J**. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: a systematic review. Psychiatry Research 237:257-263, 2016 doi: 10.1016/j.psychres.2016.01.031. PMID: 26822064.
285. Blasco-Fontecilla H, Fernández-Fernández R, Colino L, Fajardo L, Perteguer-Barrio R, **de Leon J**. The addictive model of self-harming (non-suicidal and suicidal) behavior. Frontiers in Psychiatry 2016 Feb 1;7:8. doi:10.3389/fpsy.2016.00008. PubMed PMID: 26869941.
286. Spina E, Hiemke C, **de Leon J**. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology 12(4):407-422, 2016. PMID: 26878495.
287. Spina E, Pisani F, **de Leon J**. Clinically significant pharmacokinetic drug interactions of antiepileptics drugs with new antidepressants and new antipsychotics. Pharmacological Research 106(4):72-86, 2016. pii: S1043-6618(16)00044-X. doi:10.1016/j.phrs.2016.02.014. PMID: 26896788.
288. **de Leon J**. Beyond the corrupting influence of pharmaceutical companies on antidepressant meta-analyses (letter to the editor). Journal of Clinical Epidemiology 78:127-129, 2016. pii: S08954356(15)00429-1. doi: 10.1016/j.jclinepi.2015.08.021. PMID: 26987506.
289. **de Leon J**. Pharmacogenetic tests in psychiatry: From fear to failure to hype (editorial). Journal of Clinical Psychopharmacology 36(4):299-304, 2016. doi:10.1097/JCP.00000000000005222016. PMID: 27269957.

290. Lana F, Martí-Bonany J, Fuster J, **de Leon J**. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. *Actas Españolas de Psiquiatría* 44(4):136-144, 2016. PMID: 27388105. <https://www.ncbi.nlm.nih.gov/pubmed/27388105>
291. Stephens DB, **de Leon J**. CYP2D6 ultrarapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients. *Pharmacogenomics* 17(12):1295-304, 2016. doi: 10.2217/pgs-2016-0086. PMID: 27463022.
292. Lana F, Martí-Bonany J, **de Leon J**. Ibuprofen may increase pharmacological action of valproate by displacing it from the plasma proteins: a case report (letter to the editor). *American Journal of Psychiatry* 173(9):941-2, 2016. doi: 10.1176/appi.ajp.2016.16030326. PMID: 27581700.
293. Blasco-Fontecilla H, Rodrigo-Yanguas M, Giner L, Lobato-Rodriguez MJ, **de Leon J**. Patterns of comorbidity of suicide attempters: an update. *Current Psychiatry Report* 18(10):93, 2016. doi: 10.1007/s11920-016-0733-y. PMID: 27595859.
294. Wahid N, Johnson KJ, Brenzel A, **de Leon J**. Two sudden and unexpected deaths of patients with schizophrenia associated with intramuscular injections of antipsychotics and practice guidelines to limit the use of high doses of intramuscular antipsychotics. *Case Reports in Psychiatry* 2016;2016:9406813. doi: 10.1155/2016/9406813. PMID: 27597919. pdf available at <https://www.ncbi.nlm.nih.gov/pubmed/27597919>
295. Zheng W, Zheng YJ, Li XB, Tang YL, Wang CY, Xiang YQ, **de Leon J**. Efficacy and safety of adjunctive aripiprazole in schizophrenia: Meta-analysis of randomized controlled trials. *Journal of Clinical Psychopharmacology* 36(6):628-636, 2016. PMID: 27755219.
296. Baptista T, Carrizo E, Rojas N, Fernandez E, Velaz G, Servigna M, Serrano A, Sandia I, **de Leon J**, Perez-Lopesti S. Clozapine-induced myocarditis in cross-sectional and follow-up evaluations: comparison with other antipsychotics in naturalistic settings. *Investigación Clínica* 57(4):352-359, 400-403, 2016. PMID: 29938983.
297. **de Leon J**, De las Cuevas C. The art of pharmacotherapy: reflections on pharmacophobia. *Journal of Clinical Psychopharmacology* 37(2):131-137, 2017. doi: 10.1097/JCP.0000000000000675. PMID: 28166081.
298. De las Cuevas C, **de Leon J**. Reviving research on medication attitudes for improving pharmacotherapy: focusing on adherence. *Psychotherapy and Psychosomatics* 86(2):73-79, 2017. doi: 10.1159/000450830. PMID: 28183085.

299. Zheng W, Xiang YT, Yang XH, Xiang YQ, **de Leon J**. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 2017 May;78(5):e498-e505. doi: 10.4088/JCP.16r10782. PMID: 28355041.
300. Bilbily J, McCollum B, **de Leon J**. Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review. Case Reports in Psychiatry 2017:2402731, 2017. doi: 10.1155/2017/2402731. PMID: 28396815
301. De las Cuevas C, **de Leon J**, Peñate W, Betacort M. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Preference and Adherence 11:681-690, 2017. doi: 10.2147/PPA.S133513. PMID: 28405160.
302. McGrane IR, Loveland JG, **de Leon J**. Possible oxcarbazepine inductive effects on aripiprazole metabolism: a case report. Journal of Pharmacy Practice 31(3):361-363, 2018. doi: 10.1177/0897190017710523. PMID: 28539103.
303. Ruan CJ, Zhen XY, Ge XL, Wang CY, Guo W, Tang YL, Li WB, **de Leon J**. Pneumonia can cause clozapine intoxications: a case report. Psychosomatics 58(6):652-656, 2017. doi: 10.1016/j.psych.2017.05.003. PMID: 28669537.
304. Irigoyen-Otiñano M, Puigdevall-Ruestes M, Prades-Salvador N, Salort-Seguí S, Gayubo L, **de Leon J**, Blasco-Fontecilla H. Further evidence for major repeaters as a subgroup of suicide attempters. Revista de Psiquiatria y Salud Mental 11(1):60-61, 2018 doi: 10.1016/j.rpsm.2017.04.004. PMID: 28687461.
305. Schoretsanitis G, Spina E, Hiemke C, **de Leon J**. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Review in Clinical Pharmacology 10(9):965-981, 2017. doi: 10.1080/17512433.2017.1345623. PMID: 28699847.
306. Puente R, Brenzel A, **de Leon J**. Pulmonary embolism during stuporous episodes of catatonia was found to be the most frequent cause of preventable death according to a state mortality review: 6 deaths in 15 years. Clinical Schizophrenia and Related Psychoses 2017 Aug 4. doi: 10.3371/CSRP.RPAB.071317 PMID: 28777033
307. de Leon VC, Bilbily J, Shelton C, **de Leon J**. Moria: an unrecognized frontal lobe symptom. Primary Companion of CNS Disorders 2017 Aug 3;19(4). pii: 16102089. doi: 10.4088/PCC.16102089. PMID: 28796941.
308. Spina E, **de Leon J**. Potentially clinically relevant pharmacodynamics drug interactions between antiepileptic and psychotropic medications: an update. Current Pharmaceutical Design 23(37):5625-5638, 2017. doi: 10.2174/1381612823666170809102258. PMID: 28799514.

309. **de Leon J.** A critical commentary on the 2017 AGNP guidelines for therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 51(1-02):63-68, 2018. doi: 10.1055/s-0043-117891. PMID: 28922669
310. Schoretsanitis G, **de Leon J**, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M. Pharmacokinetics of risperidone in different application forms-comparing long-acting injectable. European Neuropsychopharmacology 28(1):130-137, 2018. doi: 10.1016/j.euroneuro.2017.11.009. PMID: 29153926.
311. **de Leon J.** Have we successfully implemented CYP2D6 genotyping in psychiatry? Expert Opinion on Drug Metabolism and Toxicology 13(12):1201-1203, 2017. doi: 10.1080/17425255.2017.1406920. PMID: 29164956.
312. **de Leon J.** Young researchers and young clinicians should not pay much attention to the journal impact factor when selecting a journal for publishing articles: Comment on the editorial "The impact non-factor" by Greenblatt and Shader . Journal of Clinical Psychopharmacology 38(1):86-87, 2018. doi: 10.1097/JCP.0000000000000823. PMID: 29257788.
313. Ruan CJ, Zhang XL, Guo W, Li WB, Zhuang HY, Li YQ, Wang CY, Tang YL, Zhou FC, **de Leon J.** Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients. International Journal of Psychiatry in Medicine 53(4) 292–305, 2018. doi: 10.1177/0091217417749799. PMID: 29292668.
314. **de Leon J**, Wise TN, Balon R, Fava GA. Dealing with difficult medical colleagues. Psychotherapy & Psychosomatics 2018;87(1):5-11, 2018. doi: 10.1159/000481200. PMID: 29306944.
315. McCollum, B, Barclay J, **de Leon J.** Unexpected falls during clozapine treatment explained by myoclonus: a case report. Primary Companion of CNS Disorders 18;20(1), 2018. pii:17102151. doi: 10.4088/PCC.17102151. PMID: 29360288.
316. Ruan CJ, Guo W, Zhou M, Guo GX, Wang CY, Li WB, **de Leon J.** Quantitative determination of risperidone, paliperidone and olanzapine in human serum by liquid chromatography-tandem mass spectrometry coupled with online solid phase extraction. Biomedical Chromatography 2018 Jul;32(7):e4209. doi: 10.1002/bmc.4209. PMID: 29473184.
317. De las Cuevas C, Motuca M, Baptista T, **de Leon J.** Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina and Venezuela. Patient Preference and Adherence 12:301-310, 2018. doi: 10.2147/PPA.S158443. eCollection 2018. PMID: 29503532.

318. **de Leon J**, Spina E. Possible pharmacodynamic and pharmacokinetic drug-drug interactions that are likely to be clinically relevant and/or frequent in bipolar disorder. Current Psychiatry Reports 20(3):17, 2018. doi: 10.1007/s11920-018-0881-3. Review. PMID: 29527636.
319. Colino L, Herranz-Herrer J, Gil-Benito E, Ponte-Lopez T, del Sol-Calderon P, Rodrigo-Yanguas M, Gil-Ligero M, Sánchez-López AJ, **de Leon J**, Blasco-Fontecilla H. Cannabinoid receptors, mental pain and suicidal behavior: a systematic review. Current Psychiatry Reports 20(3):19, 2018. doi: 10.1007/s11920-018-0880-4. PMID: 29546501.
320. Schoretsanitis G, Spina E, Hiemke C, **de Leon J**. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Review in Clinical Pharmacology 11(6):1-15, 2018. doi: 10.1080/17512433.2018.1478727. PMID: 29776316.
321. Baptista T, de Leon J. Positive response to clozapine augmentation in a patient with obsessive-compulsive disorder complicated by a tardive movement disorder. Revista Brasileira de Psiquiatria 40(2):229-230, 2018. doi: 10.1590/1516-4446-2017-2565. PMID: 29846470.
322. Wahidi, N, **de Leon J**. Rapid development of lorazepam tolerance within 48 hours in an adult with intellectual disability who presented with stuporous catatonia and refused electroconvulsive therapy. Primary Companion of CNS Disorders 20(3):17102162, 2018. doi: 10.4088/PCC.17102162. PMID: 29878725.
323. Schoretsanitis G, **de Leon J**, Diaz FJ. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Pharmacogenomics 19(10):815-823, 2018. doi: 10.2217/pgs-2018-0053. PMID: 29914302.
324. Zwiebel S, Villasante Tejanos AG, de Leon J. Periodic catatonia marked by hypercortisolemia and exacerbated by the menses: A case report and a literature review. Case Reports in Psychiatry Case Rep Psychiatry 2018:4264763, 2018. doi: 10.1155/2018/4264763. PMID: 30073108.
325. **de Leon J**. Teaching medical students how to think: narrative, mechanistic and mathematical thinking. Actas Españolas de Psiquiatria 2018;46(4):133-145. PMID: 30079927.
326. Diaz FJ, Jossiasen RC, **de Leon J**. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. Journal of Clinical Psychopharmacology 38(5):442-446, 2018. doi: 10.1097/JCP.0000000000000926. PMID: 30106876.

327. Zwiebel S, Rayapati AO, **de Leon J**. Catatonia following abrupt cessation of oxcarbazepine in a patient with Prader-Willi syndrome. Psychosomatics 60 (3): 311-315, 2019. doi: 10.1016/j.psym.2018.07.014. PMID: 30166119.
328. **de Leon J**. Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice? My failure to convince clinicians. Journal of Clinical Psychopharmacology 39(1):1-4, 2019. doi: 10.1097/JCP.0000000000000924. PMID: 30212396.
329. Ruan CJ, **de Leon J**. Thirty years of both ignorance and clinical experience suggest that clozapine intoxication during co-occurring infections and inflammation may have higher morbidity and mortality than is currently believed. Psychosomatics 60:221-222, 2019. doi:10.1016/j.psym.2018.07.009. PMID: 30268342.
330. Schoretsanitis G, Villasante-Tezanos AG, **de Leon J**. Studies of half-lives of long-acting antipsychotics are needed. Pharmacopsychiatry 52(1):45-46, 2019. doi: 10.1055/a-0755-7692. PMID: 30347421.
331. Blasco-Fontecilla H, Artieda-Urrutia P, **de Leon J**. A proposal for using the ratio of attempted to completed suicides across several countries worldwide. Epidemiology and Psychiatric Sciences 28(5):473-477, 2019. doi: 10.1017/S2045796018000628. PMID: 30355373.
332. Baptista T, Araujo H, **de Leon J**. I Clozapine addition following brain surgery in severe primary obsessive-compulsive disorder with tardive movement disorder. Journal of Clinical Psychopharmacology 39(1):85-87, 2019. doi: 10.1097/JCP.0000000000000982. PMID: 30418255.
333. Schoretsanitis G, Spina E, Hiemke C, **de Leon J**. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Review in Clinical Pharmacology 11(12):1237-1253, 2018. doi: 10.1080/17512433.2018.1549489. PMID: 30449206.
334. De Las Cuevas C, Peñate W, Manuel García de Cecilia J, **de Leon J**. Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients. International Journal of Clinical and Health Psychology 18(2):133-142, 2018. doi: 10.1016/j.ijchp.2017.11.003. PMID: 30487918.
335. De Las Cuevas C, **de Leon J**. A clinimetric approach for improving the measurement of pharmacophobia with replication in two other samples. Psychotherapy and Psychosomatics 88(2):116-118, 2019 doi: 10.1159/000495940. PMID: 30650413.

336. Arcos-Burgos M, Vélez JI, Martínez AF, Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, Richarte V, Roncero C, Cormand B, Fernández-Castillo N, Casas M, Lopera F, Pineda DA, Palacio JD, Acosta-López JE, Cervantes-Henriquez ML, Sánchez-Rojas MG, Puentes-Rozo PJ, Molina BSG; MTA Cooperative Group, Boden MT, Wallis D, Lidbury B, Newman S, Eastal S, Swanson J, Patel H, Volkow N, Acosta MT, Castellanos FX, **de Leon J**, Mastronardi CA, Muenke M. ADGRL3 (LPHN3) variants predict substance use disorder. Translational Psychiatry 9(1):42, 2019. doi: 10.1038/s41398-019-0396-7. PMID: 30696812.
337. De Las Cuevas C, Motuca M, Baptista T, Villasante-Tezanos AG, **de Leon J**. Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications. Human Psychopharmacology: Clinical and Experimental 2019 Mar; 34(2):e2688, 2019. doi: 10.1002/hup.2688. PMID: 30698292.
338. Cicala G, Barbieri MA, Spina E, **de Leon J**. A comprehensive review of the swallowing difficulties and dysphagia in adults associated with antipsychotic. Expert Review in Clinical Pharmacology 12(3):219-234, 2019. doi: 10.1080/17512433.2019.1577134. PMID: 30700161.
339. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, **de Leon J**, Leeder SJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and atomoxetine therapy. Clinical Pharmacology & Therapeutics 106(1):94-102, 2019. doi: 10.1002/cpt.1409. PMID: 30801677.
340. Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, Spina E, **de Leon J**. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. Journal of Clinical Psychopharmacology 39;(2):135–144, 2019. doi: 10.1097/JCP.0000000000001018. PMID: 30811372.
341. **de Leon J**. Genetics guideline is excellent but the pharmacogenetics section is weak. Journal of Clinical Psychiatry 2019 Apr 9;(3). pii: 19lr12741. doi: 10.4088/JCP.19lr12741. PMID: 30997962.
342. De Las Cuevas C, **de Leon J**. Development and validation of the Patient's Health Belief Questionnaire on Psychiatric Treatment. Patient Preference and Adherence 13:527-536 2019. doi: 10.2147/PPA.S201144. eCollection 2019. PMID: 31040653.
343. Goldberg JF, Rosenblat JD, McIntyre RS, Preskorn SH, **de Leon J**. Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed? Journal of Psychiatric Research 114:208-209, 2019. doi: 10.1016/j.jpsychires.2019.04.002. PMID: 31064655.

344. Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, **de Leon J**. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review in Clinical Pharmacology 12 (7), 603–621, 2019. doi: 10.1080/17512433.2019.1617695. PMID: 31075044.
345. **de Leon J**. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology 168:107656, 2020. doi: 10.1016/j.neuropharm.2019.05.033. PMID: 31150659.
346. Barclay J, McCollum B, Schoretsanitis G, **de Leon J**. Gemfibrozil may decrease norclozapine elimination: a case report. Journal of Clinical Psychopharmacology 39(4):405-407, 2019 Jun 11. doi: 10.1097/JCP.0000000000001050. PMID: 31205191.
347. Verdoux H, Quiles C, **de Leon J**. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. Schizophrenia Research 211:1-9, 2019. doi: 10.1016/j.schres.2019.07.040. PMID: 31378552.
348. **de Leon J**, Rhee DW, Kondracke A, Diuguid-Gerber J. Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York hospital. Psychosomatics 61(1):102–103, 2020, doi: 10.1016/j.psych.2019.08.008. PMID: 31611046.
349. **de Leon J**. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations and should consider that inducer and/or inhibitory effects may vary with time, the individual and the auto-induction of valproic acid. Therapeutic Drug Monitoring 42(1):159-161, 2020. doi: 10.1097/FTD.0000000000000705. PMID: 31633608.
350. Ruan CJ, Wang CY, Tang YL, Lin SK, Lee ST, Hong KS, Rajkumar AP, Jacob KS, **de Leon J**. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2 and 13%. Journal of Clinical Psychopharmacology 39(6):644-648, 2019. doi: 10.1097/JCP.0000000000001125. PMID: 31688448.
351. Schoretsanitis G, **de Leon J**, Eap CB, Kane JM, Paulzen M. Clinically significant drug-drug interactions with agents for attention-deficit/hyperactivity disorder. CNS Drugs 33(12):1201-1222, 2019. doi: 10.1007/s40263-019-00683-7. PMID: 31776871.
352. Spina E, Barbieri MA, Cicala G, Bruno A, **de Leon J**. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opinion on Drug Metabolism and Toxicology 16(1):31-44, 2020. doi: 10.1080/17425255.2020.1700952. PMID: 31795773.

353. Rohde C, Siskind D, **de Leon J**, Nielsen J. Antipsychotic medication exposure, clozapine and pneumonia: results from a self-controlled study. Acta Psychiatrica Scandinavica 142(2):78-86, 2020. doi: 10.1111/acps.13142. PMID: 31875941.
354. **de Leon J**, Sanz EJ, De las Cuevas C. Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophrenia Bulletin 46(1):1-3, 2020. doi: 10.1093/schbul/sbz093. PMID: 31901099. *In May of 2021, according to ResearchGate there were 58 citations of this article.*
355. **de Leon J**, Sanz EJ, Norén GN, De las Cuevas C. Pneumonia may be more frequent and have more fatal outcomes in clozapine than in other second-generation antipsychotics. World Psychiatry 19(1):120-121, 2020. doi: 10.1002/wps.20707. PMID: 31922665.
356. **de Leon J**, Ruan CJ, Schoretsanitis G, Kane JM. Dose and safety concerns of clozapine: worldwide package inserts need revisions. Schizophrenia Research 216: 2–4, 2020. doi: 10.1016/j.schres.2019.12.009. PubMed PMID: 31926811. WITHDRAWN: Corrigendum to "Dose and safety concerns of clozapine: Worldwide package inserts need revisions" [Schizophr. Res. 08619]. Schizophr Res. 2020 Feb 2:S0920-9964(20)30031-1. doi: 10.1016/j.schres.2020.01.015. PMID: 32019683.
357. De Las Cuevas C, Betancort M, **de Leon J**. The necessity-concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample. Human Psychopharmacology: Clinical and Experimental 35(1):e2721, 2020. doi: 10.1002/hup.2721. PubMed PMID: 31961461.
358. **de Leon J**, Rajkumar AP, Kaithi AR, Schoretsanitis G, Kane JM, Wang CY, Tang YL, Lin SK, Hong KS, Farooq S, Ng CH, Ruan CJ, Andrade C. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian Journal of Psychological Medicine 42, 4-10, 2020. doi: 10.4103/IJPSYM.IJPSYM_379_19. PMID: 31997860.
359. Schoretsanitis G, Mendelowitz A, Malur C, Braga RJ, Schooler NR, John M, **de Leon J**, Kane JM, Petrides G. Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia Research 218:309-311, 2020. doi: 10.1016/j.schres.2020.02.008. Epub 2020 Feb 24. PMID: 32107101.
360. Ruan CJ, Zang YN, Cheng YH, Wang CY, **de Leon J**. Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing Hospital in-patients with more than 24,000 days of clozapine treatment. Psychotherapy and Psychosomatics 89(4):255-257, 2020. doi: 10.1159/000506355. PMID: 32114581.

361. **de Leon J**, Schoretsanitis G, Kane JM, Ruan CJ. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asian-Pacific Psychiatry 12(2):e12384, 2020. doi: 10.1111/appy.12384. PMID: 32119764.
362. **de Leon J**, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychotherapy and Psychosomatics 89(4):200-214, 2020. doi: 10.1159/000507638. PMID: 32289791.
363. Ruan CJ, **de Leon J**. Is there a future for *CYP1A2* pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics 21(6):369-373, 2020. doi: 10.2217/pgs-2020-0015. PMID: 32308139.
364. Schoretsanitis G, Kane JM, **de Leon J**. Adding oral contraceptives to clozapine may require halving clozapine dose: a new case and a literature review. Journal of Clinical Psychopharmacology 40(3):308-310 2020. doi: 10.1097/JCP.0000000000001202. PubMed PMID: 32332470.
365. **de Leon J**, De las Cuevas C, Sanz E, Verdoux H. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. Psychological Medicine 51, 1405–1406, 2021. doi: 10.1017/S0033291720001233. PubMed PMID: 32372739.
366. Villasante-Tezanos AG, Rohde C, Nielsen J, **de Leon J**. Pneumonia risk: one third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiatrica Scandinavica 142(1):66–67:2020. doi: 10.1111/acps.13184. PMID: 32415875.
367. **de Leon J**, Ruan CJ, Verdoux H, Wang CY. Clozapine is strongly associated with pneumonia and other infections: Clinical relevance of the relationship between clozapine and inflammation. General Psychiatry 33(2):e100183, 2020. doi: 10.1136/gpsych-2019-100183. PMID: 32420521.
368. Chopra C, Ruan CJ, McCollum B, Ognibene J, Shelton C, **de Leon J**. High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers. Revista Colombiana de Psiquiatría 49(2):83-9, 2020. doi: 10.1016/j.rcp.2018.07.002. PMID: 32446424.
369. Zhang X, Crespo-Facorro B, **de Leon J**, Diaz F. Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users. Journal of Biopharmaceutical Statistics 30(5):916-940, 2020. doi: 10.1080/10543406.2020.1765371. PMID: 32511941.

370. Zhang L, Brown SJ, Shan Y, Lee AM, Allen JD, Eum S, **de Leon J**, Bishop JR. CYP2D6 genetic polymorphisms and risperidone pharmacokinetics: a systematic review and meta-analysis. Pharmacotherapy 40(7):632–647, 2020. doi: 10.1002/phar.2434. PMID: 32519344.
371. **de Leon J**, Schoretsanitis G. CYP2D6 pharmacogenetics and risperidone: Reflections after 25 years of research. Pharmacogenomics 21(16):1139-1144, 2020. doi: 10.2217/pgs-2020-0115. PMID: 33054667.
372. Schoretsanitis G, Kane JM, **de Leon J**. Edentulousness in severely mentally ill patients: a pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. Schizophrenia Research 224:178–179, 2020. doi: 10.1016/j.schres.2020.09.023. PMID: 33067056.
373. De Las Cuevas C, **de Leon J**. Self-report for measuring and predicting medication adherence: experts' experience on predicting adherence in stable psychiatric outpatients and on pharmacokinetics. Patient Preference and Adherence 14:1823-1842, 2020. doi: 10.2147/PPA.S242693. PMID: 33116427.
374. Spina E, Barbieri MA, Cicala G, **de Leon J**. Clinically relevant drug interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel). 2020 Dec 2;13(12):E439. doi: 10.3390/ph13120439. PMID: 33276675.
375. Schoretsanitis G, Ruan CJ, Rohde C, Verdoux H, De las Cuevas C, Spina E, **de Leon J**. An update on the complex relationship between clozapine and pneumonia. Expert Review in Clinical Pharmacology 14(2):145-149, 2021. doi 10.1080/17512433.2021.1877135. PMID: 33461363.
376. De Las Cuevas C, Villasante-Tezanos AG, Motuca M, **de Leon J**. Effect of necessity-concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample. Human Psychopharmacology: Clinical and Experimental Jul;36(4):e2776, 2021. doi: 10.1002/hup.2776. PMID: 33508164.
377. Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Vázquez M, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, **de Leon J**. European Whites may need lower minimum therapeutic clozapine doses than those customarily proposed. Journal of Clinical Psychopharmacology 41(2):140-147, 2021. doi: 10.1097/JCP.0000000000001341. PMID: 33587398.
378. Zang YN, Dong F, Li AN, Wang CY, Guo CX, Wang Q, Zhang YF, Zhang L, **de Leon J**, Ruan CJ. The impact of smoking, sex, infection and co-medication administration on olanzapine: a population pharmacokinetic model in Chinese psychiatric patients. European Journal of Drug Metabolism and Pharmacokinetics 46(3):353-371, 2021. doi: 10.1007/s13318-021-00673-5. PMID: 33677821. Correction PMID: 33743172.

379. Verdoux H, Debruyne AL, Queuille E, **De Leon J**. A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review. Expert Opinion in Drug Safety 2021 Jul;20(7):827-838. doi: 10.1080/14740338.2021.1912011. PMID: 33789560.
380. Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, **de Leon J**, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World Journal of Biological Psychiatry 2021 Oct;22(8):561-628. doi: 10.1080/15622975.2021.1878427. PMID: 33977870.
381. **de Leon J**. Reflections on US Psychiatry: How the baton was passed from European psychiatry and the contributions of US psychiatry. Journal of Nervous and Mental Diseases 209(6):403-408, 2021. doi: 10.1097/NMD.0000000000001324. PMID: 34037550.
382. Carrozzino D, Patierno C, Guidi J, Berrocal Montiel C, Cao J, Charlson ME, Christensen KS, Concato J, De Las Cuevas C, **de Leon J**, Eöry A, Fleck MP, Furukawa TA, Horwitz RI, Nierenberg AA, Rafanelli C, Wang H, Wise TN, Sonino N, Fava GA. Clinimetric criteria for patient-reported outcome measures. Psychotherapy and Psychosomatics 90(4):222-232, 2021. doi: 10.1159/000516599. Epub 2021 May 26. PMID: 34038901.
383. Cuevas CL, Sanz EJ, Ruan CJ, **de Leon J**. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. Revista de Psiquiatria y Salud Mental 2021 Jul 20:S1888-9891(21)00070-7. English, Spanish. doi: 10.1016/j.rpsm.2021.07.004. Epub ahead of print. PMID: 34298164.
384. **de Leon J**. Commentary on tools for optimizing pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. Pharmacogenomics 22(13):805-808, 2021. doi: 10.2217/pgs-2021-0090. PMID: 34344160.
385. González-Esquivel DF, Jung-Cook H, Baptista T, de Leon J. Amerindians may need clozapine dosing similar to that of Asians. Revista de Psiquiatria y Salud Mental 14(3):177-179, 2021. doi: 10.1016/j.rpsm.2020.11.002. PMID: 34456032. (Epub version was listed as PMID: 33259963).

386. Kirilochev OO, De las Cuevas C, **de Leon J**. Clozapine-induced myocarditis in Russia: animal studies but no clinical studies. Revista de Psiquiatria y Salud Mental 2021 Sep17:S1888-9891(21)00100-2. English, Spanish. doi 10.1016/j.rpsm.2021.09.001.Epub ahead of print. PMID: 34543772.
387. **de Leon J**, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Yağcıoğlu AEA, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ristic DI, Ortiz BB, Elkis H, Pacheco Palha AJ, Llerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Saffian SM, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An international adult guideline for making clozapine titration safer by using 6 ancestry-based personalized dosing titrations, CRP and clozapine levels. Pharmacopsychiatry 55(2):73-86, 2022. doi: 10.1055/a-1625-6388. PMID: 34911124. These guidelines include 104 authors from 50 countries/regions and are freely available <https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1625-6388>
Correction on last names was published on Pharmacopsychiatry 55(2):e1, 2022. doi: 10.1055/a-1737-1527. PMID: 35052001
Japanese translation http://www.jscnp.org/clozapine/pdf/submit_form.pdf
388. De Las Cuevas C, Lazary J, Poganyi L, **De Leon J**. Practical approach to measuring and predicting medication adherence by outpatient's self report after more than 10 years of research in psychopharmacology. Neuropsychopharmacologia Hungarica 23(4):336-346, 2021. PMID: 34971305.
389. De Las Cuevas C, Villasante-Tezanos GA, Motuca M, Baptista T, Lazary J, Pogany L, **De Leon J**. Poor Adherence to oral psychiatric medication in adults with bipolar disorder: the psychiatrist may have more influence than in other severe mental illnesses. Neuropsychopharmacologia Hungarica 23(4):347-362, 2021. PMID: 34971399.
390. Lazary J, Pogany L, De Las Cuevas C, Villasante-Tezanos GA, **De Leon J**. Adherence to psychiatric medications: Comparing patients with schizophrenia, bipolar disorder and major depression. Neuropsychopharmacologia Hungarica 23(4):363-373, 2021. PMID: 34971494.

391. De Las Cuevas C, Motuca M, Baptista T, Villasante-Tezanos GA, Lazary J, Pogany L, **De Leon J**. Poor adherence to oral psychiatric medication in adults with depression: psychological reactance may have specific effects in depression. Neuropsychopharmacologia Hungarica 23(4):374-387, 2021. PMID: 34971495.
392. De Las Cuevas C, Baptista T, Motuca M, Villasante-Tezanos GA, Lazary J, Pogany L, **De Leon J**. Poor adherence to oral psychiatric medication in adults with schizophrenia may be influenced by pharmacophobia, high internal health locus of control and treatment duration. Neuropsychopharmacologia Hungarica 23(4):388-404, 2021. PMID: 34971496.
393. De las Cuevas C, Sanz EJ, Rohde C, **de Leon J**. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Review in Clinical Pharmacology 15(1):65-78, 2022. doi: 10.1080/17512433.2022.2032659. PMID: .
394. **de Leon J**. Precision psychiatry: The complexity of personalizing antipsychotic dosing. European Neuropsychopharmacology 58:80–85, 2022. doi: 10.1016/j.euroneuro.2022.03.001. PMID: 35314415.
395. McGrane I, Spina E, Hiemke C, **de Leon J**. Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis. Expert Opinion in Drug Metabolism and Toxicology 18(2):135–149, 2022 doi: 10.1080/17425255.2022.2057297. PMID: 35331064.
396. **de Leon J**, Schoretsanitis G, Ruan C-J, De las Cuevas C, Kane JM, Correll CU. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. European Archives of Psychiatry and Clinical Neurosciences 2022 Apr 8. doi: 10.1007/s00406-022-01407-7. Epub ahead of print. PMID: 35394202. The articles is freely available <https://link.springer.com/article/10.1007/s00406-022-01407-7>
397. Koenig M, McCollum B, Spivey JK, Coleman JK, Shelton C, Cotes RO, Goldsmith DR, **De Leon J**. Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. Neuropsychopharmacologia Hungarica 24(1):29-41, 2022. PMID: 35451590. Pdf is freely available at <https://mppt.hu/en/project/volume-24-issue-1-march-2022/>
398. Zang Y-N, Guo W, Dong F, Li AN, **de Leon J**, Ruan CJ. Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample with bipolar disorder. Expert Review in Clinical Pharmacology 2022;15(5):621-635, 2022. doi: 10.1080/17512433.2022.2075849. PMID: 35536685.

399. Pisani F, Rosa Pisani L, Barbieri MA, **de Leon J**, Spina E. Optimization of therapy in patients with epilepsy and psychiatric comorbidity: key points. Current Neuropharmacology 2022 May 26. doi: 10.2174/1570159X20666220526144314. Epub ahead of print. PMID: 35619263.
400. **de Leon J**. The history of clozapine in clinical practice: from its introduction to a guideline proposing personalized titrations. Journal of Psychopharmacology 36(6):657-660, 2022. doi: 10.1177/02698811221101059. PMID: 35634693.
401. de Filippis R, Kane JM, Kuzo N, Spina E, De Sarro G, **de Leon J**, De Fazio P, Schoretsanitis G. Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. European Neuropsychopharmacology 60:25-37, 2022. doi: 10.1016/j.euroneuro.2022.04.009. PMID: 35635994.
402. **de Leon J**, De las Cuevas C, Sanz EJ, Ruan C-J, Correll CU. Clozapine and the risk of haematological malignancies. Lancet Psychiatry 9(7):537-538, 2022. doi: 10.1016/S2215-0366(22)00154-7. PMID: 35717956.
403. **de Leon J**, Baptista T, Motuca M, Ruan CJ, Schoretsanitis G, De Las Cuevas C. Promoting safer clozapine dosing in the Americas. Brazilian Journal of Psychiatry 44(4):363–365, 2022. doi: 10.47626/1516-4446-2021-0041. PMID: 35751620. Free pdf available at PubMed <https://pubmed.ncbi.nlm.nih.gov/35751620/>
404. Arrojo-Romero M, Codesido-Barcala MR, **de Leon J**. A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels. Revista de Psiquiatria y Salud Mental 2022; 15(4):290-292. PMID: 35782582. Free pdf available at PubMed <https://pubmed.ncbi.nlm.nih.gov/36513405/>
405. Schoretsanitis G, **de Leon J**. C Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s). Journal of Clinical Psychiatry 83(4):22ac14500, 2022. doi: 10.4088/JCP.22ac14500. PMID: 35802932. Free pdf available at PubMed <https://pubmed.ncbi.nlm.nih.gov/35802932/>
406. **de Leon J**, Ruan CJ, Schoretsanitis G, Rohde C, Anıl Yağcıoğlu, Baptista T, Kirilochev OO, De Las Cuevas C, Correll CU. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine. General Psychiatry 2022 Jun 29;35(3):e100773. doi: 10.1136/gpsych-2022-100773. PMID: 35866000. Free pdf available at PubMed <https://pubmed.ncbi.nlm.nih.gov/35866000/>

407. Schoretsanitis G, Deligiannidis KM, Paulzen M, Spina E, **de Leon J. C** Drug-drug interactions between psychotropic medications and oral contraceptives: implications for the management of psychiatric disorders in women of reproductive age. Expert Opinion in Drug Metabolism and Toxicology 18(6):395-411, 2022. doi: 10.1080/17425255.2022.2106214. PMID: 35876180.
408. **de Leon J.** An international clozapine titration guideline for clozapine: an opportunity for moving forward on personalizing clozapine treatment in India and other countries. Indian Journal of Psychiatry 2022 ;64(4):331-334. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_423_22. PMID: 36060712 Free pdf available at PubMed <https://pubmed.ncbi.nlm.nih.gov/36060712/>
409. De Las Cuevas C, Sanz EJ, **de Leon J.** Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase. Expert Opinion in Drug Metabolism and Toxicology 18(9):541-553, 2022. doi: 10.1080/17425255.2022.2122813. PMID: 36073179.
410. **de Leon J.** According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world. British Journal of Clinical Pharmacology 2022 Sep 15. doi: 10.1111/bcp.15522. Epub ahead of print. PMID: 36106607.
411. Leung JG, **de Leon J**, Frye MA, Singh B, Cotes RO, McElroy S. The modernization of clozapine: a recapitulation of the past in the United States and the view forward. Journal of Clinical Psychopharmacology 42(6):565-580, 2022. doi: 10.1097/JCP.0000000000001606. PMID: 36170148.
412. **de Leon J.** Reflections on the complex history of the concept of clozapine-induced inflammation during titration. Psychiatria Danubina 34(3):411-421 2022. doi: 10.24869/psyd.2022.411. PMID: 36256975.
413. Ertuğrul A, Yağcıoğlu EA, Ağaoğlu E, Karakaşlı AA, Ak S, Yazıcı K, **Leon J.** Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: A re-analysis of a study in a Turkish hospital. Revista de Psiquiatria y Salud Mental (Engl Ed) 2022 15(4):281-286, 2022. doi: 10.1016/j.rpsmen.2021.10.001. PMID: 36513403.
414. Jiménez-Fernández S, Gurpegui M, **de Leon J**, Gutiérrez-Rojas L. Clozapine for the treatment of pediatric encephalopathy associated with nonketotic hyperglycinemia. Revista de Psiquiatria y Salud Mental (Engl Ed). 15(4):287-289, 2022. doi: 10.1016/j.rpsmen.2022.10.001. PMID: 36513404.

415. De las Cuevas C, Arrojo-Romero M, Ruan C-J, Schoretsanitis G, Sanz EJ, **de Leon J**. Clozapine-induced myocarditis in children and adolescents: A pharmacovigilance study using VigiBase and a systematic literature review. Expert Opinion in Drug Metabolism and Toxicology 18(11):715-727, 2022. doi: 10.1080/17425255.2022.2160318. PMID: 36526610.

de Leon J. Reflections on the lack of consideration of ethnic ancestry to stratify clozapine dosing. Psychiatry Investigation in press.

de Leon J, Arrojo-Romero M, Verdoux H, Ruan C-J, Schoretsanitis G, Rohde C, Cohen D, Schulte PFJ, Kim SH, Cotes RO, o, Jonathan G. Leung JG, Otsuka Y, Kirilochev OO, Baptista T, Grover S, Every-Palmer S, Clark SR, McGrane IR, Motuca M, Olmos I, Wilkowska A, Sagud M, Anıl Yağcıoğlu AE, Ignjatovic Ristic D, Lazary J, Sanz EJ, De Las Cuevas C. Escaping the long shadow of agranulocytosis. Reflections on a clozapine pharmacovigilance focused on the United Kingdom. Journal of Clinical Psychopharmacology (in press).

**B) 14 ARTICLES AND 6 LETTERS TO EDITOR NOT INCLUDED IN PUBMED:
14 ARTICLES NOT INCLUDED IN PUBMED:**

de Leon J. Psychosocial considerations about pediatric oncology (in Spanish). Revista de Pediatría 41:203-210, 1985.

de Leon J, Simpson GM. Do schizophrenic negative symptoms respond to neuroleptics? Integrative Psychiatry 7:39-47, 1991.

Gurpegui M, **de Leon J**. Extrapiramidal effects induced by neuroleptics (in Spanish). Folia Neuropsiquiátrica 29:183-189, 1994.

Pelegrin C, **de Leon J**, Fernandez JM. Depression in stroke (in Spanish). Revista Española de Neurología 4:485-494, 1989.

Ciudad-Herrera A, **de Leon J**, Calcedo A. Depressive symptomatology in the course of schizophrenia. A six month follow-up study. Neurology, Psychiatry and Brain Research 3:85-90, 1995.

Nair CJ, Abraham G, Stanilla JK, Tracy JI, **de Leon J**, Simpson GM, Jossiasen RC. Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioral Practice 5:119-127, 1998.

Martínez Ortega JM, Gurpegui M, Díaz FJ, **de Leon J**. Tobacco and schizophrenia (in Spanish). Addicciones 16:177-180, 2004.

Ruktanonchai D, **de Leon J**. Polydipsia in autistic disorder. Review Series: Psychiatry 4:12-13, 2004.
https://www.researchgate.net/publication/299338570_Polydipsia_in_autistic_disorder

Pinninti NR, Mago R., **de Leon J**. Coffee, cigarettes and meds: What are the metabolic effects? Psychiatric Times 22:20-23, 2005.

Baca-Garcia E, Parra CP, Perez-Rodriguez MM, Diaz-Sastre C, Torres R, Saiz-Ruiz J, **de Leon J**. Psychosocial stressor may be strongly associated with suicide attempts. Stress and Health 23: 191-198, 2007.

de Leon J, Gurpegui M, Diaz FJ. Epidemiology of comorbid tobacco use and schizophrenia: thinking about risks and protective factors. Journal of Dual Diagnosis 3:9-25, 2007.
http://www.tandfonline.com/doi/abs/10.1300/J374v03n03_03

de Leon J. Get ready to become ignorant with age: letter to James. The Other Side (A University of Kentucky Literary Magazine) 3:14-15, 2014.

Levy F, **de Leon J**. Dopamine ADHD/OCD Theories: Is Glutamine Part of the Story? Neurotransmitter (in press).

- de Leon J.** You should not use non-validated pharmacogenetic tests in psychiatry. Part I: an embarrassed Professor of Psychiatry proposes his argument. Psychiatric Times October 2, 2016.
- López-Jaramillo C, Díaz-Zuluaga AM, **de Leon J**, Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C. TDM in psychiatry and neurology: A Spanish translation of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Psiquiatria Biologica 27(3):83-95, 2020.
- Zhang X, Pantazis N, **de Leon J**, Diaz FJ. Measuring individual benefits of medical treatments using longitudinal hospital data with non-ignorable missing responses caused by patient discharge: application to the study of benefits of pain management post spinal fusion. Revista Colombiana de Estadística-Applied Statistics 45(2):275-300,2022.
- Yasui-Furakori N, Otsuka Y, **de Leon J**. Japanese patients need slower, personalized clozapine titrations. A comment on the case described by Kikuchi et al. Psychiatry and Clinical Neurosciences Reports 2023;2:e70. Freely available <https://onlinelibrary.wiley.com/doi/10.1002/pcn5.70>

7 LETTERS TO EDITOR NOT INCLUDED IN PUBMED:

de Leon-Molina J, Muñoz-Ruata J, Pico-Soler E. Is there a right-hemisphere dysfunction in Asperger's syndrome? British Journal of Psychiatry 148:745-746, 1986.

Vitiello B, **de Leon J**. On dysmorphophobia misdiagnosed as obsessive-compulsive disorder (reply). Psychosomatics 31:469, 1990.

de Leon J. Schizophrenia, smoking and boredom (reply). American Journal of Psychiatry 153: 583-584, 1996.

de Leon J, Bork JA. Risperidone-carbamazepine interaction: Is cytochrome P450 3A involved (reply). Journal of Clinical Psychiatry 59:431, 1998.

Durrenberger S, **de Leon J**. The high costs of care (reply). Psychiatric Services 51:676, 2000.

Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, **de Leon J**. Reply to Lian et al. Progress in Neuro-Psychopharmacology & Biological Psychiatry 34: 1159, 2010.

Yasui-Furakori N, Otsuka Y, **de Leon J**. Japanese patients need slower, personalized clozapine titrations. A comment on the case described by Kikuchi et al. Psychiatry and Clinical Neurosciences Reports in press.

C) SUBMITTED PAPERS:

De las Cuevas C, Sanz EJ, Villasante-Tezanos AG, **de Leon J**. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase. Expert Opinion in Drug Metabolism and Toxicology (submitted).

D) PSYCHOPHARMACOLOGY LECTURES IN POWERPOINT

de Leon J. Training Psychiatrists To Think Like Pharmacologists”

Course to teach pharmacodynamics and pharmacokinetics of psychiatric drugs using many real psychiatric patient cases.

The course is placed at <https://www.inhn.org/about/courses/jose-de-leon-training-psychiatrists-to-think-like-pharmacologists> a web page developed by INHN (International Network for the History of Neuropsychopharmacology).

The 2015 psychopharmacology course has 14 theoretical lectures and 18 cases. Most of these cases have already been published in peer-reviewed journals.

E) BOOKS (AUTHOR):

de Leon J, Chambers, A, Hyatt M, Shertz E, Aug R, Sinclair K, Bensalem-Owen M, Milteer W, Pradeep M, Maxwell M, Spina E, Kinsella LJ, Singh NN. A Practitioner’s Guide for Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. New York: Springer Verlag (2012). ISBN-13: 978-1461420118.

This book includes 21 pharmacological guidelines (carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lithium, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproate and zonisamide), 24 chapters, more than 500 pages and more than 2000 references. Dr. de Leon wrote these guidelines to meet the Strategic Action Plan developed by the Department of Justice to improve patient care at Kentucky facilities for adults with intellectual disabilities.

Publisher: <http://www.springer.com/medicine/psychiatry/book/978-1-4614-2011-8>

Amazon: http://www.amazon.com/Practitioners-Prescribing-Antiepileptics-Intellectual-Disabilities/dp/1461420113/ref=sr_1_2?s=books&ie=UTF8&qid=1333385489&sr=1-2

It has two five-star reviews on Amazon.com.

F) CHAPTERS IN BOOKS (AUTHOR) (5 chapters):

de Leon J, Simpson GM. Assessment of neuroleptic-induced extrapyramidal symptoms. In Adverse Effects of Psychotropic Drugs. Kane JM, Lieberman JA (eds). Guilford Press: New York, 1992, pp 218-234. <http://works.bepress.com/jdeleon/91/>
https://www.researchgate.net/publication/310304621_Assessment_of_neuroleptic-induced_extrapyramidal_symptoms

de Leon J, Mueser K. Relapse prevention (in Spanish). In Schizophrenia: Psychological and Psychiatric Fundamentals of Rehabilitation, Aldaz JA, Vázquez C (eds). Siglo XXI Editores S.A.: Madrid, 1996, pp 247-264.

de Leon J. Pharmacogenetics of Schizophrenia (in Spanish). In Crisis Intervention and Acute Treatment of Severe Mental Disorders, Pichot P, Ezcurra J, Gonzales-Pinto A, Gutierrez-Fraile M (eds). Aula Medica Ediciones: Madrid, 2003, pp 323-330.

de Leon J. Future of personalized prescription in psychiatry. In Pharmacogenomics in Psychiatry. Schwab M, Kaschka WP, Spina E (eds). Advances in Biological Psychiatry 25, pp 118–134, 2010. Karger: Basel.

Blasco-Fontecilla H, **de Leon J**. Scales for the evaluation of suicide risk (Chapter 44, pp 373-6). In Oxford Textbook of Suicidology and Suicide Prevention. Wasserman d (ed). Oxford University Press: Oxford, UK. doi: 10.1093/med/9780198834441.003.0044

G) BOOK REVIEWS: (4 book reviews)

de Leon J. The Natural History of Mania, Depression, and Schizophrenia. Winokur G, Tsuang T. Washington, D.C: American Psychiatric Press, 1996. New England Journal of Medicine 335:1164, 1996.

de Leon J. The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political and Ethical Concerns. Hertzman M and Fletner DD (eds). New York: New York University Press, 1997. New England Journal of Medicine 338:205-206, 1998.

de Leon J. Suicidal Behavior In Europe: Results From The WHO/Euro Multicentre Study On Suicidal Behavior. Schmidtke A, Bille-Brahe U, De Leo D, and Kerkhof A. Gottingen Germany: Hogrefe & Huber, 2004. Community Mental Health Journal 41:625-626, 2005. PMID: 16142544.

de Leon J. Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment and Treatment, *Mendelson, SD*. Burlington, MA: Academic Press 2008. American Journal of Psychiatry 165:1056-1057, 2008.

H) VIDEOS: (1 video)

Gurpegui M, **de Leon J**. Assessment of Neurological Side Effects Induced by Neuroleptics (in Spanish). Department of Psychiatry, Medical School, University of Granada, Spain. October, 1993.

I) TELE LECTURE: (1 lecture)

de Leon J. Polydipsia in severe mental illness. Journal of Psychotic Disorders 3, 8-9, 2001.

J) ABSTRACTS

(Abstracts are from posters unless oral presentation is specified. 79 abstracts in international meetings and 2 in national meetings):

de Leon J, Simpson GM, Wilson WH. Comparison of negative symptoms scales (NR11). New research program and abstracts. American Psychiatric Association 142nd Annual Meeting, San Francisco, CA, May 6-11, 1989.

de Leon J, Peralta V, Cuesta MJ. Symptoms and syndromes associated with clinical response in schizophrenia. 30th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 9-13, 1991.

de Leon J, White AO, Simpson GM. Test-retest reliability of attention disturbances in schizophrenic patients. 47th Annual Meeting of the Society of Biological Psychiatry, Washington D.C., April 29-May 3, 1992. Biological Psychiatry 31:113A, 1992.

Tracy J, Ferguson M, Qureshi G, Jordan Y, Johnson C, Lewis K, **de Leon J**, Simpson G. Prevalence of water intoxication in a state hospital. 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 14-18, 1992.

de Leon J, Tracy J, Josiassen R, Simpson G. A comparison of biological and clinical report estimates of polydipsia: Data from a state hospital sample. 48th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 19-23, 1993. Biological Psychiatry 33:93-94A, 1993.

Tracy J, **de Leon J**, Josiassen R, White A, Simpson G. The demographic and clinical characteristics of polydipsia and water intoxication: Data from a state hospital sample. 48th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 19-23, 1993. Biological Psychiatry 33:94A, 1993.

Simpson GM, **de Leon J**. Factors contributing to Institutionalization (oral presentation). Symposium "Chronic Institutionalization: Current Status." American Psychiatric Association 146th Annual Meeting, San Francisco, CA, May 22-27, 1993.

Tracy J, **de Leon J**, Doonan R, Josiassen R. A comparison of the stability of "fluid" and "crystallized" cognitive measures in schizophrenia. Cognitive Neuroscience Society Annual Meeting, San Francisco, CA, February 15-17, 1994.

White AO, Oesterling R, Tracy J, Cloud B, **de Leon J**, Josiassen RC, Simpson G. Attentional effects on a test of ecological memory in schizophrenia. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:634, 1994.

Cloud BS, White AO, Tracy J, Oesterling R, **de Leon J**, Josiassen R, Simpson G. The effects of chronic psychosis on Rivermead Behavioral Memory Test Performance. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:637, 1994.

Tracy J, Eby L, **de Leon J**, Doonan R, Ballas T, Josiassen R. The stability and agreement of general impairment indicators in schizophrenia. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:637, 1994.

Peralta V, Cuesta MJ, **de Leon J**. Confirmatory factor analysis to test schizophrenic models. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:695, 1994.

de Leon J, Tracy J, Mc Cann E, Mc Grory A, Josiassen R. Do polydipsia patients display other repetitive behaviors? 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:698, 1994.

de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Epidemiological and clinical factors associated with polydipsia in a state hospital. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:698, 1994.

Vergheze C, McGrory A, Nair C, McCann E, Martin N, **de Leon J**. Urine concentration of creatinine: Comparison of methods to detect polyuria. 49th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, May 18-22, PA, 1994. Biological Psychiatry 35:702, 1994.

de Leon J, Tracy J, Vergheze C, Josiassen RC. Epidemiology of polydipsia in chronic inpatients (oral presentation). Symposium "Polydipsia/Hyponatremia in Chronic Mental Illness" American Psychiatric Association 147th Annual Meeting, Philadelphia, PA, May 21-26, 1994.

Tracy J, **de Leon J**, Vergheze C, Josiassen RC. Repetitive behaviors: Discrete or inter-related? (oral presentation) Symposium "Polydipsia/Hyponatremia in Chronic Mental Illness" American Psychiatric Association 147th Annual Meeting, Philadelphia, PA, May 21-26, 1994.

Vergheze C, **de Leon J**, Simpson GM. Neuroendocrine factors in polydipsia: a model. Symposium "Polydipsia/Hyponatremia in Chronic Mental Illness" American Psychiatric Association 147th Annual Meeting, Philadelphia, PA, May 21-26, 1994.

- de Leon J**, Canuso C, White AO, Stanilla JK, Simpson GM. High dosages of neuroleptics-A survey in a long-term hospital. XIX Collegium Internationale Neuro-Psychopharmacologicum Congress. Washington D.C., June 27-July 1, 1994. Neuropsychopharmacology 11:267, 1994.
- de Leon J**, Doonan R, Simpson GM. Mini-Mental State Examination and Trail Making Test in schizophrenic inpatients. 5th International Congress on Schizophrenia Research. Warm Springs, VA, April 8-12, 1995. Schizophrenia Research 15:114, 1995.
- Vergheese C, **de Leon J**, Nair C, McGrory A, McCann E, Stanilla JK, Josiassen, R. Urine specific gravity may not measure polydipsia in the presence of water retention. 5th International Congress on Schizophrenia Research. Warm Springs, VA, April 8-12, 1995. Schizophrenia Research 15:138, 1995.
- de Leon J**, Odom-White A, Stanilla JK, Josiassen R, Simpson GM. Does clozapine induce akathisia? 5th International Congress on Schizophrenia Research. Warm Springs, VA, April 8-12, 1995. Schizophrenia Research 15:206, 1995.
- de Leon J**, Abraham G, Nair C, Vergheese C, McGrory A, McCann E. Nicotine addiction in chronic schizophrenic inpatients. 50th Annual Meeting of the Society of Biological Psychiatry, Miami, FL, May 17-21, 1995. Biological Psychiatry 37:640, 1995.
- de Leon J**, Simpson G, Nair C, Stanilla JK, Josiassen R, Bridger WH. Double blind clozapine in treatment resistant schizophrenia. 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11-15, 1995.
- Stanilla JK, Nair C, **de Leon J**, Josiassen R, Simpson G. Lack of akathisia during clozapine treatment. 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11-15, 1995.
- Vergheese C, Simpson GM, Abraham G, Nair C, **de Leon J**, Stanilla JK, Philips I, Kimura B. Biochemical and endocrine changes during clozapine treatment of polydipsia. 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11-15, 1995.
- Nair C, Abraham G, **de Leon J**, Stanilla JK, Josiassen RC, Simpson G. Dose-related effects of clozapine on tardive dyskinesia among "treatment-refractory" patients with schizophrenia. 51st Annual Meeting of the Society of Biological Psychiatry, New York, NY, May 1-5, 1996. Biological Psychiatry 39:529, 1996.
- Stanilla JK, Buchel C, Alarcon J, **de Leon J**, Simpson GM. Instrumental assessment of longitudinal variations of tardive dyskinesia. 51st Annual Meeting of the Society of Biological Psychiatry, New York, NY, May 1-5, 1996. Biological Psychiatry 39:548, 1996.

- de Leon J**, Wedlund P, Ehlers R, Josiassen R, Cooper T, Simpson G. Cytochrome P450-2D6 (CYP2D6) genotype: Relationship with clozapine and haloperidol metabolism. 51st Annual Meeting of the Society of Biological Psychiatry, New York, NY, May 1-5, 1996. Biological Psychiatry 39:591, 1996.
- Cuesta M, Peralta V, **de Leon J**. Relationship between frontal signs and neuropsychological disturbances in schizophrenic patients. International Congress of Neuropsychiatry, Sevilla, Spain, August 28, 1996.
- Rogers T, **de Leon J**. Nicotine Dependence Among Schizophrenic Inpatients. Sixth International Congress on Schizophrenia Research. Colorado Springs, CO, April 12-17, 1997. Schizophrenia Research 24:257, 1997.
- Barnhill J, Boyle J, Rogers T, Wedlund P, Chou W, **de Leon J**. Screening for the Cytochrome P-450 2D6 in a state hospital. 52nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA, May 14-18, 1997. Biological Psychiatry 41:24S, 1997.
- Abraham G, Nair C, **de Leon J**, Simpson GM, Josiassen RC. Factor structure of the Simpson-Angus Neurological Rating Scale. 52nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA, May 14-18, 1997. Biological Psychiatry 41:98S, 1997.
- Nair C, Abraham G, Stanilla JK, **de Leon J**, Simpson GM, Josiassen RC. Akathisia influences response of BPRS symptom clusters to clozapine. 52nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA, May 14-18, 1997. Biological Psychiatry 41:99S, 1997.
- Aslam M, Nair C, **de Leon J**, Simpson GM, Josiassen RC. Factor structure of the Abbreviated Dyskinesia Rating Scale. 52nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA, May 14-18, 1997. Biological Psychiatry 41:99S, 1997.
- Bork JA, Rogers T, Wedlund P, Chou W, **de Leon J**. Risperidone metabolism and drug interaction in treatment refractory patients. New Research Program and Abstracts (NR 117). American Psychiatric Association 150th Annual Meeting, San Diego, CA, May 30-June 4, 1997.
- de Leon J**, Mosquera F, Gonzalez-Pinto A, Gutierrez M, Figuerido JL, Lopez P. Alcohol abuse and bipolar disorder: A family study. New Research Program and Abstracts (NR 430). American Psychiatric Association 150th Annual Meeting, San Diego, CA, May 30-June 4, 1997.
- de Leon J**, Gonzalez-Pinto A, Mosquera F, Gutierrez M, Perez de Heredia, Ezcurra J. Psychosis and bipolar disorder: Family history. New Research Program and Abstracts (NR 431). American Psychiatric Association 150th Annual Meeting, San Diego, CA, May 30-June 4, 1997.

- Rogers T, Merrick B, Decious B, Bowe T, Boyle J, **de Leon J**. Nicotine Dependence in Schizophrenic Inpatients Versus Other Psychiatric Inpatients (Poster A45). Third Annual Scientific Conference. The Society for Research on Nicotine and Tobacco. Nashville, TN, June 13-14, 1997.
- Baca-Garcia E, Diaz-Sastre C, **de Leon J**, Saiz Ruiz J. Suicide attempts and female gonadotropins. 28th Annual Meeting of the International Society of Psychoneuroendocrinology, San Francisco, CA, July 26-30, 1997. Psychoneuroendocrinology 22 (Suppl 2): S177, 1997.
- Diaz-Sastre C, Baca-Garcia E, Cebollada A, **de Leon J**, Saiz J. Bipolar disorder and serum lipid profile. 28th Annual Meeting of the International Society of Psychoneuroendocrinology, San Francisco, CA, July 26-30, 1997. Psychoneuroendocrinology 22 (Suppl 2):S200, 1997.
- Durrenberger SD, Rogers T, **de Leon J**. Lack of treatment compliance: high costs in five manics (Poster 88). 49th Institute on Psychiatric Services. Washington, D.C., October 24-28, 1997. National meeting.
- de Leon J**, Rogers T, Brumagen J, Weddle L, Wedlund PJ, Chou WH. Cytochrome P450-2D6 (CYP2D6) genotypes in normal controls. 53rd Annual Meeting of the Society of Biological Psychiatry, Toronto, Canada, May 27-31, 1998. Biological Psychiatry 43:47S, 1998.
- de Leon J**, Gonzalez-Pinto A, Gutierrez M, Perez de Heredia JL, Mosquera F, Figuerido-Poulain JL, Elizagarate E Antipsychotic agents in bipolar disorder. New Research Program and Abstracts (NR 249). American Psychiatric Association 151st Annual Meeting, Toronto, Canada, May 30-June 4, 1998.
- de Leon J**, Gonzalez-Pinto A, Gutierrez M, Lopez P, Mosquera F, Figuerido-Poulain JL, Ramirez F. Suicide attempts in bipolar disorder (oral presentation). New Research Program and Abstracts (NR 653). American Psychiatric Association 151st Annual Meeting, Toronto, Canada May 30-June 4, 1998.
- Chou WH, **de Leon J**, Barnhill J, Rogers T, Wedlund PJ. Cytochrome P450-2D6: Impact on response and costs in severe mental illness. Biomedicine 98, Washington, DC, May 1-3, 1998.
- Crooks P, Ghosheh O, Dwoskin LP, Rogers T, **de Leon J**. Increased concentration of plasma cotinine in schizophrenic smokers compared to normal smokers. 60th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc, Scottsdale, AZ, June 12-17, 1998. NIDA Research Monograph 179:192, 1998.

- Diaz-Sastre C, Basurte E, Baca-Garcia E, Prieto R, Ceverino A, **de Leon J**, Saiz-Ruiz J. A paradox in studies of impulsivity in suicide attempts. 54th Annual Meeting of the Society of Biological Psychiatry, Washington, D.C., May 13-15, 1999. Biological Psychiatry 45:8S, 140S, 1999.
- Baca-Garcia E, Diaz-Sastre C, Ceferino A, Zabala S, **de Leon J**, Saiz Ruiz J. Premenstrual symptoms and suicide. New Research Program and Abstracts (NR 27). American Psychiatric Association 152nd Annual Meeting, Washington, D.C., May 15-20, 1999.
- de Leon J**, Gonzalez-Pinto A, Gutierrez M, Lopez P, Lalaguna B, Corres B, Figuerido-Poulain JL, Perez de Herdia JL, Mosquera F. Mania in women. New Research Program and Abstracts (NR 434). American Psychiatric Association 152nd Annual Meeting, Washington, D.C., May 15-20, 1999.
- Diaz-Sastre C, Baca-Garcia E, Ceverino A, Garcia-Resa E, **de Leon J**, Saiz-Ruiz J. Suicide attempts, impulsivity, and low serum cholesterol levels in male patients. 55th Annual Meeting of the Society of Biological Psychiatry, Chicago, IL, May 11-13, 2000. Biological Psychiatry 47:8S, 168S, 2000.
- de Leon J**, Lalaguna B, Mosquera F, Gutierrez M, Fernandez de Corres B, Perez de Herdia JL, Gonzalez-Pinto A. Dysphoric mania and suicide risk. New Research Program and Abstracts (NR 471). American Psychiatric Association 152th Annual Meeting, Chicago, IL, May 13-18, 2000.
- Perez de Heredia JL, Figuerido JL, Lalaguna B, **de Leon J**, Gutierrez M, Ezcurra J, Gonzalez-Pinto A. Incongruent psychotic symptoms and age of onset in bipolar disorders. New Research Program and Abstracts (NR 474). American Psychiatric Association 153rd Annual Meeting, Chicago, IL, May 13-18, 2000.
- Gurpegui M, Aguilar MC, **de Leon J**. Smoking and schizophrenia: Prevalence and associated features. 10th Congress of the Association of European Psychiatrists. Prague, Czech Republic, October 28-November 1, 2000. European Psychiatry 15 (Suppl 2): 306s, 2000.
- de Leon J**, Diaz F, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking in schizophrenia and mood disorders. Eighth International Congress on Schizophrenia Research. British Columbia, Canada, April 28-May 2, 2001. Schizophrenia Research 49:29, 2001.
- Baca-Garcia E, Diaz-Sastre C, Ceverino A, Garcia-Resa E, Zabala S, Saiz-Ruiz J, **de Leon J**. Are state impulsivity and trait impulsivity related in suicide attempts? 56th Annual Meeting of the Society of Biological Psychiatry, New Orleans, LA, May 3-5, 2001. Biological Psychiatry 49:8S, 133S, 2001.

de Leon J, Garcia-Resa E, Baca-Garcia E, Blasco H, Braquehais D, Saiz Ruiz J. Gender, suicide attempts and low serum cholesterol levels. New Research Program (NR 808). American Psychiatric Association 154th Annual Meeting, New Orleans, LA, May 5-10, 2001.

Ceverino A, Baca-Garcia E, Diaz-Sastre C, Garcia-Resa E, Saiz-Ruiz J, **de Leon J**. An interaction between menopause and the serotonin transporter gene in suicide attempts. 57th Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 16-18, 2002. Biological Psychiatry 51:8S, 80S, 2002.

de Leon J, Garcia-Resa E, Baca-Garcia E, Diaz-Sastre C, Braquehais D, Ramirez A, Jimenez Trevino L, Navio M. Exploring why clinicians choose hospitalization after suicide attempts. New Research Program (NR 456). American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18-23, 2002.

de Leon J, Diaz FJ, Cooper TB, Simpson GM. Clozapine increases prolactin levels: the increases are small and may be more evident in women. 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8-12, 2002.

Botts SR, **de Leon J**, Diaz F. Influence of smoking and gender on olanzapine dosing. 2003 American College of Clinical Pharmacy Spring Practice and Research Forum/Update in Therapeutics. Palm Springs, CA. April 27-30, 2003. National Meeting. Pharmacotherapy 23:412, 2003.

Ramirez-Garcia AJ, Vaquero C, Baca-Garcia E, Diaz-Sastre C, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J**. Repeated suicide attempts and the serotonin transporter gene polymorphism. 58th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 15-17, 2003. Biological Psychiatry 53:8S, 217S, 2003.

de Leon J, Baca-Garcia E, Vaquero C, Diaz-Hernandez M, Diaz-Sastre C, Giner L, Saiz-Ruiz J, Fernandez-Piqueras J. Serotonin transporter gene expression in patients with acute suicidal behavior: preliminary results. 59th Annual Meeting of the Society of Biological Psychiatry, New York, NY, April 29-May 1, 2004. Biological Psychiatry 55:8S, 87S, 2004.

Gonzalez-Pinto A, **de Leon J**, Alonso M, Mosquera FM, Ramirez F, Aldama AM. Predictive factors of suicidal behavior after a first admission for psychosis: A four-year follow-up study. 59th Annual Meeting of the Society of Biological Psychiatry, New York, NY, April 29-May 1, 2004. Biological Psychiatry 55:8S, 180S, 2004.

Baca-Garcia E, Rodriguez-Salgado B, Dolengevich-Segal H, Vaquero-Lorenzo C, Fernandez-Piqueras J, Diaz-Hernandez M, **de Leon J**, Saiz-Ruiz J. Serotonin transporter promoter region gene polymorphism as a genetic support for the obsessive-compulsive spectrum. 59th Annual Meeting of the Society of Biological Psychiatry, New York, NY, April 29-May 1, 2004. Biological Psychiatry 55:8S, 228S, 2004.

Zawacki A, Susce MT, Wedlund PJ, **de Leon J**, Glaser PEA. Benefits and adverse effects of risperidone treatment in children and adolescents: Identification of Cytochrome P450 2D6 (CYP2D6) phenotypes in a naturalistic study. Pediatric Academic Society Meeting, San Francisco, CA, May 2004. Pediatric Research 55:81A-81A, Part 2 Suppl Apr 2004.

de Leon J, Baca-Garcia E, Rodriguez Salgado B, Dolengevich Segal H, Fernandez Piqueras J, Vaquero Lorenzo C, Diaz Hernandez M, , Saiz Ruiz J, Arrojo Romero M. Serotonin genes and obsessive-compulsive disorder. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005. Biological Psychiatry 57:8S, 207S-208S, 2005.

Jimenez-Trevino L, Baca-Garcia E, Vaquero C, Perez-Rodriguez MM, Saiz-Ruiz J, Fernandez-Piqueras J, **de Leon J**. Lack of association between polymorphic variations in GABRA3 gene and lethality in suicide attempts. 60th Annual Meeting of the Society of Biological Psychiatry, Atlanta, GA, May 19-21, 2005. Biological Psychiatry 57:8S, 208S, 2004.

de Leon J, Susce M, Diaz FJ. Obesity in severe mental illness: The effect of smoking. New Research Program (NR 262). American Psychiatric Association 158th Annual Meeting, Atlanta, GA, May 21-26, 2005.

Crooks P, **de Leon J**, Nasim S, Wei, X. Identification of 2,2'-Dipyridyl in human plasma. The American Association of Pharmaceutical Scientist Annual Meeting and Exposition. Nashville, TN, November 6-10, 2005. The AAPS Journal 7, S2, Abstract W5053, 2005.

de Leon J. Tardive dyskinesia in the naturalistic setting: the effects of atypical and typical antipsychotics. 61st Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario, Canada. May 18-20, 2006. Biological Psychiatry 59:8S, 134S, 2006.

Perez-Rodriguez MM, Arce-Cordon R, Baca-Garcia E, Baca-Baldomero E, **de Leon J**. Thyroid disturbances in psychiatric inpatients. 61st Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario, Canada. May 18-20, 2006. Biological Psychiatry 59:8S, 159S, 2006.

Blasco-Fontecilla H, Baca-Garcia E, Perez-Rodriguez M, Ceverino-Dominguez A, **de Leon J**, Saiz-Ruiz J. Recent life events preceding suicide attempts: role of personality disorders. New Research Program (NR 11). American Psychiatric Association 159th Annual Meeting, Toronto, Ontario, Canada, May 20-25, 2006.

- Baca-Garcia E, Blasco-Fontecilla H, Jimenez-Trevino L, Braquehais D, **de Leon J**, Saiz-Ruiz J. New Research Program (NR 742). Severity of personality disorders and suicide attempts. American Psychiatric Association 159th Annual Meeting, Toronto, Ontario, Canada, May 20-25, 2006.
- Campo-Arias A, Díaz-Martínez LA, Rueda-Jaimes GE, Rueda-Sánchez M, Farelo D, Diaz FJ, de Leon J. Cigarette smoking among psychiatric outpatients: a matched case-control study in Bucaramanga, Colombia (oral presentation). Scientific and Clinical Report Sessions No 123. Syllabus and Proceedings Summary, page 123. American Psychiatric Association 159th Annual Meeting, Toronto, Ontario, Canada, May 20-25, 2006.
- de Leon J**. The epidemiology of tobacco use (oral presentation). In Panel Session: Determinants of vulnerability to nicotine addiction in schizophrenia. 45th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 3-7, 2006. Neuropsychopharmacology 31, Suppl 1 (S2).
- de Leon J**, Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. 62nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA. May 17-19, 2007. Biological Psychiatry 61:8S, 82S, 2007.
- Baca-Garcia E, Perez-Rodriguez MM, Negueruela M, Lopez-Castroman J, Navarro R, Martinez-Vigo M, **de Leon J**. Low plasma cholesterol levels in suicide attempters: a case-control study of suicide attempters and nonattempters. 62nd Annual Meeting of the Society of Biological Psychiatry, San Diego, CA. May 17-19, 2007. Biological Psychiatry 61:8S, 85S, 2007.
- de Leon J**, Meary A, Arranz MJ, Diaz FJ. Exploring SNPs of the neuropeptide Y and acetyl-coenzyme A carboxylase α and β genes that may be associated with the direct effects of some antipsychotics on lipid levels. 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC May 1-3, 2008. Biological Psychiatry 63:7S, 283S, 2008.
- Baca-Garcia E, Diaz-Sastre C, Ceverino A, Perez-Rodriguez MM, Saiz-Ruiz J, **de Leon J**, Oquendo MA. Suicide attempts among women during hypoestrogenic phases. 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC May 1-3, 2008. Biological Psychiatry 63:7S, 291S, 2008.
- Blasco-Fontecilla H, Dervic K, **de Leon J**, Oquendo MA, Baca-Garcia E. Differences in suicide behavior may help differentiate between narcissistic and antisocial personality disorders. 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC May 1-3, 2008. Biological Psychiatry 63:7S, 291S, 2008.

de Leon J. Pharmacogenetics of mood stabilizers in bipolar disorder (oral presentation). In Symposium 28 Advances of Pharmacogenetics of Psychotropic Drugs. 21st ECNP (European College of Neuropsychopharmacology) Congress, Barcelona, Spain, August 30-September 3, 2008. European Neuropsychopharmacology 18, Suppl 4 (S197).

PRESENTATIONS

A) UNPUBLISHED RESEARCH POSTER PRESENTATIONS: (20 posters)

Chinchilla-Moreno A, Gonzalez-Pinto Arrillaga A, Martin Carrasco M, **de Leon-Molina J**, Morales-Socorro P, Dios-Perriño C de. Sending motive and type of pathology in outpatients referred for psychiatry consultation in a general hospital (in Spanish). 16th National Congress of the Spanish Society of Psychiatry. La Manga del Mar Menor (Spain), May 27-30, 1985. National Meeting.

Chinchilla-Moreno A, Martin-Carrasco M, **de Leon-Molina J**, Gonzalez-Pinto-Arrillaga A, Morales-Socorro P, Dios Perriño C de. Withdrawal of pharmacologic treatments in schizophrenics treated with long-acting neuroleptics (in Spanish). 16th National Congress of the Spanish Society of Psychiatry. La Manga del Mar Menor (Spain), May 27-30, 1985. National Meeting.

Saiz J, **de Leon J**. Insufficiency of DSM-III criteria in somatizing patients (in Spanish). 12th Reunion of the Spanish Society of Biological Psychiatry. Valencia (Spain), November 21, 1986. National Meeting.

de Leon J, Mauri JA, Medrano M, Gobernado J, Saiz-Ruiz J. Pathological crying and affective incontinence: Therapeutic importance of their distinction (in Spanish). 38th Annual Reunion of the Spanish Society of Neurology. Barcelona (Spain), December 5, 1986. National Meeting.

Rogers T, Decious B, Merrick B, Bowe T, **de Leon J**. Nicotine Dependence in Schizophrenic versus Non-Schizophrenic Inpatients. Fourth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 13, 1996. State Meeting.

Satterly R, Boyle J and **de Leon J**. The Case Manager Rating Scale (CMRS) as an Assessment of Drug Abuse. Fourth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 13, 1996. State Meeting.

Barnhill J, McGuire S, Dunn A, Wedlund P, **de Leon J**. Screening for the Cytochrome P-450 2D6. Fourth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 13, 1996. State Meeting.

de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund P. A pilot study of the Cytochrome P450-2D6. Fifth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 5, 1997. State Meeting.

de Leon J, Brumagen J, Weddle L, Rogers T. Nicotine metabolism in normal subjects (caffeine and CYP2D6). Fifth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 5, 1997. State Meeting.

Durrenberger SD, Rogers T, **de Leon J**. Lack of treatment compliance: high costs in five manics. Fifth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 5, 1997. State Meeting.

de Leon J, Rogers T, Brumagen J, Weddle L, Wedlund PJ, Chou WH. Cytochrome P450-2D6 (CYP2D6) genotypes in normal controls. Sixth Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 18, 1998. State Meeting.

Jorgensen K, Dinsmore L, Coffman M, Morishetty N, **de Leon J**. Nicotine, caffeine, and the menstrual cycle in severely mentally ill women. 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.

Durrenberger SD, Rogers T, **de Leon J**. Lack of treatment compliance: high costs in five manics. 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.

Kinney K, Escobar E, **de Leon J**. Brain metabolism of nicotine: The need for CSF studies (poster). 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.

Haydon JS, **de Leon J**. Cycloid psychosis (poster). 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.

Rogers T, Diaz F, Browne D, Dinsmore L, **de Leon J**. Caffeine and smoking. Seventh Annual Eastern State Hospital Research Poster Day. Lexington, KY, November 16, 1999. State Meeting.

de Leon J. Genetic testing for an enzyme that destroys psychiatric medication. NAMI Kentucky Convention 2000. Lexington, KY, May 20, 2000. State Meeting.

de Leon J, Wedlund P. Risperidone Response: Therapeutic Complications from Genetic Variation in Cytochrome P450-2D6 Expression. Zyprexa Investigator-Initiated Trial Program. Dallas, TX, February 2, 2001. National Meeting.

Baca-Garcia E, Diaz-Sastre C, Vaquero C, **de Leon J**, Fernandez-Piqueras J, Saiz-Ruiz J. Saiz-Ruiz J. Lethality of suicide attempts in women and serotonin transporter gene (in Spanish). International Congress AMP-AEP-SEP-SEPB. Madrid, Spain September 30-October 4, 2001. Award for best poster of the meeting from the Spanish Society of Psychiatry. National Meeting.

B) UNPUBLISHED RESEARCH ORAL PRESENTATIONS: (7 presentations)

- Barnhill J, **de Leon J**, Rogers T, Boyle J, Chou WH, Wedlund P. A pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital (oral presentation). 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.
- Bork J, Rogers T, Boyle J, Wedlund P, **de Leon J**. A pilot study of risperidone metabolism: The role of Cytochrome P-450 2D6 and 3A (oral presentation). 11th Annual Meeting Southern Psychiatric Association for Research in Psychiatry. Lexington, KY, April 2-4, 1998. Regional Meeting.
- Gurpegui M, Aguilar MC, Diaz FJ, **de Leon J**. Interactions between nicotine dependence and symptoms in schizophrenia. 6th National Psychiatric Congress. Barcelona, Spain, November 5-9, 2002. National Meeting.
- de Leon J**. It is difficult to define impulsivity in suicidal behavior. In a Symposium titled "Impulsivity and Associated Disorders." 8th Spanish Psychiatric Congress. Bilbao, Spain, October 26-30, 2004. National Meeting.
- de Leon J**. Tobacco self-medication and alternative hypotheses. In a Symposium titled "Nicotine and Caffeine as Substances of Psychiatric Interest." 9th Spanish Psychiatric Congress. Pamplona, Spain, October 24-26, 2005. National Meeting.
- de Leon J**. Discussant. Translational Medicine and Personalized Medicine in Psychiatry (supported by Bristol-Myers Squibb). In an International Meeting called "Translational Research and Personalized Medicine" Fundacion Jimenez Diaz, Madrid, Spain, February 9, 2006. Local audience.
- de Leon J**. Co-Chair. Anti-neuron-surface Antibodies: Any Role in Chronic Psychoses. Symposium 487. On September 18, 2014. XVI World Congress of Psychiatry, September 14-18, 2014 Madrid, Spain. International audience

C) INVITED LECTURES BY DR. DE LEON: (173 lectures)

- Jan. 15, 1992 “Positive and Negative Symptoms of Schizophrenia”
Department of Psychiatry, General Hospital of Guadalajara, Spain
Local audience
- Oct. 15, 1992 “Are There More than Two Syndromes in Schizophrenia: A Critique of the Positive-negative Dichotomy”
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Local audience
- Dec. 16, 1992 “Assessment of Neuroleptic-Induced Extrapiramidal Symptoms”
Department of Psychiatry, Medical School, University of Granada, Spain
Local audience
- Dec. 16, 1992 “Positive and Negative Symptoms of Schizophrenia”
Department of Psychiatry, Medical School, University of Granada, Spain
Local audience
- Oct. 3, 1993 “Study of Factors Associated with Somatizations in Medical and Surgical Patients”
Department of Psychiatry, Medical School, University of Granada, Spain
Local audience
- Nov. 8, 1993 “Study of Factors Associated with Somatizations in Medical and Surgical Patients”
Academy of Medical Sciences, Bilbao, Spain
Local audience
- Dec. 13, 1993 “Polydipsia - Review and Update: Epidemiological and Clinical Aspects”
Department of Psychiatry, Norristown State Hospital, Norristown, PA
Local audience
- Jan. 6, 1994 “Polydipsia - Review and Update: Epidemiological and Clinical Aspects”
Department of Psychiatry, Medical College of PA, Philadelphia, PA
Local audience
- Jul. 7, 1994 “Polydipsia - Review and Update: Epidemiological and Clinical Aspects”
Department of Psychology, Norristown State Hospital, Norristown, PA
Local audience

- Jan. 5, 1995 “Negative Symptoms of Schizophrenia: The Role of Psychopharmacology”
Carrier Foundation, New Jersey
Local audience
- Mar. 24, 1995 “Syndromes in Chronic Schizophrenic Patients: Clinical and Brain Implications”
Course on Neuroscience and Psychiatry organized by the Federico Oloriz Neurosciences Institute and Department of Psychiatry, Medical School, University of Granada, Spain
Local audience
- Apr. 28, 1995 “Positive and Negative Symptoms of Schizophrenia”
Cleveland VAMC, Department of Psychiatry, Brecksville, OH
Local audience
- May 12, 1995 “Questions and Hypothesis about Polydipsia”
10th Annual Pennsylvania Conference on Schizophrenia. Norristown, PA
State meeting
- Jun. 6, 1995 “Polydipsia: Epidemiological and Neuroendocrinological Aspects”
Department of Psychiatry, Medical College of PA, Philadelphia, PA
Local audience
- Jul. 27, 1995 “Clozapine, Polydipsia and Water Intoxication”
Department of Psychiatry, Seattle Veterans Administration Medical Center, Seattle, WA
Local audience
- Jul. 28, 1995 “Clozapine, Polydipsia and Water Intoxication”
Department of Psychiatry, American Lake Veterans Administration Medical Center, Tacoma, WA
Local audience
- Sep. 23, 1996 “Assessment of Neuroleptic-Induced Extrapyrarnidal Symptoms”
Grand Rounds, Eastern State Hospital. Lexington, KY
Local audience
- Nov. 13, 1996 “Severe Mental Illness and Research”
4th Annual Eastern State Hospital Research Poster Day. Lexington, KY
Local audience

- Jan. 22, 1997 “Research Approach for the Problem of Polydipsia in Psychiatric Patients”
Psychiatry Grand Rounds. University of Kentucky, Lexington, KY
Local audience and teleconferenced to other state institutions
- Feb. 18, 1997 “The Use of Clozapine for the Treatment of Polydipsia”
Department of Psychiatry, Appalachian Regional Healthcare Psychiatric
Center, Hazard, KY
(supported by Sandoz)
Local audience
- Jan. 30, 1998 “Research in Psychiatry”
XX Anniversary of the Residency Program at the Ramon y Cajal Hospital,
Madrid, Spain
Local audience
- May 19, 1998 “Clinical Use of Risperidone Levels”
Medical Staff Inservice. Eastern State Hospital, Lexington, KY
Local audience
- Dec. 4, 1998 “Phenomenology: Positive and Negative Symptoms”
In “An Update on Schizophrenia.” LX National Medical Congress
Organized by the Medical Association of Costa Rica (Colegio de Medicos
y Cirujanos), San Jose, Costa Rica
National Meeting in Costa Rica
- May 20, 1999 “Clinical Implications of the Cytochrome P450”
Issue Workshop 72 Proceedings Summary (page 203).
American Psychiatric Association 152nd Annual Meeting
Washington, D.C., May 15-20, 1999
International audience
- Jul. 26, 1999 “The Cytochrome P450”
Western State Hospital, Hopkinsville, KY
Local audience
- Sep. 17, 1999 “Drug Interactions and the Cytochrome P450 System”
5th Annual Midwestern Neuro-Psychiatric Pharmacy Conference
September 17-18, 1999, Lexington, KY
Regional meeting organized by the UK College of Pharmacy
- Oct. 6, 1999 “The Cytochrome P450 and Drug Interactions”
Kentucky Correctional Psychiatric Center, LaGrange, KY
Local audience

- Oct 22, 1999 “Clinical Implications of the Cytochrome P450 System for Psychiatrists”
Hospital Onze Lieve Vrouw, Bruges, Belgium
(supported by Lundbeck)
Local audience
- Oct 24, 1999 “CYP450: Clinical Implications for Psychiatrists”
Reserve Hotel Knokke, Belgium
(supported by Lundbeck)
National meeting for Belgian psychiatrists
- Mar 21, 2000 “Menstrual Cycle and Suicide Behavior”
Women's Health Grand Rounds, University of Kentucky. Lexington, KY
Local audience and teleconferenced to other state institutions
- Apr 7, 2000 “Clinical Implications of the Cytochrome P450”
Psychiatry Grand Rounds, Marshall University School of Medicine,
Huntington, WV
Local audience
- May 24, 2000 “Cytochrome P450 System and its Role in the Metabolism of Second
Generation Antipsychotic Agents”
Grand Rounds, Mayview State Hospital, Pittsburgh, PA
(Organized by Mayview State Hospital and supported by Janssen)
Local audience
- Nov. 15, 2000 “Severe Mental Illness and Research”
8th Annual Eastern State Hospital Research Poster Day. Lexington, KY
Local audience
- March 8, 2001 “Clinical Implications of the Cytochrome P450”
37th Annual Advances in Clinical Psychiatry and Psychopharmacology,
University of Louisville Department of Psychiatry and Behavioral
Sciences and the Kentucky Psychiatric Association. Louisville, KY
State meeting
- April 26, 2001 “Polydipsia”
Central State Hospital ICF/MR, Louisville, KY
Local audience
- May 8, 2001 “Women and suicide: Hormones and genes.”
Issue Workshop 40. Chair and lecturer with E. Baca-Garcia, M.D.
American Psychiatric Association 154th Annual Meeting, New Orleans,
LA, May 5-10, 2001
International audience

- May 30, 2001 “Clinical Implications of the Cytochrome P450 for Psychiatrists”
Grand Rounds, Central State Hospital, Louisville, KY
Local audience
- Aug. 23, 2001 “Women and suicide: Hormones and genes”
(2-day visit supported by Pfizer)
Psychiatry Grand Rounds, Marshall University School of Medicine,
Huntington, WV
Local audience
- Aug. 24, 2001 “Clinical Implications of the Cytochrome P450”
(2-day visit supported by Pfizer)
Lecture to Internal Medicine Residents
Marshall University School of Medicine, Huntington, WV
Local audience
- Mar. 8, 2002 “Pharmacogenetics of Schizophrenia”
10th Update Course in Psychiatry
March 7-8, Vitoria, Spain
National meeting organized by Hospital Santiago Apostol
and the Department of Neurosciences of the Basque Country University
- May 8, 2002 “Women and Suicide: Hormones and genes”
Western State Hospital, Hopkinsville, KY
Local audience
- Jun.28, 2002 “Pharmacogenetics of Schizophrenia”
Course on Neuroscience and Psychiatry organized by the Federico Oloriz
Neurosciences Institute and Department of Psychiatry, Medical School,
University of Granada, Spain
Local audience
- Aug.29, 2002 “Association between Schizophrenia, Tobacco Smoking, and Polydipsia”
John Umstead Hospital, Butner, NC
Local audience
- May 22, 2003 “An Update on Management of Suicide Attempts: A Review for
Clinicians.” Issue Workshop 107. Co-chair with Maria Oquendo, M.D.
“Variables used by Clinicians to Select Hospitalization after a Suicide
Attempt.” Presented by Dr. de Leon.
American Psychiatric Association 156th Annual Meeting
San Francisco, CA, May 17-22, 2003
International audience

- May 28, 2003 “Clinical Implications of Drug Interactions”
Western State Hospital, Hopkinsville, KY
Local audience
- May 29, 2003 “Clinical Implications of Drug Interactions”
Central State Hospital, Louisville, KY
Local audience
- Jun. 5, 2003 “Clinical Implications of Drug Interactions”
Oakwood (hospital for mentally retarded patients), Somerset, KY
Local audience
- Jun.12, 2003 “Schizophrenia and Nicotine Dependence”
Dual Diagnosis-The Evolving Conceptual Framework
University Psychiatric Hospital (Burghölzli), Zurich, Switzerland
International audience
- Jun. 27, 2003 “Research in Psychiatry”
XXV Anniversary of the Residency Program at the Ramon y Cajal
Hospital, Madrid, Spain
Local audience
- Oct. 3, 2003 “Treatment Refractory Schizophrenia: Clinical Management”
Neurogenetics and Psychiatry.
VII Research Update in Psychiatry
Galician Psychiatric Association
Hospital Xeral-Cies, Vigo, Spain
(Organized by Galician Psychiatric Association; the lecture was supported
by Eli Lilly)
Local audience
- Oct. 7, 2003 “Clinical Implications of Drug Interactions”
Eastern State Hospital, Lexington, KY
Local audience
- Oct. 10, 2003 “Drug Interactions and the Cytochrome P450 System”
9th Annual Midwestern Neuropsychopharmacology Update
October 10-11, 2003, Lexington, KY
Regional meeting
- Nov. 12, 2003 “Clinical Implications of Drug Interactions in Aggressive Patients”
Caritas Peace Center, Louisville, KY
Local audience

- June 16, 2004 “Women and Suicide: Hormones and genes”
Course on Neuroscience and Psychiatry organized by the Federico Oloriz
Neurosciences Institute and Department of Psychiatry, Medical School,
University of Granada, Spain
Local audience
- Feb. 23, 2005 “The CYP2D6 poor metabolizer phenotype may be associated with
risperidone adverse drug reactions and discontinuation.”
Psychiatry Grand Rounds, University of Kentucky, Lexington, KY
Local audience and teleconferenced to other state institutions
- Mar. 25, 2005 “Using pharmacogenetics to improve psychiatric treatment: CYP2D6
genotyping and risperidone”
Psychiatry Grand Rounds, University of Louisville, Louisville, KY
Local audience.
- Apr. 14, 2005 “Drug-Drug Interactions in Psychiatry: An Update Focus on Atypical
Antipsychotics”
Department of Psychiatry, Appalachian Regional Healthcare Psychiatric
Center, Hazard, KY
Local audience
- May 27, 2005 “Cytochrome P450 2D6 (CYP2D6) and codeine-like drugs”
Orofacial Pain Center, College of Dentistry,
Lexington, KY
Local audience (Department members)
- Jun. 29, 2005 “Pharmacokinetics of New Antipsychotics”
Course on Neuroscience and Psychiatry organized by the Federico Oloriz
Neurosciences Institute and Department of Psychiatry, Medical School,
University of Granada, Spain
Local audience
- Jul. 15, 2005 “Drug-Drug Interactions in Psychiatry: An Update Focus on Atypical
Antipsychotics”
Hazelwood Center, Louisville, KY
Local audience
- Aug. 24, 2005 “Applications of Pharmacogenetics to the Psychiatry Clinical Practice”
The Methodist Hospital
Houston, TX
(Organized by The Methodist Hospital, Molecular Laboratory
and supported by Roche Molecular Systems, Inc.)
Local audience

- Sep. 8, 2005 “Drug-Drug Interactions in Psychiatry: An Update Focus on Atypical Antipsychotics”
Kentucky Correctional Psychiatric Center, LaGrange, KY
Local audience
- Sep. 22, 2005 “The Association of Schizophrenia and Smoking; A genetic approach
Special Grand Rounds Presentation,
University Behavioral Health Care
Robert Wood Johnson Medical School, Piscataway, NJ
Local audience.
- Oct. 6, 2005 “Using pharmacogenetics to Improve Psychiatric Treatment: CYP2D6
Genotyping and Risperidone”
Caritas Peace Center, Louisville, KY
Local audience
- Nov. 8, 2005 “Applying Cytochrome P450 Research to Clinical Practice”
18th Annual US Psychiatric & Mental Health Congress,
November 7-10, 2005, Las Vegas, NV
National audience
- Jan. 11, 2006 “Using Pharmacokinetic Advances to Select Atypical Antipsychotic
Dosages”
Sant Joan de Déu Hospital,
Sant Boi de Llobregat, Barcelona, Spain
Local audience
- Jan. 25, 2006 “Drug-Drug Interactions in Psychiatry: An Update Focus on Atypical
Antipsychotics”
Oakwood, Somerset, KY
Local audience
- Feb. 23, 2006 “Using Pharmacokinetic Knowledge to Modify Atypical Antipsychotic
Dosing”
Grand Rounds Presentation
Department of Psychiatry and Health Behavior
Medical College of Georgia
Augusta, GA
(Organized by Department of Psychiatry and Health Behavior, Medical
College of Georgia and supported by Roche Molecular Systems, Inc.)
Local audience

- Feb. 23, 2006 “Pharmacogenetic Testing in Treatment with Antidepressants and Antipsychotics”
Keynote address
One Size Does Not Fit All: Predicting Response in the Management of Mood Disorders (CME educational activity)
Department of Psychiatry and Health Behavior
Medical College of Georgia
Augusta, GA
(Organized by Department of Psychiatry and Health Behavior, Medical College of Georgia and supported by Roche Molecular Systems, Inc.)
Local audience
- Apr. 19, 2006 “Polydipsia in Psychiatric Patients”
Oakwood, Somerset, KY
Local audience
- Apr. 25, 2006 “Review of Pharmacogenomic Studies of CNS Drugs with Focus on CYP2D6 and CYP2C19”
Applications of Pharmacogenomics in CNS (ACPE educational activity)
CPNP 9th Annual Meeting, Baltimore, MD
(Supported by Roche Molecular Systems, Inc.)
National audience
- May 18, 2006 “Personalized Prescription Has Arrived in Clinical Practice: CYP2D6 and CYP2C19 Genotyping.” Workshop 8. Chair and presenter.
“Methodological Issues in Taking CYP2D6 and CYP2C19 Testing from Research Laboratories to Clinical Practice.”
Presented by Dr. de Leon.
61st Annual Meeting of the Society of Biological Psychiatry,
Toronto, Ontario, Canada. May 18-20, 2006.
International audience
Biological Psychiatry 59:8S, 134S, 2006.
- May 20, 2006 “Clinical Evidence: Risperidone Studies” US Roche Diagnostics 2006 Psychiatry Advisory Board Meeting. Toronto, Ontario, Canada.
National audience
- Jun. 4, 2006 “Genotyping of the Cytochrome P450: Clinical Benefits in Psychiatry”, II Annual Meeting of the Spanish of Pharmacogenetics and Pharmacogenomics. Valencia, Valencia, Spain. June 4-6, 2006.
(Supported by Roche Molecular Systems, Inc.)
National audience

- Aug. 1, 2006 “Polydipsia in Psychiatric Patients”
Hazelwood, Louisville, KY
Local audience
- Sep 9, 2006 “CYP450 Testing and Psychiatry” in collaboration with Adrian Foster,
M.D.
US Roche Diagnostics 2006 Molecular Diagnostics Advisory Board
Meeting, Jersey City, New Jersey.
National audience
- Sep 15, 2006 “Personalized Medicine in Psychiatry: Present (CYP2D6 and CYP2C19
Genotyping) and Future (Multiple Gene Genotyping)”
In a Mental Health Teaching Day, University of Southern California
Department of Psychiatry and the Los Angeles County Department of
Mental Health, Los Angeles, CA.
(Organized by George Simpson, Department of Psychiatry, University of
Southern California, Los Angeles, CA and the lecture was supported by
Janssen).
Local audience.
- Sep 16, 2006 “Applications of Pharmacogenomics in the Psychiatry Practice”
Sharp Health Care’s 12th Annual Psychiatry Update, San Diego, CA.
(Organized by George Simpson, Department of Psychiatry, University of
Southern California, Los Angeles, CA and the lecture was supported by
Eli Lilly).
Local audience.
- Oct. 6, 2006 “Clinical Use of Pharmacogenetic Testing”
X Research Update in Psychiatry, Galician Psychiatric Association
Hospital Xeral-Cies, Vigo, Spain
(Organized by Galician Psychiatric Association; the lecture was supported
by Eli Lilly)
Local audience
- Oct 31, 2006 “Psychiatric Applications of Pharmacogenomic Testing: CYP 450 2D6
(CYP2D6) and CYP450 2C19 (CYP2C19).” XIV World Congress on
Psychiatric Genetics, Cagliari, Italy, October 28-November, 1, 2006.
(Supported by Roche Molecular Systems, Inc.)
International audience.
- Nov 5, 2006 “Tobacco and Schizophrenia”
XLV Congress of the Colombian Psychiatric Association,
Medellin, Colombia, November, 2-5, 2006.
National audience.

- Nov 5, 2006 “Metabolism of Atypical Antipsychotics”
XLV Congress of the Colombian Psychiatric Association,
Medellin, Colombia, November, 2-5, 2006.
National audience.
- Nov 7, 2006 “Genetic and Environmental Variables that May Influence Risperidone
Plasma Levels” Department of Statistics, Universidad Nacional, Sede
Medellin, Medellin, Colombia.
Local audience.
- Feb 2, 2007 “Tobacco Smoking in Bipolar Disorders”
VIII Symposium on Bipolar Disorders (Catalan Psychiatric Society),
Barcelona, Spain
National Audience.
- Feb 26, 2007 “Pharmacogenomics Case Studies in Psychiatry/Neurology”
Clinical Applications of Pharmacogenetics: Case Reports on the Practice
of Personalized Medicine, Cristal City, VA. Presented by the American
College of Clinical Pharmacology.
National audience.
- Mar. 21, 2007 “Polydipsia in Psychiatric Patients”
Colorado Mental Health Institute, Pueblo, CO
Local audience
- Mar. 21, 2007 “Applying the Cytochrome P450 Research to Clinical Practice”
Colorado Mental Health Institute, Pueblo, CO
Local audience
- May 1, 2007 “Applications of Pharmacogenetic Testing in Antidepressant and
Antipsychotic Treatment: Focusing on CYP2D6 and CYP2C19.”
Symposium 390. Impact of Pharmacogenomics on the Treatment of
Psychiatric Disorders: From Drug Targets to Targeted Therapy.
Experimental Biology, April 28-May 2, 2007, Washington, DC,
International audience
- May 19, 2007 “Are Pharmacodynamic Genes Ready for Psychiatric Clinical Practice or
not? Workshop 583. Chair and presenter.
“Pharmacodynamic Genes Are Not Ready for Antipsychotic Clinical
Practice.” Presented by Dr. de Leon.
62nd Annual Meeting of the Society of Biological Psychiatry,
San Diego, CA. May 17-19, 2007.
Biological Psychiatry 61:8S, 180S, 2007.
International audience

- Jun. 28, 2007 “Genetic and Environmental Variables that May Influence Plasma Risperidone levels.”
Course on Neuroscience and Psychiatry organized by the Federico Oloriz Neurosciences Institute and Department of Psychiatry, Medical School, University of Granada, Spain. Local audience
- Sep. 27, 2007 “Personalized Psychopharmacology (Pharmacogenetics)”
11th National Meeting of the Spanish Psychiatric Association
September 25-28, 2007, Santiago de Compostela, Spain
National audience
- May 30, 2008 “Tobacco Use and Schizophrenia”
International Congress of Dual Pathology, May 29-31, 2008,
Madrid, Spain
International audience
- Nov. 12, 2008 “The Future of Personalized Medicine in Psychiatry”
Sant Joan de Déu Hospital, 6th Meeting on Research in Mental Health,
Sant Boi de Llobregat, Barcelona, Spain
Local audience
- Nov. 13, 2008 “Clinical Interpretation of Risperidone and Clozapine Plasma Levels”
Department of Psychiatry, Hospital Parc Tauli
Sabadell, Barcelona, Spain
Local audience
- Dec. 16, 2008 “Pharmacogenomics: The Promised of Personalized Medicine for CNS Disorders”
1st Annual Meeting CNS Drug Development, London, United Kingdom
International audience
- Jan. 7, 2009 “The Future of Personalized Medicine in Psychiatry”
Grand Rounds, Department of Psychiatry, University of Utah
Salt Lake City, UT
Local audience
- Jan. 14, 2009 “Beyond the ‘Hype’ on the Association Between Metabolic Syndrome and Atypical Antipsychotics: the Confounding Effects of Cohort, Typical Antipsychotics, Severe mental illness, and Co-morbid Substance Use”
Psychiatry Grand Rounds, University of Kentucky, Lexington, KY
Local audience and teleconferenced to other state institutions

- April 27, 2009 “Pharmacogenomics: Predicting Patients at Risk for Drug Interactions”.
Dinner Seminar: “Important Drug Interactions for Neurologists and Psychiatrists.” 61st Annual Meeting of the American Academy of Neurology, Seattle, WA. April 25-May 2, 2009.
International audience
- Jun. 4, 2009 “Clinical Interpretation of Risperidone and Clozapine Plasma Levels”
Workshop (2 hours).
Catalan Psychiatric Association Annual Meeting 2008-09.
Tossa de Mar, Gerona, Spain
Regional audience
- April 11, 2010 “Pharmacogenomics: Predicting Patients at Risk for Drug Interactions”.
Dinner Seminar: “Important Drug Interactions for Neurologists and Psychiatrists.” 62nd Annual Meeting of the American Academy of Neurology, Seattle, WA. April 10-April 17, 2010.
International audience
- Apr. 14, 2010 “The Future of Personalized Medicine in Psychiatry”
Psychiatry Grand Rounds, University of Kentucky, Lexington, KY
Local audience and teleconferenced to other state institutions
- Sep. 22, 2010 “The Future (or Lack of Future) of Personalized Medicine in Psychiatry”
Health Department, Galicia Government, (Conselleria de Sanidad y de Sergas). Santiago de Compostela, Galicia, Spain.
Local audience
- Sep. 22, 2010 “The Future (or Lack of Future) of Personalized Medicine in Psychiatry”
University Hospital, Santiago de Compostela, Galicia, Spain.
Local audience
- Sep. 23, 2010 “Pharmacokinetics Models and Response to Clozapine, Olanzapine, Quetiapine, Ziprasidone, Risperidone and Aripiprazole”
University Hospital, Santiago de Compostela, Galicia, Spain.
Local audience
- Sep. 23, 2010 “Clozapine Plasma Levels and Clinical Response”
University Hospital, Santiago de Compostela, Galicia, Spain.
Local audience
- Jun. 8, 2011 “The Future (or Lack of Future) of Personalized Medicine in Psychiatry”
12th International Congress of the Romanian Society of Pharmacology, Therapeutics and Clinical Toxicology, Bucharest, Romania.
International audience.

- Sep. 8, 2011 “Beyond the “Hype” on the Association Between Metabolic Syndrome and Atypical Antipsychotics: the Confounding Effects of Cohort, Typical Antipsychotics, Severe mental illness, and Co-morbid Substance Use”
Psychiatry Grand Rounds, University of Louisville, Louisville, KY
Local audience and teleconferenced to other state institutions
- Sep. 13, 2011 “Evidence-based Medicine versus Personalized Medicine: Are They Enemies?”
Psychiatry Grand Rounds, University of Kentucky, Lexington, KY
Local audience and teleconferenced to other state institutions
- Feb. 23, 2012 “Genetics of Schizophrenia and Smoking: an Approach to Studying Their Comorbidity Based on Epidemiological Findings.”
Center on Drug and Alcohol Research
University of Kentucky, Lexington, KY
Local audience (Neuroscientists and Trainees Interested in Drug Abuse)
- Sep. 27, 2012 “Evidence-based Medicine versus Personalized Medicine: Are They Enemies?”
16th National Meeting of the Spanish Psychiatric Association
September 25-28, Bilbao, Spain
National audience
- Nov. 28, 2012 “Evidence-based Medicine versus Personalized Medicine: Are They Enemies?”
Meeting on Biological Psychiatry, Santiago de Compostela, Spain
Organized by Department of Mental Health, Regional Government of Galicia
Regional audience
- Jun. 27, 2014 “Is it time to wake up Sleeping Beauty? European psychiatry has been sleeping since 1980”
2nd Meeting on Biological Psychiatry, Santiago de Compostela, Spain
Organized by Department of Mental Health, Regional Government of Galicia
Regional audience
- Jul. 15, 2014 “Evidence-based Medicine versus Personalized Medicine: Are They Enemies?”
The 5th Bootes Course on Translational Medicine
The John Curtis School of Medicine,
ANU College of Medicine, Biology & Environment,
Canberra, Australia
Regional audience

- Jul. 15, 2014 “Genomics of Substance Use Disorder and Other Psychiatric Illnesses”
 Workshop on Genomic of “ADHD and SUD”
 The Science Forum
 The John Curtis School of Medicine,
 ANU College of Medicine, Biology & Environment,
 Canberra, Australia
 National audience
- Sep. 18, 2014 “Personalized Medicine”
 Symposium 326. Personalized Medicine, Adherence to Treatment and
 Adverse Events in Psychosis
 XVI World Congress of Psychiatry,
 September 14-18, 2014
 Madrid, Spain
 International audience
- Oct. 28, 2014 “Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring
 Medicine to Genomic Medicine”
 Beijing Anding Hospital,
 Beijing, China
 Local audience
 Invited for the Hospital 100th Anniversary
- Oct. 29, 2014 “Psychiatric Research in the US”
 Beijing Anding Hospital,
 Beijing, China
 Local audience
 Invited for the Hospital 100th Anniversary
- Mar 11, 2015 “Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring
 Medicine to Genomic Medicine”
 Institut D’Investigaciones Biomediques August Pi I Sunyer (IDIBAPS)
 Barcelona, Spain
 Local audience
- Mar 11, 2015 “Training Future Psychiatrists: Alternatives to DSM-5
 Grand Rounds
 Hospital del Mar
 Barcelona, Spain
 Local audience

- Mar 12, 2015 “DSM: Is it Useful for Daily Clinical Practice”
IV Annual Meeting on Therapeutics in Psychiatry
Barcelona, Spain
Clinic Hospital Universitary
Barcelona, Spain
National audience
- Mar. 25, 2015 “Paradoxes of US Psychopharmacology Practice in 2013: Between
Undertreatment of the Severe Mentally Ill and Overtreatment of Minor
Psychiatric Problems”
Psychiatry Grand Rounds, University of Kentucky,
Eastern State Hospital, Lexington, KY
Local audience and teleconferenced to other university locations
- Jun. 15, 2015 “Drug versus Disease Mechanisms to Advance Personalized Medicine in
Psychiatry”
Brixia International Conference
Brescia, Italy
Organized from June 11th-June13th, 2015
by the Department of Mental Health, University of Brescia.
Regional audience
- Jun. 15, 2015 “Clinical Applications of Genotyping in Psychiatry and Clinical
Pharmacopsychiatry”
Brixia International Conference
Brescia, Italy
Organized from June 11th-June13th, 2015
by the Department of Mental Health, University of Brescia.
Regional audience
- Aug. 28, 2015 “An Update for Clinicians on the Relevance of Induction by Antiepileptic
Drugs”
Neurology Grand Rounds
The Methodist Hospital
Houston, TX
Local audience
- Sep. 24, 2015 “Personalized Medicine vs Medicine Based in Mechanism”
18th National Meeting of the Spanish Psychiatric Association
September 24-26, 2015, Santiago de Compostela, Spain
National audience

- Sep. 26, 2015 “Is Psychiatry Only Neurology? Or Only Abnormal Psychology?”
Closing Lecture
18th National Meeting of the Spanish Psychiatric Association
September 24-26, 2015, Santiago de Compostela, Spain
National audience
- Nov. 12, 2015 “Can Pharmacogenetic Tests be Used in the Day to Day Activity for
Psychiatry Clinical Practice?”
4th International Meeting for New Treatments in Schizophrenia
CIBERSAM (Spanish Research Network for Mental Health)
November 12-13, 2015, Madrid, Spain
National audience
- Sep. 14, 2016 “Training Psychiatrists To Think Like Pharmacologists: An Introduction”
Department of Psychiatry,
University Hospital of Psychiatry
Bern, Switzerland
- Sep. 16, 2016 “Past, Present and Future of Pharmacogenetic Testing in Psychiatry”
Centre for Psychiatric Neurosciences,
Department of Psychiatry,
Lausanne University Hospital,
Prilly, Switzerland
- Sep. 16, 2016 “Psychopharmacological Treatment in Adults with Intellectual
Disabilities”
Present and Future of Pharmacogenetic Testing in Psychiatry”
Centre for Psychiatric Neurosciences,
Department of Psychiatry,
Lausanne University Hospital,
Prilly, Switzerland
- Oct. 25, 2016 “Clozapine Case 5: High Clozapine Doses”
Psychopharmacology Master
Maza University
Mendoza, Argentina
Local audience
- Oct. 26, 2016 “Is Psychiatry Only Neurology? Or Only Abnormal Psychology?”
Opening Lecture
4th International Congress of Clinical Psychiatry and Psychopharmacology
October 26-29, 2016, Mendoza, Argentina
International audience

- Oct. 28, 2016 “How the US Psychiatry Modified the Classic Concept of Schizophrenia”
Symposium “Past and Present of Psychopathology of Psychosis”
4th International Congress of Clinical Psychiatry and Psychopharmacology
October 26-29, 2016, Mendoza, Argentina
International audience
- Apr. 26, 2017 “The Mentor in Research”
Introductory Course to Clinical Research
Spanish Society of Biological Psychiatry
April 26, 2017, Vitoria, Spain
Spanish Psychiatry Residents
- May 24, 2017 “Pharmacogenetic Testing in Psychiatry”
Psychiatry Grand Rounds, University of Kentucky,
Lexington, KY
Local audience and teleconferenced to other university locations
- July 27, 2017 “Pharmacokinetics of Lithium”
Chillicothe VAMC
Chillicothe, OH
Local audience
- July 27, 2017 “Pharmacokinetics of Oral Second-Generation Antipsychotics”
Chillicothe VAMC
Chillicothe, OH
Local audience
- Oct. 28, 2017 “Narrative, Mechanistic and Mathematical Thinking in Psychiatry”
LVI Congress of the Colombian Psychiatric Association
Medellin, Colombia, October 26-29, 2017
National audience.
- Aug. 31, 2018 “Is Psychiatry Only Neurology? Or Only Abnormal Psychology?”
XXII International Symposium
Chilean College of Neuropsychopharmacology
Santiago, Chile
National audience.
- Aug. 31, 2018 “Evidence-Based Medicine vs Personalized Medicine”
XXII International Symposium
Chilean College of Neuropsychopharmacology
Santiago, Chile
National audience.

- Aug. 31, 2018 “Importance of Drug-Drug Interactions”
XXII International Symposium
Chilean College of Neuropsychopharmacology
Santiago, Chile
National audience.
- Sep 1, 2018 “The Art of Pharmacotherapy”
XXIV International Course of Psychiatry
Psychiatric Unit, Hospital L. Calvo Mackenna
Santiago, Chile
National audience.
- Sep 1, 2018 “Pharmacology of Mood Stabilizers: Lithium, Valproate and Lamotrigine”
XXIV International Course of Psychiatry
Psychiatric Unit, Hospital L. Calvo Mackenna
Santiago, Chile
National audience.
- Sep 1, 2018 “Pharmacology of Antidepressants”
XXIV International Course of Psychiatry
Psychiatric Unit, Hospital L. Calvo Mackenna
Santiago, Chile.
National audience.
- Sep 3, 2018 “Clozapine case 1. The Relevance of the Cytochrome P450”
Department of Psychiatry, School of Medicine,
Pontifical Catholic University of Chile,
Santiago, Chile
Local audience.
- Oct. 19, 2018 “Pharmacogenetics and Drug Interactions in Psychiatry: What Does The Clinician Need To Know?”
21st National Meeting of the Spanish Psychiatric Association
October 18-20, 201, Granada, Spain
National audience
- Jan. 16, 2019 “Why Do You Keep Telling Me that Drug-Drug Interactions are Important in Psychopharmacology When I Do Not See Them in My Clinical Practice? My Failure To Convince Clinicians”
Psychiatry Grand Rounds, University of Kentucky, Lexington, KY
Local audience

- Jan. 30, 2019 “Why Do You Keep Telling Me that Drug-Drug Interactions are Important in Psychopharmacology When I Do Not See Them in My Clinical Practice? My Failure To Convince Clinicians”
Psychiatry Grand Rounds, Department of Psychiatry and Health Behavior
Medical College of Georgia, Augusta, GA
Local audience
- Jan. 30, 2019 “Clozapine Case 5: High Clozapine Doses”
Resident Teaching, Department of Psychiatry and Health Behavior
Medical College of Georgia, Augusta, GA
Local audience
- Mar. 15, 2019 “A Learning Experience of 30 Years: A Critical Review by 28-yo Psychiatrist”
Fifth International Annual Reunion on Psychiatry Centered in the Patient
Jose de Leon Molina 60th Birthday (focus on this year)
March 15, 2019
Madrid, Spain
National audience
- Mar. 27, 2019 “Catatonia: A Brief Reminder”
Western State Hospital, Hopkinsville, KY
Local audience
- Apr. 10, 2019 “Pharmacogenetic Testing in Psychiatry”
Psychiatry Grand Rounds, Citrus Health Network, Inc.
and Florida International University,
Miami, FL
Local audience and teleconferenced to other network locations
- Jun 3, 2019 “Personalized Prescription in Psychiatry: The Point of View of a Clinician”
Pharmacogenetics, Therapeutic Drug Monitoring and Brain Imaging
Methods as Tools for Optimizing Antidepressants in Psychiatry
14th World Congress of Biological Psychiatry
Vancouver, Canada, June 3-6, 2019
International audience.
- Jun. 7, 2019 “Catatonia: A Brief Reminder”
Eastern State Hospital, Lexington, KY
Local audience

- Aug. 27, 2019 “Psychopharmacology Master Class”: 4 lectures
 “Introduction to Clinical Pharmacology”
 “The Relevance of CYP”
 “Pharmacogenetic Testing in Psychiatry”
 “Psychiatric Nosology”
 Department of Psychiatry,
 Vanderbilt University
 Nashville, TN
 Local audience
- Sep. 20, 2019 “Why Do You Keep Telling Me that Drug-Drug Interactions are Important
 in Psychopharmacology When I Do Not See Them in My Clinical
 Practice? My Failure To Convince Clinicians”
 Psychiatry Grand Rounds, Department of Psychiatry
 Queen’s University, Kingston, Ontario, Canada
 Local audience
- Oct. 2, 2019 “Clozapine Levels”
 Grand Rounds, Department of Psychiatry
 Elmhurst Hospital Center, Elmhurst, NY
 Local audience
- Oct. 3, 2019 “Clozapine Levels for Clinicians”
 James J. Peters VA Medical Center, Bronx, NY
 Local audience
- Oct. 4, 2019 “Clozapine Levels” One lecture in a Course:
 “All You Ever Wanted to Know About Clozapine: Basics and Beyond”
 American Psychiatric Association IPS 2019
 The Mental Health Services Conference
 New York, NY, October 3-6, 2019
 National audience
- Aug. 26, 2020 “Clozapine: Levels, Metabolism and Pneumonia” (by Zoom)
 Department for Psychosis,
 Aarhus University Psychiatric Hospital,
 Aarhus, Denmark.
 Local audience in Denmark
- Oct. 15, 2020 “Clozapine: Levels, Metabolism and Pneumonia” (by Zoom)
 Vilardebó Hospital
 Montevideo, Uruguay.
 Local audience in Montevideo (half of country population)

- Nov. 5, 2020 “Risperidone Case 1: Drug-Drug Interaction” (by Zoom)
Pharmacy students and pharmacy residents
Department of Drug Industry and Pharmaceutical Biotechnology
University of Medicine and Pharmacy Carol Davila,
Bucharest, Romania
Local audience
- Nov. 5, 2020 “Risperidone Case 1: Drug-Drug Interaction” (by Zoom)
Resident teaching, Department of Psychiatry
Elmhurst Hospital Center, Elmhurst, NY
Local audience
- Nov. 12, 2020 “Quetiapine Case 1: Warfarin” (by Zoom)
Resident teaching, Department of Psychiatry
Elmhurst Hospital Center, Elmhurst, NY
Local audience
- Nov. 19, 2020 “Quetiapine Case 1: Warfarin” (by Zoom)
Pharmacy students and pharmacy residents
Department of Drug Industry and Pharmaceutical Biotechnology
University of Medicine and Pharmacy Carol Davila,
Bucharest, Romania
Local audience
- Mar. 19, 2021 “Pharmacokinetics of Oral Second Generation Antipsychotics” (by Zoom)
Vilardebó Hospital
Update for Psychiatrist on Antipsychotics
Montevideo, Uruguay.
National audience
- Mar. 26, 2021 “Clozapine: Levels for Clinicians” (by Zoom)
Psychosis Program
University of Illinois at Chicago
Chicago, IL
Local audience
- Apr. 24, 2021 “Clozapine: Levels, Metabolism and Pneumonia” (by Zoom)
Third Intensive Course on Clozapine
University Hospital
Jerez, Spain.
National audience

- Sep. 8, 2021 “Clozapine Case 2: Infection” (by Zoom)
Child and Adolescent Psychiatry Fellowship Teaching
University of South Carolina School of Medicine Greenville
Greenville, SC
Local audience
- Sep. 8, 2021 “Risperidone Case 2: Genetics” (by Zoom)
Child and Adolescent Psychiatry Fellowship Teaching
University of South Carolina School of Medicine Greenville
Greenville, SC
Local audience
- Sep. 15, 2021 “Valproate Case 1: Pharmacokinetics” (by Zoom)
Child and Adolescent Psychiatry Fellowship Teaching
University of South Carolina School of Medicine Greenville
Greenville, SC
Local audience
- Sep. 16, 2021 “Quetiapine Case 2: Therapeutic Drug Monitoring” (by Zoom)
Vilardebó Hospital
Update for Psychiatrist on Antipsychotics
Montevideo, Uruguay.
National audience
- Sep. 16, 2021 “Quetiapine Case 3: Akathisia” (by Zoom)
Vilardebó Hospital
Update for Psychiatrist on Antipsychotics
Montevideo, Uruguay.
National audience
- Sep. 22, 2021 “Lamotrigine Case 1: Stevens-Johnson Syndrome” (by Zoom)
Child and Adolescent Psychiatry Fellowship Teaching
University of South Carolina School of Medicine Greenville
Greenville, SC
Local audience
- Jun. 3, 2022 “Promoting Safer Clozapine Dosing in the Americas” (by Zoom)
BC Mental Health & Substance Use Services
Vancouver, British Columbia, Canada
Regional audience

D) SERVICE PRESENTATIONS BY DR. DE LEON**(EDUCATION OF THE LAY COMMUNITY: 10 presentations)**

- Jul. 18, 1993 "Schizophrenia: Clozapine and Polydipsia"
Alliance for the Mentally Ill of Eastern Pennsylvania, Montgomery
County Chapter
Local Meeting
- Aug. 15, 1994 "Atypical Neuroleptics: Zotepine"
Alliance for the Mentally Ill of Eastern Pennsylvania, Montgomery
County Chapter
Local Meeting
- Apr. 7, 1997 "Patients Who Have Difficulties Eliminating Medication: An Innovative
Screening Program at Eastern State Hospital"
Advocates Taking Action in KY Against Mental Illness
The 2nd Annual Open Minds Open Doors Conference. Louisville, KY
State Meeting
- Feb.1, 1998 "Patients Who Have Difficulties Eliminating Medication: An Innovative
Screening Program at Eastern State Hospital"
National Alliance for the Mentally Ill (NAMI), Lexington (KY)
Local Meeting
- Aug. 2, 1998 "Involuntary Commitment Criteria and Recidivism"(co-lecturer, John
Barnhill, M.D. was the main lecturer)
National Alliance for the Mentally Ill (NAMI), Lexington (KY)
Local Meeting
- Mar. 16, 2004 "Polypharmacy"
Protection & Advocacy Staff Meeting
Frankfort, KY
State Meeting
- Mar.7, 2005 "Schizophrenia Research: Personalized Prescription in Psychiatry"
National Alliance for the Mentally Ill (NAMI), Lexington (KY)
Local Meeting
- Jun.13, 2005 "Personalized Prescription in Psychiatry: CYP2D6 Genotyping and
Risperidone"
National Alliance for the Mentally Ill (NAMI), Louisville (KY)
Local Meeting
- Mar.2, 2008 "Research at the UK Mental Health Research Center since 2005"
National Alliance for the Mentally Ill (NAMI), Lexington (KY)
Local Meeting

Apr. 9, 2019 "Pharmacogenetic Testing in Psychiatry"
National Alliance for the Mentally Ill (NAMI), Miami, FL
Local Meeting

PUBLICATIONS

- May 5, 1995 "Jose de Leon: Schizophrenia increases the risk of tobacco addiction"
by J.M. Fernandez-Rua. Interview for ABC de la Ciencia
Scientific section of ABC. One of the major newspapers in Madrid, Spain.
- Jun. 20, 2000 "Stigma of Mental Illness" by Jose de Leon. Letter to editor.
Lexington Herald Leader
- Apr. 26, 2001 "Gene Test Hailed as a Way of Matching Drugs, Patients" by Jim Warren.
Article on the first page of the Lexington Herald Leader describing studies
by Drs. Wedlund and de Leon in pharmacogenetics.
- Jan. 24, 2005 "Roche Takes Medicine Personal" by Daniel S. Levine. San Francisco
Business Time. Article described FDA approval of Roche AmpliChip
CYP450 and included a short interview with Dr. de Leon.
- Sep. 5, 2005 "Drugs Get Smart" by Kerry Capeland and Michael Arndt. Business
Week (one of the top two business journals in the world), September 5,
2005 cover article. The article described on page 84 Dr. de Leon's
CYP2D6 study published in the Journal of Clinical Psychiatry's January
2005 issue and Dr. de Leon's ongoing pharmacogenetic research study.

F) MEDICAL EDUCATIVE PUBLICATIONS

- October, 1995 “Osteoporosis in Psychiatric Patients” Brown University Psychopharmacology Update 18(4):2-3. It comments on an article published in Biological Psychiatry 38:131-132, 1995.
- January, 2000 “Clozapine/Perphenazine Interaction” Psychiatry Drug Alerts 14(1):1. It comments on an article published in Journal of Clinical Psychiatry 60:710, 1999.
- March, 2004 “Drug-Drug Interactions: Clozapine toxicity attributed to respiratory infection” by Y.W. Francis Lam. Brown University Psychopharmacology Update 15(3):2-3. It comments on an article published in Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 1059-1063, 2003.
- Jan. 31, 2005 "FDA Approves Genotyping Test for Drug Response" by Victoria Stagg Elliot amednews.com (AMA newspaper). Article described FDA approval of Roche AmpliChip CYP450 and included a short interview with Dr. de Leon.
- April, 2005 “Drug-Drug Interactions: CYP2D6 Genotype May Be Linked to Risperidone Adverse Drug Reactions” by Y.W. Francis Lam. Brown University Psychopharmacology Update 18(4):2-3. It comments on an article published in the Journal of Clinical Psychiatry 66:15-27, 2005.
- May 28, 2005 "Gene Testing Could Help Predict Drug Response" by Joan Arehart-Treichel. Psychiatric News 40;10:33. The article describes CYP2D6 testing and includes a picture of Dr. de Leon’s laboratory.
- June, 2005 "Advances in Pharmacogenomics Reduce Side Effects and Save Lives" by Arline Kaplan. Psychiatric Times 22;7:1, 4-5. The article describes CYP2D6 testing and includes comments by Dr. de Leon.
- Aug. 30, 2006 "Tailor-Made Treatment: The Advent of Pharmacogenomics”. Peter Cook interviewed Dr. de Leon. Psychiatric Weekly.
- Dec. 1, 2006 "Nicotine Receptor Agonist Could Aid Smoking Cessation" by Joan Arehart-Treichel. Psychiatric News 41;23:22. The article describes studies on schizophrenia and smoking and includes Dr. de Leon’s comments.
- Sep. 2, 2011 "Gene Linked to Suicide Risk in Those with Eating Disorders” by Joan Arehart-Treichel. Psychiatric News 46;17:24. The article includes comments by Dr. de Leon and includes Dr. de Leon’s picture.